Hla binding peptides and their uses

ABSTRACT

Provided herein are peptides in certian pathogens and/or human or murine proteins that are identified as capable of binding one or more MHC molecules and inducing an immume response in a system. Also provided are compositions that include one or more of the peptides and methods for inducing an immune reponse in a system by administering the compositions to the system.

FIELD OF THE INVENTION

The invention relates to peptides that bind major histocompatibility (MHC) molecules and the use of these peptides to induce and modulate an immune response.

BACKGROUND

The recognition of foreign pathogens, foreign cells (e.g., tumor), or one's own cells by the immune system occurs largely through major histocompatibility (MHC) molecules. MHC molecules present unique molecular fragments of foreign and self molecules that permit recognition and, when appropriate, stimulation of various immune effectors, namely B and T lymphocytes. MHC molecules are classified as either class I or class II. Class II MHC molecules are expressed primarily on activated lymphocytes and antigen-presenting cells. CD4+ T lymphocytes are activated with recognition of a unique peptide fragment presented by a class II MHC molecule, usually found on an antigen presenting cell like a macrophage or dendritic cell. Often known as helper T lymphocytes (HTL), CD4+ lymphocytes proliferate and secrete cytokines that either support a antibody-mediated response through the production of IL-4 and IL-10 or support a cell-mediated response through the production of IL-2 and IFN-γ. Class I MHC molecules, on the other hand, are expressed on virtually all nucleated cells. Peptide fragments presented in the context of Class I MHC molecules are recognized by CD8+ T lymphocytes. CD8+ T lymphocytes frequently mature into cytotoxic effector which can lyse cells bearing the stimulating antigen. Otherwise known as cytotoxic T lymphocytes (CTLs), CTLs are particularly effective in eliminating tumor cells and in fighting viral infections.

T lymphocytes recognize an antigen in the form of a peptide fragment bound to the MHC class I or class II molecule rather than the intact foreign antigen itself. An antigen presented by a MHC class I molecule is typically one that is endogenously synthesized by the cell (e.g., an intracellular pathogen). The resulting cytoplasmic antigens are degraded into small fragments in the cytoplasm, usually by the proteosome (Niedermann et al., Immunity, 2: 289-99(1995)). Some of these small fragments are transported into the endoplasmic reticulum where the fragment interacts with class I heavy chains to facilitate proper folding and association with the subunit β2 microglobulin to result in a stable complex formation between the fragment, MHC class I chain and β2 microglobulin. This complex is then transported to the cell surface for expression and potential recognition by specific CTLs. Antigens presented by MHC class II molecules are usually soluble antigens that enter the antigen presenting cell via phagocytosis, pinocytosis, or receptor-mediated endocytosis. Once in the cell, the antigen is partially degraded by acid-dependent proteases in endosomes. The resulting fragments or peptide associate with the MHC class II molecule after the release of the CLIP fragment to form a stable complex that is then transported to the surface for potential recognition by specific HTLs. See Blum et al., Crit. Rev. Immunol., 17: 411-17 (1997); Arndt et al., Immuno.l Res., 16: 261-72 (1997).

Peptides that bind some MHC complexes have been identified by acid elution methods (Buus et al., Science 242: 1065 (1988)), chromatography methods (Jardetzky, et al., Nature 353: 326 (1991) and Falk et al., Nature 351: 290 (1991)), and by mass spectrometry methods (Hunt, et al., Science 225: 1261 (1992)). A review of naturally processed peptides that bind MHC class I molecules is set forth in Rötzschke and Falk, Immunol. Today 12: 447 (1991).

Peptides that bind a particular MHC allele frequently will fit within a motif and have amino acid residues with particular biochemical properties at specific positions within the peptide. Such residues are usually dictated by the biochemical properties of the MHC allele. Peptide sequence motifs have been utilized to screen peptides capable of binding MHC molecules (Sette et al., Proc. Natl. Acad. Sci. USA 86:3296 (1989)), and it has been reported that class I binding motifs identified potential immunogenic peptides in animal models (De Bruijn et al., Eur. J. Immunol. 21: 2963-2970 (1991); Pamer et al., Nature 353: 852-955 (1991)). Also, binding of a particular peptide to a MHC molecule has been correlated with immunogenicity of that peptide (Schaeffer et al., Proc. Natl. Acad. Sci. USA 86:4649 (1989)).

Of the many thousand possible peptides that are encoded by a complex foreign pathogen, only a small fraction ends up in a peptide form capable of binding to MHC class I or class II antigens and thus of being recognized by T cells. This phenomenon is known as immunodominance (Yewdell et al., Ann. Rev. Immunol., 17: 51-88 (1997)). More simply, immunodominance describes the phenomenon whereby immunization or exposure to a whole native antigen results in an immune response directed to one or a few “dominant” epitopes of the antigen rather than every epitope that the native antigen contains. Immunodominance is influenced by a variety of factors that include MHC-peptide affinity, antigen processing, and antigen availability.

Accordingly, while some MHC binding peptides have been identified, there is a need in the art to identify novel MHC binding peptides from pathogens that can be utilized to generate an immune response in vaccines against the pathogens from which they originate. Further, there is a need in the art to identify peptides capable of binding a wide array of different types of MHC molecules such they are immunogenic in a large fraction a human outbred population.

SUMMARY

The present invention relates to compositions and methods for preventing, treating or diagnosing a number of pathological states such as viral diseases and cancers. Thus, provided herein are novel peptides capable of binding selected major histocompatibility complex (MHC) molecules and inducing or modulating an immune response. Some of the peptides disclosed are capable of binding human class II MHC (HLA) molecules, including HLA-DR and HLA-DQ alleles. Other peptides disclosed herein are capable of binding to human class I molecules, including one or more of the following: HLA-A1, HLA-A2.1, HLA-A3.2, HLA-A11, HLA-A24.1, HLA-B7, and HLA-B44 molecules. Other peptides disclosed are capable of binding to murine class I molecules. Also provided are compositions that include immunogenic peptides having binding motifs specific for MHC molecules. The peptides and compositions disclosed can be utilized in methods for inducing an immune response, a cytotoxic T lymphocyte (CTL) response or helper T lymphocyte (HTL) response in particular, when administered to a system. The peptides and compositions disclosed herein are also useful as diagnostic reagents (e.g., tetramer reagents; Beckman Coulter).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Preferred Motif Table.

FIG. 2. HLA superfamilies for HLA-A and HLA-B alleles. Various alleles of HLA-A and HLA-B are classified according to superfamily based on sequencing analysis or binding assays (verified supertype members) or on the basis of B and F pocket structure (predicted supertype members).

DEFINITIONS

The following definitions are provided to enable one of ordinary skill in the art to understand some of the preferred embodiments of invention disclosed herein. It is understood, however, that these definitions are exemplary only and should not be used to limit the scope of the invention as set forth in the claims. Those of ordinary skill in the art will be able to construct slight modifications to the definitions below and utilize such modified definitions to understand and practice the invention disclosed herein. Such modifications, which would be obvious to one of ordinary skill in the art, as they may be applicable to the claims set forth below, are considered to be within the scope of the present invention. If a definition set forth in this section is contrary to or otherwise inconsistent with a definition set forth in patents, published, patent applications and other publications and sequences from GenBank and other data bases that are herein incorporated by reference, the definition set forth in this section prevails over the definition that is incorporated herein by reference.

As used herein, the term “HLA supertype or HLA family,” refers to sets of HLA molecules grouped based on shared peptide-binding specificities. The terms HLA superfamily, HLA supertype family, HLA family, and HLA xx-like molecules (where xx denotes a particular HLA type), are synonyms.

As used herein, the term “IC₅₀” refers to the concentration of peptide in a binding assay at which 50% inhibition of binding of a reference peptide is observed. Depending on the conditions in which the assays are run (e.g., limiting MHC proteins and labeled peptide concentrations), these values may approximate K_(D) values.

As used herein, the term “peptide” is used interchangeably with “epitope” in the present specification to designate a series of residues, typically L-amino acids, connected one to the other, typically by peptide bonds between the α-amino and carboxyl groups of adjacent amino acids, that binds to a designated MHC allele.

As used herein, the term “pharmaceutically acceptable” refers to a generally non-toxic, inert, and/or physiologically compatible composition.

As used herein, the term “protective immune response” or “therapeutic immune response” refers to a CTL and/or an HTL response to an antigen derived from an infectious agent or a tumor antigen, which in some way prevents or at least partially arrests disease symptoms, side effects or progression. The immune response may also include an antibody response that has been facilitated by the stimulation of helper T cells.

As used herein, the term “residue” refers to an amino acid or amino acid mimetic incorporated in a peptide by an amide bond or amide bond mimetic.

As used herein, the term “motif” refers to the pattern of residues in a peptide of defined length, usually a peptide of from about 8 to about 13 amino acids for a class I MHC motif and from about 6 to about 25 amino acids for a class II MHC motif, which is recognized by a particular MHC molecule. Peptide motifs are typically different for each protein encoded by each MHC allele and differ in the pattern of the highly conserved and negative residues.

As used herein, the term “supermotif” refers to an amino acid sequence for a peptide that provides binding specificity shared by MHC molecules encoded by two or more MHC alleles. Preferably, a supermotif-bearing peptide is recognized with high or intermediate affinity (as defined herein) by two or more MHC antigens.

As used herein, the term “conserved residue” refers to an amino acid which occurs in a significantly higher frequency than would be expected by random distribution at a particular position in a peptide. Typically a conserved residue is one where the MHC structure may provide a contact point with the immunogenic peptide. At least one to three or more, preferably two, conserved residues within a peptide of defined length defines a motif for an immunogenic peptide. These residues are typically in close contact with the peptide binding groove, with their side chains buried in specific pockets of the groove itself Typically, an immunogenic peptide will comprise up to three conserved residues, more usually two conserved residues.

As used herein, “negative binding residues” are amino acids which if present at certain positions (for example, positions 1, 3, 6 and/or 7 of a 9-mer) will result in a peptide being a nonbinder or poor binder and in turn fail to be immunogenic, e.g., induce a CTL response.

As used herein, the term “synthetic peptide” refers to a peptide that is not naturally occurring, but is man-made using such methods as chemical synthesis or recombinant DNA technology.

As used herein, the term “immunogenic peptide” refers to a peptide which comprises an allele-specific motif such that the peptide will bind an MHC molecule and induce a CTL or HTL response. An immunogenic response includes one that stimulates a CTL and/or HTL response in vitro and/or in vivo as well as modulates an ongoing immune response through directed induction of cell death (or apoptosis) in specific T cell populations.

As used herein, the phrases “isolated” or “biologically pure” refer to material which is substantially or essentially free from components which normally accompany it as found in its native state. Thus, the peptides of this invention do not contain materials normally associated with their in situ environment, e.g., MHC I molecules on antigen presenting cells. Even where a protein has been isolated to a homogeneous or dominant band, there are trace contaminants in the range of 5-10% of native protein which co-purify with the desired protein. Isolated peptides of this invention do not contain such endogenous co-purified protein.

Nomenclature used to describe peptide compounds follows the conventional practice wherein the amino group is presented to the left (the N-terminus) and the carboxyl group to the right (the C-terminus) of each amino acid residue. In the formulae representing selected specific embodiments of the present invention, the amino- and carboxyl-terminal groups, although not specifically shown, are in the form they would assume at physiologic pH values, unless otherwise specified. In the amino acid structure formulae, each residue is generally represented by standard three letter or single letter designations. The L-form of an amino acid residue is represented by a capital single letter or a capital first letter of a three-letter symbol, and the D-form for those amino acids having D-forms is represented by a lower case single letter or a lower case three letter symbol. Glycine has no asymmetric carbon atom and is simply referred to as “Gly” or G.

DETAILED DESCRIPTION

A. Peptide and Motif Identification

The present invention relates to allele-specific peptide motifs and binding peptides for human and murine MHC allele. It is contemplated that the peptide binding motifs of the invention are relatively specific for each allele. In an embodiment of the invention, the allele-specific motifs and binding peptides are for human class I MHC (or HLA) alleles. HLA alleles include HLA-A, HLA-B, and HLA-C alleles. In another embodiment of the invention the allele-specific motifs and binding peptides are for human class II MHC (or HLA) alleles. Such HLA alleles include HLA-DR and HLA-DQ alleles. HLA molecules that share similar binding affinity for peptides bearing certain amino acid motifs are grouped into HLA supertypes. See, e.g., Stites, et al., IMMUNOLOGY, 8^(TH) ED., Lange Publishing, Los Altos, Calif. (1994). Peptides that bind one or more alleles in one or more supertypes are contemplated as part of the invention. Examples of the supertypes within HLA-A and HLA-B molecules are shown in FIG. 2. In yet another embodiment, the allele-specific motifs and binding peptides are for murine class I (or H-2) MHC alleles. Such H-2 alleles include H-2Dd, H-2 Kb, H-2 Kd, H-2 Db, H-2Ld, and H-2Kk. Exemplary tables describing allele-specific motifs are presented below. Binding within a particular supertype for murine MHC alleles is also contemplated.

To identify peptides of the invention, MHC-peptide complex isolation, and isolation and sequencing of naturally processed peptides was carried out as described in the related applications. This application may be relevant to U.S. Ser. No. 09/189,702 filed Nov. 10, 1998, which is a CIP of U.S. Ser. No. 08/205,713 filed Mar. 4, 1994, which is a CIP of Ser. No. 08/159,184 filed Nov. 29, 1993 and now abandoned, which is a CIP of Ser. No. 08/073,205 filed Jun. 4, 1993 and now abandoned, which is a CIP of Ser. No. 08/027,146 filed Mar. 5, 1993 and now abandoned. The present application is also related to U.S. Ser. No. 09/226,775, which is a CIP of U.S. Ser. No. 08/815,396, which claims the benefit of U.S. Ser. No. 60/013,113, now abandoned. Furthermore, the present application is related to U.S. Ser. No. 09/017,735, which is a CIP of abandoned U.S. Ser. No. 08/589,108; U.S. Ser. No. 08/53,622, U.S. Ser. No. 08/822,382, abandoned U.S. Ser. No. 60/013,980, U.S. Ser. No. 08/454,033, U.S. Ser. No. 09/116,424, and U.S. Ser. No. 08/349,177. The present application is also related to U.S. Ser. No. 09/017,524, U.S. Ser. No. 08/821,739, abandoned U.S. Ser. No. 60/013,833, U.S. Ser. No. 08/758,409, U.S. Ser. No. 08/589,107, U.S. Ser. No. 08/451,913, U.S. Ser. No. 08/186,266, U.S. Ser. No. 09/116,061, and U.S. Ser. No. 08/347,610, which is a CIP of U.S. Ser. No. 08/159,339, which is a CIP of abandoned U.S. Ser. No. 08/103,396, which is a CIP of abandoned U.S. Ser. No. 08/027,746, which is a CIP of abandoned U.S. Ser. No. 07/926,666. The present application may also be relevant to U.S. Ser. No. 09/017,743, U.S. Ser. No. 08/753,615; U.S. Ser. No. 08/590,298, U.S. Ser. No. 09/115,400, and U.S. Ser. No. 08/452,843, which is a CIP of U.S. Ser. No. 08/344,824, which is a CIP of abandoned U.S. Ser. No. 08/278,634. The present application may also be related to provisional U.S. Ser. No. 60/087,192 and U.S. Ser. No. 09/009,953, which is a CIP of abandoned U.S. Ser. No. 60/036,713 and abandoned U.S. Ser. No. 60/037,432. In addition, the present application may be relevant to U.S. Ser. No. 09/098,584, and U.S. Ser. No. 09/239,043. The present application may also be relevant to co-pending U.S. Ser. No. 09/583,200 filed May 30, 2000, U.S. Ser. No. 09/260,714 filed Mar. 1, 1999, and U.S. Provisional Application “Heteroclitic Analogs And Related Methods”, Attorney Docket Number 018623-015810US filed Oct. 6, 2000. All of the above applications are incorporated herein by reference.

These peptides were then used to define specific binding motifs for each of the following alleles A3.2, A1, A11, and A24.1. These motifs are described previously. The motifs described in Tables 1-4, below, are defined from pool sequencing data of naturally processed peptides as described in the related applications. Preferred (i.e., canonical) and tolerated (i.e., extended) residues associated with anchor positions of the indicated HLA supertypes are presented in FIG. 1 and Table 5.

In one embodiment, the motif for HLA-A3.2 comprises from the N-terminus to C-terminus a first conserved residue of L, M, I, V, S, A, T and F at position 2 and a second conserved residue of K, R or Y at the C-terminal end. Other first conserved residues are C, G or D and alternatively E. Other second conserved residues are H or F. The first and second conserved residues are preferably separated by 6 to 7 residues. In another embodiment, the motif for HLA-A1 comprises from the N-terminus to the C-terminus a first conserved residue of T, S or M, a second conserved residue of D or E, and a third conserved residue of Y. Other second conserved residues are A, S or T. The first and second conserved residues are adjacent and are preferably separated from the third conserved residue by 6 to 7 residues. A second motif consists of a first conserved residue of E or D and a second conserved residue of Y where the first and second conserved residues are separated by 5 to 6 residues.

In yet another embodiment, the motif for HLA-A11 comprises from the N-terminus to the C-terminus a first conserved residue of T, V, M, L, I, S, A, G, N, C D, or F at position 2 and a C-terminal conserved residue of K, R, Y or H. The first and second conserved residues are preferably separated by 6 or 7 residues. In one embodiment, the motif for HLA-A24.1 comprises from the N-terminus to the C-terminus a first conserved residue of Y, F or W at position 2 and a C terminal conserved residue of F, I, W, M or L. The first and second conserved residues are preferably separated by 6 to 7 residues. TABLE 1 Summary HLA-A3, 2 Allele-Specific Motif Conserved Position Residues 1 — 2 V, L, M 3 Y, D 4 — 5 — 6 — 7 I 8 Q, N 9 K 10 K

TABLE 2 Summary HLA-A1 Allele-Specific Motif Conserved Position Residues 1 — 2 S, T 3 D, E 4 P 5 — 6 — 7 L 8 — 9 Y 10 K

TABLE 3 Summary HLA-A11 Allele-Specific Motif Conserved Position Residues 1 — 2 T, V 3 M, F 4 — 5 — 6 — 7 — 8 Q 9 K 10 K

TABLE 4 Summary HLA-A24.1 Allele-Specific Motif Conserved Position Residues 1 — 2 Y 3 I, M 4 D, E, G, K, P 5 L, M, N 6 V 7 N, V 8 A, E, K, Q, S 9 F, L 10 F, A

The MHC-binding peptides identified herein represent epitopes of a native antigen. With regard to a particular amino acid sequence, an epitope is a set of amino acid residues which is recognized by a particular antibody or T cell receptor. Such epitopes are usually presented to lymphocytes via the MHC-peptide complex. An epitope retains the collective features of a molecule, such as primary, secondary and tertiary peptide structure, and charge, that together form a site recognized by an antibody, T cell receptor or MHC molecule. It is to be appreciated, however, that isolated or purified protein or peptide molecules larger than and comprising an epitope of the invention are still within the bounds of the invention. Moreover, it is contemplated that synthesized peptides can incorporate various biochemical changes that enhance their immunological effectiveness.

The epitopes present in the invention can be dominant, sub-dominant, or cryptic. A dominant epitope is an epitope that induces an immune response upon immunization with a whole native antigen. See, e.g., Sercarz, et al., Ann. Rev. Immunol. 11: 729-766 (1993). Such a peptide is considered immunogenic because it elicits a response against the whole antigen. A subdominant epitope, on the other hand, is one that evokes little or no response upon immunization with whole antigen that contains the epitope, but for which a response can be obtained by immunization with an isolated epitope. Immunization with a sub-dominant epitope will prime for a secondary response to the intact native antigen. A cryptic epitope elicits a response by immunization with an isolated peptide, but fails to prime a secondary response to a subsequent challenge with whole antigen.

An epitope present in the invention can be cross-reactive or non-cross-reactive in its interactions with MHC alleles and alleles subtypes. Cross-reactive binding of an epitope (or peptide) permits an epitope to be bound by more than one HLA molecule. Such cross-reactivity is also known as degenerate binding. A non-cross-reactive epitope would be restricted to binding a particular MHC allele or allele subtype.

The epitopes of the present invention can be any suitable length. Class I molecule binding peptides typically are about 8 to 13 amino acids in length, and often 9, 10, 11, or 12 amino acids in length. These peptides include conserved amino acids at certain positions such as the second position from the N-terminus and the C-terminal position. Also, the peptides often do not include amino acids at certain positions that negatively affect binding of the peptide to the HLA molecules. For example, the peptides often do not include amino acids at positions 1, 3, 6 and/or 7 for peptides 9 amino acid peptides in length or positions 1, 3, 4, 5, 7, 8 and/or 9 for peptides 10 amino acids in length. Further, defined herein are positions within a peptide sequence that can be utilized as criteria for selecting HLA-binding peptide. These defined positions are often referred to herein as a binding “motif.”

Definition of motifs specific for different MHC alleles allows the identification of potential peptide epitopes from an antigenic protein whose amino acid sequence is known. Typically, identification of potential peptide epitopes is initially carried out using a computer to scan the amino acid sequence of a desired antigen for the presence of motifs. The epitopic sequences are then synthesized.

In general, class I peptide binding motifs generally include a first conserved residue at position two from the N-terminus (wherein the N-terminal residue is position one) and a second conserved residue at the C-terminal position (often position 9 or 10). As a specific example, the HLA A*0201 class I peptide binding motifs include a first conserved residue at position two from the N-terminus (wherein the N-terminal residue is position one) selected from the group consisting of I, V, A and T and a second conserved residue at the C-terminal position selected from the group consisting of V, L, I, A and M. Alternatively, the peptide may have a first conserved residue at the second position from the N-terminus (wherein the N-terminal residue is position one) selected from the group consisting of L, M, I, V, A and T; and a second conserved residue at the C-terminal position selected from the group consisting of A and M. If the peptide has 10 residues it will contain a first conserved residue at the second position from the N-terminus (wherein the N-terminal residue is position one) selected from the group consisting of L, M, I, V, A, and T; and a second conserved residue at the C-terminal position selected from the group consisting of V, I, L, A and M; wherein the first and second conserved residues are separated by 7 residues.

One embodiment of an HTL-inducing peptide is less than about 50 residues in length and usually consist of between about 6 and about 30 residues, more usually between about 12 and 25, and often between about 15 and 20 residues, for example 15, 16, 17, 18, 19, or 20 residues. One embodiment of an CTL-inducing peptide is 13 residues or less in length and usually consists of about 8, 9, 10 or 11 residues, preferably 9 or 10 residues. In one embodiment, HLA-DR3 a binding is characterized by an L, I, V, M, F or Y residue at position 1 and a D or E residue at position 4. In another embodiment, HLA-DR3 b binding is characterized by an L, I, V, M, F, Y or A residue at position 1, a D, E, N, Q, S or T residue at position 4, and a K, R or H residue at position 6. In another embodiment, key anchor residues of a DR supertype binding motif are an L, I, V, M, F, W or Y residue at position 1 and an L, I, V, M, S, T, P, C or A residue at position 6. See table 5. TABLE 5 HLA-DR motifs Anchor residues of HLA-DR core motifs p1 p4 p6 DR supertype LIVMFWY — LIVMSTPCA DR3 a LIVMFY DE — DR3 b LIVMFYA DENQST KRH

Moreover, in another embodiment, murine Db binding is characterized by an N residue at position 5 and L, I, V or M residue at the C-terminal position. In yet another embodiment, murine Kb binding is characterized by a Y or F residue at position 5 and an L, I, V or M residue at the C-terminal position. In an additional embodiment, murine Kd binding is characterized a Y or F residue at position 2 and an L, I, V, or M residue at the C-terminal position. In a further embodiment, murine Kk binding is characterized by an E or D residue at position 2 and an L, I, M, V, F, W, Y or A residue at the C-terminal position. In a further embodiment, murine Ld binding is characterized by a P residue at position 2 and an L, I, M, V, F, W or Y residue at the C-terminal position. See Table 6. TABLE 6 Murine Class I Motifs Anchor residues of mouse class I motifs Allele p2 p3 p5 C terminus Db — — N LIVM Dd G P — LVI Kb — — YF LIVM Kd YF — — LIVM Kk ED — — LIMVA Ld P — — LIMVFWY

The peptides present in the invention can be identified by any suitable method. For example, peptides are conveniently identified using the algorithms of the invention described in the co-pending U.S. patent application Ser. No. 09/894,018. These algorithms are mathematical procedures that produce a score which enables the selection of immunogenic peptides. Typically one uses the algorithmic score with a binding threshold to enable selection of peptides that have a high probability of binding at a certain affinity and will in turn be immunogenic. The algorithm are based upon either the effects on MHC binding of a particular amino acid at a particular position of a peptide or the effects on binding MHC of a particular substitution in a motif containing peptide.

Peptide sequences characterized in molecular binding assays and capture assays have been and can be identified utilizing various technologies. Motif-positive sequences are identified using a customized application created at Epimmune. Sequences are also identified utilizing matrix-based algorithms, and have been used in conjunction with a “power” module that generates a predicted 50% inhibitory concentration (PIC) value. These latter methods are operational on Epimmune's HTML-based Epitope Information System (EIS) database. All of the described methods are viable options in peptide sequence selection for IC₅₀ determination using binding assays.

Additional procedures useful in identifying the peptides of the present invention generally follow the methods disclosed in Falk et al., Nature 351:290 (1991). Briefly, the methods involve large-scale isolation of MHC class I molecules, typically by immunoprecipitation or affinity chromatography, from the appropriate cell or cell line. Examples of other methods for isolation of the desired MHC molecule equally well known to the artisan include ion exchange chromatography, lectin chromatography, size exclusion, high performance liquid chromatography, and a combination of some or all of the above techniques.

For example, isolation of peptides bound to MHC class I molecules include lowering the culture temperature from 37° C. to 26° C. overnight to destabilize β₂ microglobulin and stripping the endogenous peptides from the cell using a mild acid treatment. The methods release previously bound peptides into the extracellular environment allowing new exogenous peptides to bind to the empty class I molecules. The cold-temperature incubation method enables exogenous peptides to bind efficiently to the MHC complex, but requires an overnight incubation at 26° C. which may slow the cell's metabolic rate. It is also likely that cells not actively synthesizing MHC molecules (e.g., resting PBMC) would not produce high amounts of empty surface MHC molecules by the cold temperature procedure.

Immunoprecipitation is also used to isolate the desired allele. A number of protocols can be used, depending upon the specificity of the antibodies used. For example, allele-specific mAb reagents can be used for the affinity purification of the HLA-A, HLA-B, and HLA-C molecules. Several mAb reagents for the isolation of HLA-A molecules are available (Table 5). Monoclonal antibody BB7.2 is suitable for isolating HLA-A2 molecules. Thus, for each of the targeted HLA-A alleles, reagents are available that may be used for the direct isolation of the HLA-A molecules. Affinity columns prepared with these mAbs using standard techniques are successfully used to purify the respective HLA-A allele products.

In addition to allele-specific mAbs, broadly reactive anti-HLA-A, B, C mAbs, such as W6/32 and B9.12.1, and one anti-HLA-B, C mAb, B1.23.2, could be used in alternative affinity purification protocols as described in patents and patent applications described herein. TABLE 7 HLA CLASS I MHC MOLECULES Ab utilized HLA-A, B for Capture Allele Cell Lines assay A*0101 Steinlin, MAT W6/32 A*2601 Pure Protein, QBL W6/32 A*2902 Sweig, Pure Protein, Pitout W6/32 A*3002 DUCAF, Pure Protein W6/32 A*2301 Pure Protein, WT51 W6/32 A*2402 KT3, Pure Protein, KAS116 W6/32 A*0201 JY, OMW W6/32 A*0202 M7B W6/32 A*0203 FUN W6/32 A*0205 DAH W6/32 A*0206 CLA W6/32 A*0207 AP W6/32 A*6802 AMAI W6/32 A*0301 GM3107 W6/32 A*1101 BVR W6/32 A*3101 SPACH, OLL W6/32 A*3301 LWAGS W6/32 A*6801 CIR, 2F7 W6/32 B*0702 GM3107, JY W6/32 B*3501 CIR, BVR W6/32 B*5101 KAS116 W6/32 B*5301 AMAI W6/32 B*5401 KT3 W6/32 B*1801 DUCAF W6/32 B*4001 2F7 W6/32 B*4002 Sweig W6/32 B*4402 WT47 B1.23.1 B*4403 Pitout B1.23.1 B*4501 OMW W6/32 A*3201 Pure Protein, WT47 W6/32

The peptides bound to the peptide binding groove of the isolated MHC molecules are typically eluted using acid treatment. Peptides can also be dissociated from MHC molecules by a variety of standard denaturing means, such as, for example, heat, pH, detergents, salts, chaotropic agents, or a combination acid treatment and/or more standard denaturing means.

Peptide fractions are further separated from the MHC molecules by reversed-phase high performance liquid chromatography (HPLC) and sequenced. Peptides can be separated by a variety of other standard means well known to the artisan, including filtration, ultrafiltration, electrophoresis, size chromatography, precipitation with specific antibodies, ion exchange chromatography, isoelectrofocusing, and the like.

Sequencing of the isolated peptides can be performed according to standard techniques such as Edman degradation (Hunkapiller, M. W., et al., Methods Enzymol. 91, 399 (1983)). Other methods suitable for sequencing include mass spectrometry sequencing of individual peptides as previously described (Hunt, et al., Science 225:1261 (1992)). Amino acid sequencing of bulk heterogeneous peptides (e.g., pooled HPLC fractions) from different MHC molecules typically reveals a characteristic sequence motif for each MHC allele. A large number of cells with defined MHC molecules, particularly MHC Class I molecules, are known and readily available. For example, human EBV-transformed B cell lines have been shown to be excellent sources for the preparative isolation of class I and class II MHC molecules. Well-characterized cell lines are available from private and commercial sources, such as American Type Culture Collection (“Catalogue of Cell Lines and Hybridomas,” 6th edition (1988) Manassas, Va., U.S.A.); National Institute of General Medical Sciences 1990/1991 Catalog of Cell Lines (NIGMS) Human Genetic Mutant Cell Repository, Camden, N.J.; and ASHI Repository, Brigham and Women's Hospital, 75 Francis Street, Boston, Mass. 02115. Table 5 lists some B cell lines suitable for use as sources for HLA alleles. All of these cell lines can be grown in large batches and are therefore useful for large scale production of MHC molecules. One of skill will recognize that these are merely exemplary cell lines and that many other cell sources can be employed. Specific cell lines and antibodies used to determine class II and murine peptides disclosed herein are set forth in Tables 8 and 9. TABLE 8 HLA Class II MHC molecules HLA-DR, DQ Ab utilized for Antigen Allele Cell Line Capture assay DR1 DRB1*0101 LG2 LB3.1 DR3 DRB1*0301 MAT LB3.1 DR4 DRB1*0401 PREISS LB3.1 DR4 DRB1*0404 BIN40 LB3.1 DR4 DRB1*0405 KT3 LB3.1 DR7 DRB1*0701 PITOUT, DBB LB3.1 DR8 DRB1*0802 OLL LB3.1 DR9 DRB1*0901 HID LB3.1 DR11 DRB1*1101 SWEIG LB3.1 DR12 DRB1*1201 HERLUF LB3.1 DR13 DRB1*1302 H0301 LB3.1 DR15 DRB1*1501 L466.1 LB3.1 DR52 DRB3*0101 MAT LB3.1 DR53 DRB4*0101 L257.6 LB3.1 DR51 DRB5*0101 GM3107, L416.3 LB3.1 DQ7 DQA1*0301/B*0301 PF DQ2 DQA1*0501/B*0201 MAT, STEINLIN DQ8 DQA1*0301/B*0302 145b, PREISS, YAR

TABLE 9 Murine MHC molecules MHC Ab utilized for class Allele Cell Line Capture Assay I Db EL4 I Db P815 I Kb EL4 I Kd P815 I Kk CH27 Y3 I Ld P815 II IAb DB27.4 II IAd A20 II IAk CH12 II IAs LS102.9 II IAu 91.7 II IEd A20 II IEk CH12

The peptides of the invention can be prepared synthetically, or by recombinant DNA technology or from natural sources such as whole viruses or tumors. Although the peptide will preferably be substantially free of other naturally occurring host cell proteins and fragments thereof, in some embodiments the peptides can be synthetically or naturally conjugated to native protein fragments or particles. The peptides of the invention can be prepared in a wide variety of ways. Because of their relatively short size, the peptides can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2d. ed., Pierce Chemical Co. (1984), supra.

B. MHC Binding Assays

The capacity to bind MHC molecules is measured in a variety of different ways. One means is a MHC binding assay as described in the related applications, noted above. Other alternatives described in the literature include inhibition of antigen presentation (Sette, et al., J. Immunol. 141:3893 (1991), in vitro assembly assays (Townsend, et al., Cell 62:285 (1990), and FACS based assays using mutated cells, such as RMA. S (Melief, et al., Eur. J. Immunol. 21:2963 (1991)).

Capture Assay: Unlike the HPLC-based molecular binding assay, noted above, the high throughput screening (“HTS”) Capture assay does not utilize a size-exclusion silica column for separation of bound from unbound radioactive marker. Instead, wells of an opaque white 96-well Optiplate (Packard) are coated with 3 μg (100 μl @ 30 μg/ml) of HLA-specific antibody (Ab) that “capture” complexes of radiolabeled MHC and unlabeled peptide transferred from the molecular binding assay plate in 100 μl of 0.05% NP40/PBS. After a 3-hour incubation period, the supernatant is decanted and scintillation fluid (Microscint 20) added. Captured complexes are then measured on a microplate scintillation and luminescence counter (TopCount NXTTM; Packard).

Additional assays for determining binding are described in detail, e.g., in PCT publications WO 94/20127 and WO 94/03205. Binding data results are often expressed in terms of IC₅₀ value. IC₅₀ is the concentration of peptide in a binding assay at which 50% inhibition of binding of a reference peptide occurs. Given the conditions in which the assays are performed (e.g., limiting MHC proteins and labeled peptide concentrations), these values approximate K_(D) values. It should be rioted that IC₅₀ values can change, often dramatically, if the assay conditions are varied, and depending on the particular reagents used (e.g., MHC preparation, etc.). For example, excessive concentrations of MHC molecules will increase the apparent measured IC₅₀ of a given ligand. Alternatively, binding is expressed relative to a reference peptide. Although as a particular assay becomes more, or less, sensitive, the IC₅₀'s of the peptides tested may change somewhat, the binding relative to the reference peptide will not significantly change. For example, in an assay preformed under conditions such that the IC₅₀ of the reference peptide increases 10-fold, the IC₅₀ values of the test peptides will also increase approximately 10-fold. Therefore, to avoid ambiguities, the assessment of whether a peptide is a good, intermediate, weak, or negative binder is generally based on its IC₅₀, relative to the IC₅₀ of a standard peptide.

Binding may also be determined using other assay systems including those using: live cells (e.g., Ceppellini et al., Nature 339:392, 1989; Christnick et al., Nature 352:67, 1991; Busch et al., Int. Immunol. 2:443, 19990; Hill et al., J. Immunol. 147:189, 1991; del Guercio et al., J. Immunol. 154:685, 1995), cell free systems using detergent lysates (e.g., Cerundolo et al., J. Immunol. 21:2069, 1991), immobilized purified MHC (e.g. Hill et al., J. Immunol. 152, 2890, 1994; Marshall et al., J. Immunol. 152:4946, 1994), ELISA systems (e.g., Reay et al., EMBO J. 11:2829, 1992), surface plasmon resonance (e.g., Khilko et al., J. Biol. Cheni. 268:15425, 1993); high flux soluble phase assays (e.g., Hammer et al., J. Exp. Med. 180:2353, 1994), and measurement of class I MHC stabilization or assembly (e.g., Ljunggren et al., Nature 346:476, 1990; Schumacher et al., Cell 62:563, 1990; Townsend et al., Cell 62:285, 1990; Parker et al., J. Immunol. 149:1896, 1992).

High affinity with respect to HLA class I molecules is defined as binding with an IC₅₀, or K_(D) value, of 50 nM or less; intermediate affinity with respect to HLA class I molecules is defined as binding with an IC₅₀ or K_(D) value of between about 50 and about 500 nM. High affinity with respect to binding to HLA class II molecules is defined as binding with an IC₅₀ or K_(D) value of 100 nM or less; intermediate affinity with respect to binding to HLA class II molecules is defined as binding with an IC₅₀ or K_(D) value of between about 100 and about 1000 nM. These values are as previously defined in the related patents and applications cited above.

C. Peptide Compositions

The polypeptides or peptides of the invention can be a variety of lengths, either in their neutral (uncharged) forms or in forms which are salts, and either free of modifications such as glycosylation, side chain oxidation, or phosphorylation or containing one or more of these modifications, subject to the condition that the modification not destroy the biological activity of the polypeptides as herein described.

Desirably, the peptide will be as small as possible while still maintaining substantially all of the biological activity of the large peptide. In one embodiment, it may be desirable to optimize peptides of the invention to a length of 9 or 10 amino acid residues, commensurate in size with endogenously processed viral peptides or tumor cell peptides that are bound to MHC class I molecules on the cell surface. In another embodiment, it may be desirable to optimize peptides of the invention to about 15 to 20 amino acid residues, commensurate with peptides that are bound to MHC class II molecules on the cell surface.

Peptides having the desired activity may be modified as necessary to provide certain desired attributes, e.g., improved pharmacological characteristics, while increasing or at least retaining substantially all of the biological activity of the unmodified peptide to bind the desired MHC molecule and activate the appropriate T cell. For instance, the peptides may be subject to various changes, such as substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use, such as improved MHC binding. “Conservative substitution” refers to the replacement of an amino acid residue with another which is biologically and/or chemically similar, e.g., one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as Gly, Ala; Val, Ile, Leu, Met; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. The effect of single amino acid substitutions may also be probed using D-amino acids. Such modifications may be made using well known peptide synthesis procedures, as described in e.g., Merrifield, Science 232:341-347 (1986), Barany and Merrifield, The Peptides, Gross and Meienhofer, eds. (N.Y., Academic Press), pp. 1-284 (1979); and Stewart and Young, Solid Phase Peptide Synthesis, (Rockford, Ill., Pierce), 2d Ed. (1984).

The peptides of the invention can also be modified by extending or decreasing the compound's amino acid sequence, e.g., by the addition or deletion of amino acids. The peptides or analogs of the invention can also be modified by altering the order or composition of certain residues, it being readily appreciated that certain amino acid residues essential for biological activity, e.g., those at critical contact sites or conserved residues, may generally not be altered without an adverse effect on biological activity. The non-critical amino acids need not be limited to those naturally occurring in proteins, such as L-α-amino acids, or their D-isomers, but may include non-natural amino acids as well, such as β-γ-δ-amino acids, as well as many derivatives of L-α-amino acids.

Typically, a series of peptides with single amino acid substitutions are employed to determine the effect of electrostatic charge, hydrophobicity, etc. on binding. For instance, a series of positively charged (e.g., Lys or Arg) or negatively charged (e.g., Glu) amino acid substitutions are made along the length of the peptide revealing different patterns of sensitivity towards various MHC molecules and T cell receptors. In addition, multiple substitutions using small, relatively neutral moieties such as Ala, Gly, Pro, or similar residues may be employed. The substitutions may be homo-oligomers or hetero-oligomers. The number and types of residues which are substituted or added depend on the spacing necessary between essential contact points and certain functional attributes which are sought (e.g., hydrophobicity versus hydrophilicity). Increased binding affinity for an MHC molecule or T cell receptor may also be achieved by such substitutions, compared to the affinity of the parent peptide. In any event, such substitutions should employ amino acid residues or other molecular fragments chosen to avoid, for example, steric and charge interference which might disrupt binding.

Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final peptide. Substitutional variants are those in which at least one residue of a peptide has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Table 10 when it is desired to finely modulate the characteristics of the peptide. TABLE 10 Original Exemplary Residue Substitution Ala Ser Arg Lys, His Asn Gln Asp Glu Cys Ser Gln Asn Glu Asp Gly Pro His Lys; Arg Ile Leu; Val Leu Ile; Val Lys Arg; His Met Leu; Ile Phe Tyr; Trp Ser Thr Thr Ser Trp Tyr; Phe Tyr Trp; Phe Val Ile; Leu Pro Gly

The peptides may also comprise isosteres of two or more residues in the MHC-binding peptide. An isostere as defined here is a sequence of two or more residues that can be substituted for a second sequence because the steric conformation of the first sequence fits a binding site specific for the second sequence. The term specifically includes peptide backbone modifications well known to those skilled in the art. Such modifications include modifications of the amide nitrogen, the α-carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone crosslinks. See, generally, Spatola, Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. VII (Weinstein ed., 1983).

Modifications of peptides with various amino acid mimetics or unnatural amino acids are particularly useful in increasing the stability of the peptide in vivo. Stability can be assayed in a number of ways. For instance, peptidases and various biological media, such as human plasma and serum, have been used to test stability. See, e.g., Verhoef et al., Eur. J. Drug Metab. Pharmacokin. 11:291-302 (1986). Half life of the peptides of the present invention is conveniently determined using a 25% human serum (v/v) assay. The protocol is generally as follows. Pooled human serum (Type AB, non-heat inactivated) is delipidated by centrifugation before use. The serum is then diluted to 25% with RPMI tissue culture media and used to test peptide stability. At predetermined time intervals a small amount of reaction solution is removed and added to either 6% aqueous trichloracetic acid or ethanol. The cloudy reaction sample is cooled (4° C.) for 15 minutes and then spun to pellet the precipitated serum proteins. The presence of the peptides is then determined by reversed-phase HPLC using stability-specific chromatography conditions.

The peptides of the present invention or analogs thereof which have CTL and/or HTL stimulating activity may be modified to provide desired attributes other than improved serum half life. For instance, the ability of the peptides to induce CTL activity can be enhanced by linkage to a sequence which contains at least one epitope that is capable of inducing a HTL response. Particularly preferred immunogenic peptides/T helper conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues, for example, 3, 4, 5 or 6 residues. Alternatively, the CTL peptide may be linked to the HTL peptide without a spacer. The immunogenic peptide may be linked to the HTL peptide either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the HTL peptide may be acylated. Exemplary HTL peptides include tetanus toxoid 830-843, influenza 307-319, malaria circumsporozoite 382-398 and 378-389.

In addition, additional amino acids can be added to the termini of a peptide to provide for ease of linking peptides one to another, for coupling to a carrier support, or larger peptide, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like. Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, can be introduced at the C- or N-terminus of the peptide or oligopeptide. Modification at the C-terminus in some cases may alter binding characteristics of the peptide. In addition, the peptide or oligopeptide sequences can differ from the natural sequence by being modified by terminal-NH₂ acylation, e.g., by alkanoyl (C₁-C₂₀) or thioglycolyl acetylation, terminal-carboxylamidation, e.g., ammonia, methylamine, etc. In some instances these modifications may provide sites for linking to a support or other molecule.

Alternatively, recombinant DNA technology may be employed wherein a nucleotide sequence which encodes an immunogenic peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression. These procedures are generally known in the art, as described generally in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1982). Thus, fusion proteins which comprise one or more peptide sequences of the invention can be used to present the appropriate T cell epitope.

As the coding sequence for peptides of the length contemplated herein can be synthesized by chemical techniques, for example, using the phosphotriester method of Matteucci et al., J. Am. Chem. Soc. 103:3185 (1981), with modification made simply by substituting the appropriate base(s) for those encoding the native peptide sequence. The coding sequence can then be provided with appropriate linkers and ligated into expression vectors commonly available in the art, and the vectors used to transform suitable hosts to produce the desired fusion protein. A number of such vectors and suitable host systems are now available. For expression of the fusion proteins, the coding sequence will be provided with operably linked start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for expression in the desired cellular host. For example, promoter sequences compatible with bacterial hosts are provided in plasmids containing convenient restriction sites for insertion of the desired coding sequence. The resulting expression vectors are transformed into suitable bacterial hosts. Of course, yeast or mammalian cell hosts may also be used, employing suitable vectors and control sequences that are well-known in the art.

The peptide compositions of this invention may encode an MHC epitope operably linked to a MHC targeting sequence. The use of a MHC targeting sequence enhances the immune response to an antigen, relative to delivery of antigen alone, by directing the peptide epitope to the site of MHC molecule assembly and transport to the cell surface, thereby providing an increased number of MHC molecule-peptide epitope complexes available for binding to and activation of T cells. MHC Class I targeting sequences can be used in the present invention, e.g., those sequences that target an MHC Class I epitope peptide to a cytosolic pathway or to the endoplasmic reticulum (see, e.g., Rammensee et al., Immunogenetics 41:178-228 (1995)). Such MHC Class I targeting sequences are well known in the art, and include, e.g., signal sequences such as those from Ig, tissue plasminogen activator or insulin. See, e.g., Bonnerot et al., Immunity 3:335-347 (1995). A preferred signal peptide is the human Ig kappa chain sequence. Endoplasmic reticulum signal sequences can also be used to target MHC Class II epitopes to the endoplasmic reticulum, the site of MHC Class I molecule assembly. MHC Class II targeting sequences can also be used in the invention, e.g., those that target a peptide to the endocytic pathway. These targeting sequences typically direct extracellular antigens to enter the endocytic pathway, which results in the antigen being transferred to the lysosomal compartment where the antigen is proteolytically cleaved into antigen peptides for binding to MHC Class II molecules. For example, a group of MHC Class II targeting sequences useful in the invention are lysosomal targeting sequences, which localize polypeptides to lysosomes. Lysosomal targeting sequences are well known in the art and include exemplary sequences as described in U.S. Pat. No. 5,633,234 and Copier et al., J. Immunol. 157:1017-1027 (1996).

Substantial changes in function (e.g., affinity for MHC molecules or T cell receptors) are made by selecting substitutions that are less conservative than those in Table 10, e.g., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in peptide properties will be those in which (a) a hydrophilic residue, e.g. seryl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a residue having an electropositive side chain, e.g., lys1, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (c) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.

Epitopes on any number of potential target proteins can be identified. Examples of suitable antigens include prostate specific antigen (PSA), prostate specific membrane antigen (PSM) hepatitis B virus core and surface antigens (HBVc, HBVs), hepatitis C antigens, malignant melanoma antigens (MAGE-1, MAGE-2, MAGE-3), Epstein-Barr virus antigens, human immunodeficiency type-1 virus (HIV-1), human immunodeficiency virus type-2 (HIV-2), papilloma virus antigens, Lassa virus, mycobacterium tuberculosis (MT) antigens, p53 and murine p53 (mp53) antigens, CEA, HER2/neu, and members of the tyrosine kinase related protein families (TKP). The peptides are thus useful in pharmaceutical compositions for both in vivo and ex vivo therapeutic and diagnostic applications.

D. Peptide Immunogenicity In Vitro and In Vivo

Peptides comprising the epitopes from these antigens are synthesized and then tested for their ability to bind to the appropriate MHC molecules in assays using, for example, purified MHC molecules and radioiodonated peptides and/or cells expressing empty MHC molecules by, for instance, immunofluorescent staining and flow microfluorometry, peptide-dependent class I assembly assays, and inhibition of CTL or HTL recognition by peptide competition. Those peptides that bind to the MHC molecule are further evaluated for their ability to serve as targets for CTLs and/or HTLs derived from infected or immunized individuals, as well as for their capacity to induce primary in vitro or in vivo T cell responses that can give rise to CTL and/or HTL populations capable of reacting with virally infected target cells or tumor cells as potential therapeutic agents.

Since mutant cell lines do not exist for every human MHC allele, it is advantageous to use various techniques to remove endogenous MHC-associated peptides from the surface of antigen presenting cell (APC) (e.g., mild acid treatment) followed by loading the resulting empty MHC molecules with the immunogenic peptides of interest. Antigen-presenting cells can be normal cells such as peripheral blood mononuclear cells or dendritic cells (Inaba, et al., J. Exp. Med. 166:182 (1987); Boog, Eur. J. Immunol. 18:219 (1988)). The use of non-transformed (non-tumorigenic), non-infected cells, and preferably, autologous cells of patients as the source of APC is desirable for the design of T cell induction protocols directed towards development of ex vivo CTL and/or HTL therapies.

Alternatively, mutant mammalian cell lines that are deficient in their ability to load class I molecules with internally processed peptides, such as the mouse cell lines RMA-S (Karre, et al., Nature, 319:675 (1986); Ljunggren, et al., Eur. J. Immunol. 21:2963-2970 (1991)), and the human somatic T cell hybrid, T-2 (Cerundolo, et al., Nature 345:449-452 (1990)) and which have been transfected with the appropriate human class I genes are conveniently used, when peptide is added to them, to test for the capacity of the peptide to induce in vitro primary CTL responses. Other eukaryotic cell lines which could be used include various insect cell lines such as mosquito larvae (e.g., ATCC cell lines CCL 125, 126, 1660, 1591, 6585, 6586), silkworm (e.g., ATTC CRL 8851), armyworm (e.g., ATCC CRL 1711), moth (e.g., ATCC CCL 80) and Drosophila cell lines (e.g., a Schneider cell line (see Schneider, J. Embryol. Exp. Morphol., 27:353-365 (1927))).

Specificity and MHC restriction of the CTL or HTL is determined by testing against different peptide target cells expressing appropriate or inappropriate MHC molecules. The peptides that test positive in the MHC binding assays and give rise to specific CTL and/or HTL responses are referred to herein as immunogenic peptides.

Analyses of CTL and HTL responses against the immunogen, as well as against common recall antigens are commonly used and are known in the art. Assays employed included chromium release, lymphokine secretion and lymphoproliferation assays. Assays useful in these determinations are described in Current Protocols in Immunology, J. E. Coligan, et al., eds., John Wiley & Sons Press (2000), chapters 3, 4, 6, and 7.

In one embodiment, the appropriate antigen-presenting cells are incubated with 10-100 μM of peptide in serum-free media for 4 hours under appropriate culture conditions. The peptide-loaded antigen-presenting cells are then incubated with the responder cell populations in vitro for 7 to 10 days under optimized culture conditions. If screening for MHC class I presented peptides, positive CTL activation can be determined by assaying the cultures for the presence of CTLs that kill radiolabeled target cells, both specific peptide-pulsed targets as well as target cells expressing the endogenously processed form of the relevant virus or tumor antigen from which the peptide sequence was derived. If screening for MHC class II-presented peptides, positive HTL activation can be determined by assaying cultures for cytokine production or proliferation.

In one embodiment, prior to incubation of the stimulator cells with the cells to be activated, e.g., precursor CD8+ cells, an amount of antigenic peptide is added to the stimulator cell culture, of sufficient quantity to become loaded onto the human Class I molecules to be expressed on the surface of the stimulator cells. In the present invention, a sufficient amount of peptide is an amount that will allow about 200, and preferably 200 or more, human Class I MHC molecules loaded with peptide to be expressed on the surface of each stimulator cell. Preferably, the stimulator cells are incubated with >20 μg/ml peptide.

Resting or precursor CD8+ cells are then incubated in culture with the appropriate stimulator cells for a time period sufficient to activate the CD8+ cells. Preferably, the CD8+ cells are activated in an antigen-specific manner. The ratio of resting or precursor CD8+ (effector) cells to stimulator cells may vary from individual to individual and may further depend upon variables such as the amenability of an individual's lymphocytes to culturing conditions and the nature and severity of the disease condition or other condition for which the within-described treatment modality is used. Preferably, however, the lymphocyte:stimulator cell ratio is in the range of about 30:1 to 300:1. The effector/stimulator culture may be maintained for as long a time as is necessary to stimulate a therapeutically useable or effective number of CD8+ cells.

The peptides of the invention can be identified and tested for in vivo immunogenicity using HLA transgenic mice. The utility of HLA transgenic mice for the purpose of epitope identification (Sette et al., J Immunol, 153:5586-92 (1994); Wentworth et al., Int Immunol, 8:651-9 (1996); Engelhard et al., J Immunol, 146:1226-32 (1991); Man et al., Int Immunol, 7:597-605 (1995); Shirai et al., J Immunol, 154:2733-42 (1995)), and vaccine development (Ishioka et al., J Immunol, 162:3915-25 (1999)) has been established. Most of the published reports have investigated the use of HLA A2.1/K^(b) mice but it should be noted that B*27, and B*3501 mice are also available. Furthermore, HLA A*11/K^(b) mice (Alexander et al., J. Immunol., 159:4753-61 (1997)), and HLA B7/K^(b) and HLA A1/K^(b) mice have also been generated. Data from 38 different potential epitopes was analyzed to determine the level of overlap between the A2.1-restricted CTL repertoire of A2.1/K^(b)-transgenic mice and A2.1+humans (Wentworth et al., Eur J Immunzol, 26:97-101 (1996)). In both humans and mice, an MHC peptide binding affinity threshold of approximately 500 nM correlates with the capacity of a peptide to elicit a CTL response in vivo. A high level of concordance between the human data in vivo and mouse data in vivo was observed for 85% of the high-binding peptides, 58% of the intermediate binders, and 83% of the low/negative binders. Similar results were also obtained with HLA A11 and HLA B7 transgenic mice (Alexander et al., J Immunol, Vol. 159(10):4753-61 (1997)). Thus, because of the extensive overlap that exists between T cell receptor repertoires of HLA transgenic mouse and human CTLs, transgenic mice are valuable for assessing immunogenicity of the multi-epitope constructs described herein. Peptides binding to MHC class II alleles can be examined using HLA-DR transgenic mice. See, e.g., Taneja V., David C. S., Immunol Rev, 169:67-79 (1999)).

More sensitive techniques such as the ELISPOT assay, intracellular cytokine staining, and tetramer staining have become available in the art to determine lymphocyte antigen responsiveness. It is estimated that these newer methods are 10- to 100-fold more sensitive than the common CTL and HTL assays (Murali-Krishna et al., Immunity, 8:177-87 (1998)), because the traditional methods measure only the subset of T cells that can proliferate in vitro, and may, in fact, be representative of only a fraction of the memory T cell compartment (Ogg G. S., McMichael A. J., Curr Opin Immunol, 10:393-6 (1998)). Specifically in the case of HIV, these techniques have been used to measure antigen-specific CTL responses from patients that would have been undetectable with previous techniques (Ogg et al., Science, 279:2103-6 (1998); Gray et al., J Immunol, 162:1780-8 (1999); Ogg et al., J Virol, 73:9153-60 (1999); Kalams et al., J Virol, 73:6721-8 (1999); Larsson et al., AIDS, 13:767-77 (1999); Come et al., J Acquir Immune Defic Syndr Hum Retrovirol, 20:442-7 (1999)).

The peptides of the present invention and pharmaceutical and vaccine compositions thereof are useful for administration to mammals, particularly humans, to treat and/or prevent viral infection and cancer. Examples of diseases which can be treated using the immunogenic peptides of the invention include prostate cancer, hepatitis B, hepatitis C, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV and chondyloma acuminatum. A protective (or prophylatic) vaccine includes one that will protect against future exposure to pathogen or cancer. A therapeutic vaccine includes one that will ameliorate, attenuate, or ablate symptoms or disease state induced by or related to a pathogen or malignancy.

In circumstances in which efficacy of a prophylactic vaccine is primarily correlated with the induction of a long-lasting memory response, restimulation assays can be the most appropriate and sensitive measures to monitor vaccine-induced immunological responses. Conversely, in the case of therapeutic vaccines, the main immunological correlate of activity can be the induction of effector T cell function, most aptly measured by primary assays. Thus, the use of sensitive assays allows for the most appropriate testing strategy for immunological monitoring of vaccine efficacy.

In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which primes CTL. Lipids have been identified as agents capable of priming CTL in vivo against viral antigens. The lipidated peptide can then be injected directly in a micellar form, incorporated into a liposome or emulsified in an adjuvant, e.g., incomplete Freund's adjuvant.

For pharmaceutical compositions, the immunogenic peptides of the invention are administered to an individual already suffering from cancer or infected with the virus of interest. Those in the incubation phase or the acute phase of infection can be treated with the immunogenic peptides separately or in conjunction with other treatments, as appropriate. In therapeutic applications, compositions are administered to a patient in an amount sufficient to elicit an effective CTL and/or HTL response to the virus or tumor antigen and to cure or at least partially arrest symptoms and/or complications. An amount adequate to accomplish this is defined as “therapeutically effective dose.” Amounts effective for this use will depend on, e.g., the peptide composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization (that is for therapeutic or prophylactic administration) from about 1.0 μg to about 5000 μg of peptide for a 70 kg patient, (e.g., 1.0 μg, 1.5 μg, 2.0 μg, 2.5 μg, 3.0 μg, 3.5 μg, 4.0 μg, 4.5 μg, 5.0 μg, 7.5 μg, 10 μg, 12.5 μg, 15 μg, 17.5 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 75 μg, 100 μg, 250 μg, 500 μg, 750 μg, 1000 μg, 1500 μg, 2000 μg, 2500 μg, 3000 μg, 3500 μg, 4000 μg, 4500 μg or 5000 μg), followed by boosting dosages of from about 1.0 μg to about 1000 μg of peptide (e.g., 1.0 μg, 2.0 μg, 2.5 μg, 3.0 μg, 3.5 μg, 4.0 μg, 4.5 μg, 5.0 μg, 7.5 μg, 10 μg, 12.5 μg, 15 μg, 17.5 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 75 μg, 100 μg, 250 μg, 500 μg, 750 μg, 1000 μg, 1500 μg, 2000 μg, 2500 μg, 3000 μg, 3500 μg, 4000 μg, 4500 μg or 5000 μg) pursuant to a boosting regimen over weeks to months depending upon the patient's response and condition by measuring specific T cell activity in the patient's blood. It must be kept in mind that the peptides and compositions of the present invention may generally be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions.

The peptide compositions can also be used for the treatment of chronic infection and to stimulate the immune system to eliminate virus-infected cells in carriers. It is important to provide an amount of immuno-potentiating peptide in a formulation and mode of administration sufficient to effectively stimulate an appropriate response. Thus, for treatment of chronic infection, a representative dose is in the range of about 1.0 μg to about 5000 μg, preferably about 5 μg to 1000 μg (e.g., 5.0 μg, 7.5 μg, 10 μg, 12.5 μg, 15 μg, 17.5 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 75 μg, 100 μg, 250 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 900 μg, 950 μg, or 1000 μg,) for a 70 kg patient per dose. Immunizing doses followed by boosting doses at established intervals, e.g., from one to four weeks, may be required, possibly for a prolonged period of time to effectively immunize an individual. In the case of chronic infection, administration should continue until at least clinical symptoms or laboratory tests indicate that the viral infection has been eliminated or substantially abated and for a period thereafter.

The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral or local administration. Preferably, the pharmaceutical compositions are administered parenterally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

A pharmaceutical composition of the invention may comprise one or more T cell stimulatory peptides of the invention. For example, a pharmaceutical composition may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more T cell stimulatory peptides of the invention. Moreover, a pharmaceutical composition of the invention may comprise one or more T cell stimulatory peptides of the invention in combination with one or more other T cell stimulatory peptides. The concentration of each unique T cell stimulatory peptide of the invention in the pharmaceutical formulations can vary widely, e.g., from less than about 0.001%, about 0.002%, about 0.003%, about 0.004%, about 0.005%, about 0.006%, 0.007%, 0.008%, 0.009%, about 0.01%, about 0.02%, about 0.025%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 20%, to about 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected. In a preferred embodiment, the concentration of each unique T cell stimulatory peptide of the invention in the pharmaceutical formulations is about 0.001%, about 0.002%, about 0.003%, about 0.004%, about 0.005%, about 0.006%, 0.007%, 0.008%, 0.009%, about 0.01%, about 0.02%, about 0.025%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1% by weight. In a more preferred embodiment, the concentration of each unique T cell stimulatory peptide of the invention in the pharmaceutical formulations is about 0.01%, about 0.02%, about 0.025%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1% by weight.

The peptides of the invention may also be administered via liposomes, which serve to target the peptides to a particular tissue, such as lymphoid tissue, or targeted selectively to infected cells, as well as increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to, e.g., a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the selected therapeutic/immunogenic peptide compositions. Liposomes for use in the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, each of which is incorporated herein by reference.

For targeting to the immune cells, a ligand to be incorporated into the liposome can include, e.g., antibodies or fragrnents thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.

For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.

For aerosol administration, the immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are 0.01%-20% by weight, preferably 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1%-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery.

In another aspect the present invention is directed to vaccines which contain as an active ingredient an immunogenically effective amount of an immunogenic peptide as described herein. The peptide(s) may be introduced into a host, including humans, linked to its own carrier or as a homopolymer or heteropolymer of active peptide units. Such a polymer has the advantage of increased immunological reaction and, where different peptides are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the virus or tumor cells. Useful carriers are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(lysine:glutamic acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine and the like. The vaccines can also contain a physiologically tolerable (acceptable) diluent such as water, phosphate buffered saline, or saline, and further typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant (“IFA”), aluminum phosphate, aluminum hydroxide, or alum are materials well known in the art. And, as mentioned above, CTL responses can be primed by conjugating peptides of the invention to lipids, such as P₃CSS. Upon immunization with a peptide composition as described herein, via injection, aerosol, oral, transdermal or other route, the immune system of the host responds to the vaccine by producing large amounts of CTLs specific for the desired antigen, and the host becomes at least partially immune to later infection, or resistant to developing chronic infection.

Vaccine compositions containing the peptides of the invention are administered to a patient susceptible to or otherwise at risk of viral infection or cancer to elicit an immune response against the antigen and thus enhance the patient's own immune response capabilities. Such an amount is defined to be an “immunogenically effective dose.” In this use, the precise amounts again depend on the patient's state of health and weight, the mode of administration, the nature of the formulation, etc., but generally range from about 1.0 μg to about 5000 μg per 70 kilogram patient, more commonly from about 10 μg to about 500 μg per 70 kg of body weight (e.g., 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 60 μg, 70 μg, 80 μg, 90 μg, 100 μg, 125 μg, 150 μg, 175 μg, 200 μg, 225 μg, 250 μg, 275 μg, 300 μg, 325 μg, 375 μg, 400 μg, 425 μg, 450 μg, 475 μg or 500 μg per 70 kg of body weight).

For therapeutic or immunization purposes, nucleic acids encoding one or more of the peptides of the invention can also be administered to the patient. A number of methods are conveniently used to deliver the nucleic acids to the patient. For instance, the nucleic acid can be delivered directly, as “naked DNA”. This approach is described, for instance, in Wolff et. al., Science 247: 1465-1468 (1990) as well as U.S. Pat. Nos. 5,580,859 and 5,589,466. The nucleic acids can also be administered using ballistic delivery as described, for instance, in U.S. Pat. No. 5,204,253. Particles comprised solely of DNA can be administered. Alternatively, DNA can be adhered to particles, such as gold particles. The nucleic acids can also be delivered complexed to cationic compounds, such as cationic lipids. Lipid-mediated gene delivery methods are described, for instance, in WO 96/18372; WO 93/24640; Mannino and Gould-Fogerite (1988) BioTechniques 6(7): 682-691; Rose U.S. Pat. No. 5,279,833; WO 91/06309; and Felgner et al. (1987) Proc. Natl. Acad. Sci. USA 84: 7413-7414. The peptides of the invention can also be expressed by attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into an acutely or chronically infected host or into a noninfected host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits a host CTL response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Pat. No. 4,722,848, incorporated herein by reference. Another suitable vector is BCG (Bacille Calmette Guerin). BCG vectors are described, e.g., in Stover, et al., (Nature 351:456-460 (1991)). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g., Salmonella typhi vectors and the like, will be apparent to those skilled in the art from the description herein.

A preferred means of administering nucleic acids encoding the peptides of the invention uses minigene constructs encoding multiple epitopes of the invention. To create a DNA sequence encoding the selected CTL epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes are reverse translated. A human codon usage table is used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences, including DNA sequence encoding a variety of spacers between none, some or all DNA sequence encoding peptides, are adjoined to create, a continuous polypeptide sequence. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequence that could be reverse translated and included in the minigene sequence include: helper T lymphocyte epitopes, a leader (signal) sequence, and an endoplasmic reticulum retention signal. In addition, MHC presentation of CTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL epitopes.

In some embodiments, a bicistronic expression vector, to allow production of the minigene-encoded epitopes and a second protein included to enhance or decrease immunogenicity can be used. Examples of proteins or polypeptides that could beneficially enhance the immune response if co-expressed include cytokines (e.g., IL2, IL12, GM-CSF), cytokine-inducing molecules (e.g., LeIF) or costimulatory molecules. Helper (HTL) epitopes could be joined to intracellular targeting signals and expressed separately from the CTL epitopes. This would allow direction of the HTL epitopes to a cell compartment different than the CTL epitopes. If required, this could facilitate more efficient entry of HTL epitopes into the MHC class II pathway, thereby improving CTL induction. In contrast to CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e.g., TGF-β) may be beneficial in certain diseases.

The immunogenic peptides of this invention may also be used to make monoclonal antibodies. Such antibodies may be useful as potential diagnostic or therapeutic agents.

The peptides are also useful as diagnostic reagents (e.g., tetramer reagents; Beckman Coulter, San Diego, Calif.). For example, a peptide of the invention may be used to determine the susceptibility of a particular individual to a treatment regimen which employs the peptide or related peptides, and thus may be helpful in modifying an existing treatment protocol or in determining a prognosis for an affected individual. In addition, the peptides may also be used to predict which individuals will be at substantial risk for developing chronic infection.

The present invention relates to the determination of allele-specific peptide motifs for human and murine MHC allele subtypes. These motifs are then used to define T cell epitopes from any desired antigen, particularly those associated with human viral diseases, cancers or autoimmune diseases, for which the amino acid sequence of the potential antigen or autoantigen targets is known. The contents of all documents cited above are expressly incorporated herein by reference.

Brief Description of Tables 11-29

Table 11. Identified HLA-A1 allele-binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., number of amino acids in peptide (AA), origin of peptide (organism), identity of originating protein, position of peptide within protein sequence, and analog status, wherein an analog is a peptide of the invention where the amino acid sequence of any naturally-occurring peptide sequence has been modified by substitution of one or more amino acid residues.

Table 12. Binding affinity of HLA-A1 binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., and binding affinity to the designated HLA-A1 alleles (expressed as an IC₅₀).

Table 13. Identified HLA-A2 allele-binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., number of amino acids in peptide (AA), origin of peptide (organism), identity of originating protein, position of peptide within protein sequence, and analog status, wherein an analog is a peptide of the invention where the amino acid sequence of any naturally-occurring peptide sequence has been modified by substitution of one or more amino acid residues.

Table 14. Binding affinity of HLA-A2 binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., and binding affinity to the designated HLA-A2 alleles (expressed as an IC₅₀).

Table 15. Identified HLA-A3 allele-binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., number of amino acids in peptide (AA), origin of peptide (organism), identity of originating protein, position of peptide within protein sequence, and analog status, wherein an analog is a peptide of the invention where the amino acid sequence of any naturally-occurring peptide sequence has been modified by substitution of one or more amino acid residues.

Table 16. Binding affinity of HLA-A3 binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., and binding affinity to the designated HLA-A3 alleles (expressed as an IC₅₀).

Table 17. Identified HLA-A24 allele-binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., number of amino acids in peptide (AA), origin of peptide (organism), identity of originating protein, position of peptide within protein sequence, and analog status, wherein an analog is a peptide of the invention where the amino acid sequence of any naturally-occurring peptide sequence has been modified by substitution of one or more amino acid residues.

Table 18. Binding affinity of HLA-A24 binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., and binding affinity to the designated HLA-A24 alleles (expressed as an IC₅₀).

Table 19. Identified HLA-B7 allele-binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., number of amino acids in peptide (AA), origin of peptide (organism), identity of originating protein, position of peptide within protein sequence, and analog status, wherein an analog is a peptide of the invention where the amino acid sequence of any naturally-occurring peptide sequence has been modified by substitution of one or more amino acid residues.

Table 20. Binding affinity of HLA-B7 binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., and binding affinity to the designated HLA-B7 alleles (expressed as an IC₅₀).

Table 21. Identified HLA-B44 allele-binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., number of amino acids in peptide (AA), origin of peptide (organism), identity of originating protein, position of peptide within protein sequence, and analog status, wherein an analog is a peptide of the invention where the amino acid sequence of any naturally-occurring peptide sequence has been modified by substitution of one or more amino acid residues.

Table 22. Binding affinity of HLA-B44 binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., and binding affinity to the designated HLA-B44 alleles (expressed as an IC₅₀).

Table 23. Identified HLA-DQ allele-binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., number of amino acids in peptide (AA), origin of peptide (organism), identity of originating protein, position of peptide within protein sequence, and analog status, wherein an analog is a peptide of the invention where the amino acid sequence of any naturally-occurring peptide sequence has been modified by substitution of one or more amino acid residues.

Table 24. Binding affinity of HLA-DQ binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., and binding affinity to the designated HLA-DQ alleles (expressed as an IC₅₀).

Table 25. Identified HLA-DR allele-binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., number of amino acids in peptide (AA), origin of peptide (organism), identity of originating protein, position of peptide within protein sequence, and analog status, wherein an analog is a peptide of the invention where the amino acid sequence of any naturally-occurring peptide sequence has been modified by substitution of one or more amino acid residues.

Table 26. Binding affinity of HLA-DR binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., and binding affinity to the designated HLA-DR alleles (expressed as an IC₅₀).

Table 27. Binding affinity of HLA-DR binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., and binding affinity to the designated HLA-DR alleles (expressed as an IC₅₀).

Table 28. Identified murine MHC class I allele-binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., number of amino acids in peptide (AA), origin of peptide (organism), identity of originating protein, position of peptide within protein sequence, and analog status, wherein an analog is a peptide of the invention where the amino acid sequence of any naturally-occurring peptide sequence has been modified by substitution of one or more amino acid residues.

Table 29. Binding affinity of murine MHC class I-binding peptides. Peptides are identified by amino acid sequence, SEQ ID NO., and binding affinity to the designated murine MHC class I alleles (expressed as an IC₅₀). TABLE 11 HLA-A1 SUPERTYPE SEQ ID Sequence NO. AA Organism Protein Position Analog AYGPGPGKF 9 Artificial Consensus A sequence AEIPYLAKY 9 Artificial pool A sequence consensus AADAAAAKY 9 Artificial PolyA sequence AYSSWMYSY 9 EBV EBNA3 176 LAEKTMKEY 9 FluA POL2 16 GTYDYWAGY 9 Gonorrhea LSVHSIQNDY 10 Gonorrhea DTGQCPELVY 10 Gonorrhea DLLDTASALY 10 HBV Core 419 WFHISCLTF 9 HBV NUC 102 LSLDVSAAFY 10 HBV pol 426 LSGPGPGAFY 10 HBV pol 426 A LSLGPGPGFY 10 HBV pol 426 A LSLDGPGPGY 10 HBV pol 426 A LTYGRKLHLY 10 HBV pol 1098 KTGPGPGHLY 10 HBV pol 1098 A KTYGPGPGLY 10 HBV pol 1098 A KTYGGPGPGY 10 HBV pol 1098 A KYTSFPWL 8 HBV pol 745 FAAPFTQCGY 10 HBV pol 631 SYQHFRKLLL 10 HBV pol 4 LYSHPIILGF 10 HBV pol 492 MS1TDLEAY 9 HBV X 103 MYVGGPGPGVF 11 HCV E1 275 A VMGSSYGF 8 HCV NS5 2639 EVDGVRLHRY 10 HCV NS5 2129 RTEILDLWVY 10 HIV NEF 182 A RQDILDLWVY 10 HIV NEF 182 A RTDILDLWYY 10 HIV NEF 182 A YTDGPGIRY 9 HIV NEF 207 A ATELHPEYY 9 HIV NEF 322 A DLWVYHTQGYY 11 HIV NEF 188 A WVYHTQGYY 9 HIV NEF 191 A FFLKEKGGF 9 HIV NEF 116 A LYVYHTQGY 9 HIV NEF 190 A ITKILYQSNPY 11 HIV REV 20 A KTLYQSNPY 9 HIV REV 22 A PVDPNLEPY 9 HIV TAT 3 A STVKHHMY 8 HIV VIF 23 A LSKISEYRHY 10 HPV E6 70 ISEYRHYNY 9 HPV E6 73 RFHNIRGRW 9 HPV E6 131 RPLSKISEY 9 HPV E6 68 RFHNISGRW 9 HPV E6 124 TLEKLTNTGLY 11 HPV E6 89 TLGPGPGTGLY 11 HPV E6 89 A TLEGPGPGGLY 11 HPV E6 89 A TLEKGPGPGLY 11 HPV E6 89 A TLEKLGPGPGY 11 HPV E6 89 A TLEKLTNTGLY 11 HPV E6 89 TLEKITNTELY 11 HPV E6 89 PYGVCIMCLRF 11 HPV E6 59 ITDIILECVY 10 HPV E6 30 A YSDISEYRHY 10 HPV E6 77 A LThIEITCVY 10 HPV E6 25 A YSDIRELRHY 10 HPV E6 72 A ELSSALEIPY 10 HPV E6 14 ETSSALEIPY 10 HPV E6 14 A ELDSALEIPY 10 HPV E6 14 A YTKVSEFRWY 10 HPV E6 70 A YSDVSEFRWY 10 HPV E6 70 A LThVSIACVY 10 HPV E6 25 A FTSRIRELRY 10 HPV E6 71 A YSDIRELRYY 10 HPV E6 72 A LTDLRLSCVY 10 HPV E6 26 A FTSKVRKYRY 10 HPV E6 72 A YSDVRKYRYY 10 HPV E6 73 A FYSKVSEFRF 10 HPV E6 69 A FYSRIRELRF 10 HPV E6 71 A PYAVCRVCLF 10 HPV E6 62 A ITEYRHYNY 9 HPV E6 73 A ISDYRHYNY 9 HPV E6 73 A ITEYRHYQY 9 HPV E6 73 A ISDYRHYQY 9 HPV E6 73 A LTDLLIRCY 9 HPV E6 99 A KTDQRSEVY 9 HPV E6 35 A AYRDLCIVY 9 HPV E6 53 A KYYSKISEY 9 HPV E6 75 A KFYSKISEF 9 HPV E6 75 A RYHNIRGRW 9 HPV E6 131 A RFHNTRGRF 9 HPV E6 131 A AYKDLFVVY 9 HPV E6 48 A LFVVYRDSF 9 HPV E6 52 A RYNNIAGHY 9 HPV E6 126 A RFHNIAGHF 9 HPV E6 126 A VYGTTLEKF 9 HPV E6 83 A AYADLTVVY 9 HPV E6 46 A AFADLTVVF 9 HPV E6 46 A RYLSKISEY 9 HPV E6 68 A RYHNISGRW 9 HPV E6 124 A AYKDLCIVY 9 HPV E6 48 A RYHSIAGQY 9 HPV E6 126 A RFHSIAGQF 9 HPV E6 126 A KYLFTDLRI 9 HPV E6 44 A KFLFTDLRF 9 HPV E6 44 A LYTDLRIVY 9 HPV E6 46 A LFTDLRIVF 9 HPV E6 46 A RFLSKISEF 9 HPV E6 68 A EYRHYQYSF 9 HPV E6 75 A RYHNIMGRW 9 HPV E6 124 A RFHNIMGRF 9 HPV E6 124 A NFACTELKF 9 HPV E6 47 A PYAVCRVCF 9 HPV E6 62 A LYYSKVRKY 9 HPV E6 71 A VYADLRIVY 9 HPV E6 46 A VFADLRIVF 9 HPV E6 46 A NYSLYGDTF 9 HPV E6 80 A RFHNISGRF 9 HPV E6 124 A FTDLTIVY 8 HPV E6 47 FTDLRIVY 8 HPV E6 47 TLEKLTNTGLY 11 HPV E6 89 LTDIEITGVY 10 HPV E6 25 A LTDVSIACVY 10 HPV E6 25 A ITDIILECVY 10 HPV E6 30 KTDQRSEVY 9 HPV B6 35 FTDLTIVY 8 HPV E6 47 YSDTRELRYY 10 HPV E6 72 A YTKVSEFRWY 10 HPV E6 70 A FTSRIRELRY 10 HPV E6 71 A FTSKVRKYRY 10 HPV E6 72 A ISDYRHYNY 9 HPV E6 73 A ISEYRHYQY 9 HPV E6 73 ISDYRHYQY 9 HPV E6 73 A EYRHYCYSLY 10 HPV E6 82 EYRHYNYSLY 10 HPV E6 75 LTDLLIRCY 9 HPV E6 99 ETRITYCYSLY 10 HPV E6 82 A EYDHYCYSLY 10 HPV E6 82 A KTRYYDYSVY 10 HPV E6 78 A KYDYYDYSVY 10 HPV E6 78 A ETRHYNYSLY 10 HPV E6 75 A EYDHYNYSLY 10 HPV E6 75 A PTLKEYVLDLY 11 HPV E7 6 HTDTPTLHEY 10 HPV E7 2 A RTETPTLQDY 10 HPV E7 2 A ETDPVDLLCY 10 HPV E7 20 A QTEQATSNYY 10 HPV E7 46 A ATDNYYIVTY 10 HPV E7 50 A LTEYVLDLY 9 HPV E7 8 A QTEQATSNY 9 HPV E7 46 A RQAKQHTCY 9 HPV E7 51 RTAKQHTCY 9 HPV E7 51 A HTDTPTLHEY 10 HPV E7 2 A RTETPTLQDY 10 HPV E7 2 A PTLKEYVLDLY 11 HPV E7 6 LTEYVLDLY 9 HPV E7 8 A QAEQATSNY 9 HPV E7 46 ATSNYYIVTY 10 HPV E7 50 ATDNYYIVTY 10 HPV E7 50 A RVLPPNWKY 9 Human 40s 132 riboprot S13 RLAHEVGWKY 10 Human 60s 139 ribo prot L13 A AYKKQFSQY 9 Human 60s 217 ribo prot L5 AADNPPAQY 9 Human CEA 261 A RSGPGPGNVLY 11 Human CEA 225 A RSDGPGPGVLY 11 Human CEA 225 A RSDSGPGPGLY 11 Human CEA 225 A RSDSVGPGPGY 11 Human CEA 225 A SLFVSNHAY 9 Human fructose 355 biphosphate- aldolase RWGLLLALL 9 Human Her2/neu 8 YTGPGPGVY 9 Human Jchain 102 A YTAGPGPGY 9 Human Jchain 102 A TQDLVQEKY 9 Human MAGE1 240 TQGPGPGKY 9 Human MAGE1 240 A TQDGPGPGY 9 Human MAGE1 240 A EVGPGPGLY 9 Human MAGE3 161 A EVDGPGPGY 9 Human MAGE3 161 A IYGPGPGLIF 10 Human MAGE3 195 A RISGVDRYY 9 Human NADH 53 ubiqoxido- reductase IMVLSFLF 8 Pf CSP 427 ALFQEYQCY 9 Pf CSP 18 LSEYYDXDIY 10 Pf 347 FQAAESNERY 10 Pf 13 ELEASISGKY 10 Pf 81 FVSSIFISFY 10 Pf 255 KVSDEIWNY 9 Pf 182 IMNHLMTLY 9 Pf 38 LIENELMNY 9 Pf 149 NVDQQNDMY 9 Pf 182 SSFFMNRFY 9 Pf 309 QAAESNERY 9 Pf 14 LEASISGKY 9 Pf 82 NLALLYGEY 9 Pf 188 SSPLFNNFY 9 Pf 14 QNADKNFLY 9 Pf 145 VSSIFISFY 9 Pf 256 SYKSSKRDKF 10 Pf 225 RYQDPQNYEL 10 Pf 21 DFFLKSKFNI 10 Pf 3 NYMKIMNHL 9 Pf 34 TYKKKNNHI 9 Pf 264 SFFMNRFYI 9 Pf 310 FYITTRYKY 9 Pf 316 KYINFINFI 9 Pf 328 TWKPTIFLL 9 Pf 135 KYNYFIHFF 9 Pf 216 HFFTWGTMF 9 Pf 222 RMTSLKNEL 9 Pf 61 YYNNFNNNY 9 Pf 77 GTDEXRNXY 9 Unknown Naturally A processed ETDXXXDRSEY 11 Unknown Naturally A processed FTDVNSXXRY 10 Unknown Naturally A processed VXDPYNXKY 9 Unknown Naturally A processed VADKVHXMY 9 Unknown Naturally A processed ETXXPDWSY 9 Unknown Naturally A processed XTHNXVDXY 9 Unknown Naturally A processed

TABLE 12 HLA-A1 SUPERTYPE SEQ ID Sequence NO. A*0101 A*2902 A*3002 AYGPGPGKF 44854 3.2 AEIPYLAKY 144 AADAAAAKY 20 AYSSWMYSY 4.9 LAEKTMKEY 174 GTYDYWAGY 141 LSVHSIQNDY 279 DTGQCPELVY 129 DLLDTASALY 74 37 WFHISCLTF 85324 95 75094 LSLDVSAAFY 267 12 7.1 LSGPGPGAIFY 25 1383 6.6 LSLGPGPGFY 21 132 8.2 LSLDGPGPGY 266 274 181 KTYGRKLHLY 171 27 1.5 KTGPGPGHLY 29 192 1.3 KTYGPGPGLY 5.7 227 0.96 KTYGGPGPGY 282 228 1.7 KYTSFPWL >172413 346 FAAPFTQCGY 461 1364 SYQHFRIKLLL >83333 28 3768 LYSHPIILGF 3166 109 1116 MSTTDLEAY 2565 396 MYVGGPGPGVF 89 2870 XTMGSSYGF 145 41967 EVDGVRLLTRY 14940 113 RTEJLDLWVY 99 10204 315 RQDILDLWvY 8995 13928 95 RTDILDLWVY 85 13424 360 YTDGPGIRY 11 562 7911 ATELHPEYY 43 6608 1734 DLWYYHTQGYY 5880 852 16 WVYHTQGYY 703 215 5.6 FFLKEKGGF 3015 141 LYVYHTQGY 216 258 ITKILYQSNPY >10060 64908 298 KTLYQSNPY 6912 1703 35 PVDPNLEPY 195 13193 7121 STVKHHMY 8132 1760 68 LSKISEYRIHY 14306 55190 186 ISEYRHYNY 25 1329 32 RFHNIRGRW 52917 18 58 RFLSKISEY >40322 34623 23 RFHNISGRW 48564 174 37 TLEKLTNTGLY 23 991 92 TLGPGPGTGLY 350 1320 7.4 TLEGPGPGGLY 11 2320 40 TLEKGPGPGLY 13 2036 40 TLEKLGPGPGY 269 4473 1962 TLEKLTNTGLY 77 5500 154 TLEKITNTELY 17 8402 3897 PYGVCIMCLRF 69 43722 ITDIILECVY 1.8 7660 505 YSDISEYRHY 3.8 1350 514 LTDIEITCVY 12 540 80 YSDIRELRHY 14 1137 740 ELSSALEIPY 171 6031 4472 ETSSALEIPY 19 12026 7144 ELDSALEIPY 38 82189 38284 YTKVSEFRWY 276 3308 420 YSDVSEFRWY 3.9 1842 1026 LTDVSIACVY 2.9 764 72 FTSRTRELRY 4.4 77 50 YSDIRELRYY 9.4 733 456 LTDLRLSCVY 45 1783 613 FTSKVRKYRY 64 6677 52 YSDVRKYRYY 19 849 794 FYSKVSEFRP 79 18453 FYSRIRELRF 83 12598 PYAVCRVCLF 407 5226 ITEYRHYNY 114 625 418 ISDYRHYNY 16 45 455 ITEYRHYQY 90 1030 526 ISDYRHYQY 13 37 382 LTDLLIRCY 13 6857 5515 KTDQRSEVY 84 200429 1174 AYRDLCIVY 7117 66 KYYSKISEY 702 1.3 KEYSKISEF 73339 306 RYHNIRGRW 122644 15 RFHINIRGRF 346 0.69 AYKDLFVVY 639 1.3 LFVVYRDSF 919 18 RYRNIAGHY 138 0.93 RFHMAGITF 635 1.4 VYGTTLEKF 75267 220 AYADLTVVY 136 9.3 AFADLTVVF 779 137 RYLSKISEY 4247 1.1 RYHNISGRW 104884 13 AYKDLCIVY 5205 29 RYHSIAGQY 544 1.4 RFHSIAGQF 481 1.2 KYLFTDLRI 78575 339 KFLFTDLRF 44 152 LYTDLR1VY 4.8 2.1 LFTDLRIVF 164 2649 RFLSKISEF 40103 201 EYRHYQYSF 13707 430 RYHMMGRW 106990 7.1 RFEINTMGRF 174 1.3 NFACTELKF 46 6826 PYAVCRVCF 5602 316 LYYSKVRKY 1452 28 VYADLRIVY 8.2 8.3 VFADLRIVF 87 24062 NYSLYGDTF 20945 64 RFHNISGRF 572 2.8 FTDLTIVY 16 1275 39043 FTDLRIVY 26 813 8060 TLEKLTNTGLY 174 LTDIEITCVY 33 LTDVSIACVY 57 ITDIILECVY 187 KTDQRSEVY 41 FTDLTIVY 34 YSDIIRELRYY 20 YTKVSEFRWY 204 FTSRIRELRY 25 FTSKVRKYRY 37 ISDYRHYNY 28 ISEYRHYQY 40 ISDYRHIYQY 28 EYRHIYCYSLY 125 198 3.7 BYRHYNYSLY 111027 956 12 LTDLLILRCY 64 ETRHYCYSLY 43 755 10 EYDHYCYSLY 110081 799 77 KTRYYDYSVY 2957 87841 0.71 KYDYYDYSVY 186339 5749 11 ETRHYNYSLY 445 5464 29 BYDHYNYSLY 11251 777 93 PTLKEYVLDLY 195 805 408 HTDTPTLHEY 20 1509 54 RTETPTLQDY 11 1987 239 BTDPVDLLCY 6.4 4110 52640 QTEQATSNYY 11 9576 500 ATDNYYIVTY 7.4 1918 65 LTEYVLDLY 6.0 941 81 QTEQATSNY 14 119081 3247 RQAKQHTCY >135135 155246 108 RTAKQHTCY 5647 130343 346 HTDTPTLHEY 30 RTETPTLQDY 40 PTLKEYVLDLY 426 LTEYVLDLY 8.0 QAEQATSNY 132 ATSNYYIVTY 428 ATDNYYIVTY 19 RVLPPNWKY 3.0 RLAHEVGWKY 3.8 AYKKQFSQY 5.3 AADNPPAQY 9.2 RSGPGPGNYLY 172 11270 6.3 RSDGPGPGVLY 12 13162 12 RSDSGPGPGLY 3.3 11856 4.2 RSDSVGPGPGY 23 31193 33 SLFVSNHAY 1.1 RWGLLLALL 61253 300 YTGPGPGVY 2.7 2015 6.4 YTAGPGPGY 7.0 28 755 TQDLVQEKY 57 33304 3796 TQGPGPGKY 4192 36746 3.2 TQDGPGPGY 381 37093 541 EVGPGPGLY 50 18183 45 EVDGPGPGY 29 25775 5766 IYGPGPGLIF 58 6845 RISGVDRYY 3.0 IMVLSFLF 111 30000 ALFQEYQCY >42016 149 1032 LSEYYDXD1Y 11 1647 489 FQAAESNERY 8958 1780 372 ELEASISGKY 142 21934 463 FVSSIFISFY 118 22 84 KVSDETWNY 435 230 1.9 IMNIILMTLY 150 1.7 1.8 LIENELMNY 412 3936 169 NVDQQNIDMY 47 22173 79057 SSFFMNRFY 239 36 7.5 QAAESNERY 353 24281 3011 LEASISGKY 57792 17824 87 NLALLYGEY 275 138 102 SSPLENNFY 117 389 73 QNADKNFLY 3811 24 663 VSSIFISFY 144 1800 55 SYKSSKRDKF 12594 88 RYQDPQNYEL 79717 189 DFFLKSKFNI 47714 491 NYMKIIVINHL 45443 110 TYKKKNNHI 21642 162 SFFMNRFYI 200 1022 FYITTRYKY 9.6 7.5 KYTNIFTNFI 25475 55 TWKPTIFLL 21155 306 KYNYFIIIFF 319 2.7 HFFTWGTMF 4.0 220 RMTSLKINEL 40270 14 YYNNFNNNY 19 34 GTDEXRNXY 0.67 ETDXXXDRSEY 2.0 FTDVNSXXRY 0.20 VXDPYNXKY 2.3 VADKVHXMY 2.4 ETXXPDWSY 11 XTHNXVDXY 1.4

TABLE 13 HLA-A2 SUPERTYPE SEQ ID Sequence NO. AA Organism Protein Position Analog FPFKYAAAV 9 Artificial A sequence AMAKAAAAV 9 Artificial PolyA sequence AMAKAAAAL 9 Artificial PolyA sequence AMAKAAAAT 9 Artificial PolyA sequence AXAKAAAAL 9 Artificial PolyA sequence FVYGGSKTSL 10 EBNA 508 ILGPGPGL 8 Flu M1 59 A GILGFVFTL 9 Flu M1 58 GLIYNRMGAV 10 FluA M1 129 VLMEWLKTRPI 11 FluA M1 41 FLPSDYFPSV 10 HBV Core 18 A FLGPGPGPSV 10 HBV core 18 A FLPGPGPGSV 10 HBV core 18 A FLPSGPGPGV 10 HBV core 18 A WLGPGPGFV 9 HBV env 335 A WLSGPGPGV 9 HBV env 335 A GVLGWSPQv 9 HBV env 62 A PVLPIFFCV 9 HBV env 377 A VVQAGFFLV 9 HBV env 177 A FLLAQFTSAI 10 HBV Pol 503 YLLTLWKAGI 10 HBV pol 147 YLGPGPGAGI 10 HBV pol 147 A YLLGPGPGGI 10 HBV pol 147 A YLLTGPGPGI 10 HBV pol 147 A HVYSHPIIV 9 HBV pol 1076 A FVLSLGIHV 9 HBV pol 562 A YVDDVVLGV 9 HBV pol 538 A IVRGTSFVYV 10 HBV pol 773 A SLGPGPGIAV 10 HIV env 814 A SLLGPGPGAV 10 HIV env 814 A SLLNGPGPGV 10 HIV env 814 A KITPLCVTL 9 HIV Env 134 A KLTPLCVTM 9 HIV Env 134 A KLTPLCVPL 9 HIV Env 134 A KLTPLCVSL 9 HIV Env 134 A KLTPLCITL 9 HIV Env 134 A QLTPLCVTL 9 HIV Env 134 A KLTPRCVTL 9 HIV Env 134 A ELTPLCVTL 9 HIV Env 134 A QMTFLCVQM 9 HIV Env 134 A KMTFLCVQM 9 HIV Env 134 A KLTPLCVAL 9 HIV Env 134 A KLTPFCVTL 9 HIV Env 134 A SLYNTVATL 9 HIV GAG 77 VLAEAMSQT 9 HIV Gag 386 A VLAEAMSQA 9 HIV Gag 386 A VLAEAMSQI 9 HIV Gag 386 A ILAEAMSQV 9 HIV Gag 386 A VLAEAMSKV 9 HIV Gag 386 A VLAEAMSHA 9 HIV Gag 386 A ILAEAMSQA 9 HIV Gag 386 A VLAEAMSRA 9 HIV Gag 386 A VLAEAMATA 9 HIV Gag 386 A ILAEAMASA 9 HIV Gag 386 A MTHNPPIPV 9 HIV Gag 271 A MTNNPPVPV 9 HIV Gag 271 A MTSNPPIPV 9 HIV Gag 271 A MTSNPPVPV 9 HIV Gag 271 A MTSDPPIPV 9 HIV Gag 271 A MTGNPPIPV 9 HIV Gag 271 A MTGNPPVPV 9 HIV Gag 271 A MTGNPAIPV 9 HIV Gag 271 A MTGNPSIPV 9 HIV Gag 271 A MTANPPVPV 9 HIV Gag 271 A SLYNTVATL 9 hiv gag 77 QAHONISRA 9 HIV gp160 332 FLKEKGGV 8 HIV NEF 117 A GLGAVSRDL 9 HIV NEF 45 A GLITSSNTA 9 HIV NEF 62 A ALEEEEVGFPV 11 HIV NEF 83 A FLKEKGGLEGV 11 HIV NEF 117 A FLKEKGGLDGV 11 HIV NEF 117 A GLIYSKKRQEV 11 HIV NEF 173 A LLYSKKRQEI 10 HIV NEF 174 A LLYSKKRQEIL 11 HIV NEF 174 A RLDILDLWV 9 HIV NEF 182 A EILDLWVYHV 10 HIV NEF 185 A ILDLWVYHV 9 HIV NEF 186 A ILDLWVYNV 9 HIV NEF 186 A WLNYTPGPGT 10 HIV NEF 204 A WQNYTPGPGV 10 HIV NEF 204 A WLNYTPGPGI 10 HIV NEF 204 A YLPGPGIRYPL 11 HIV NEF 207 A YTPGPGIRYPV 11 HIV NEF 207 A LLFGWCFKL 9 HIV NEF 221 A LTFGWCFKV 9 HIV NEF 221 A LLFGWCFKLV 10 HIV NEF 221 A FGVRPQVPL 9 HIV nef 84 A FTVRPQVPL 9 HIV nef 84 A FSVRPQVPL 9 HIV nef 84 A YLKEPVHGV 9 HIV pol 476 A FLKEPVHGV 9 HIV pol 476 PVPLQLPPV 9 HIV REV 74 A LQLPPLERV 9 HIV REV 77 A LLLPPLERLTL 11 HIV REV 77 A LQLPPLERLTV 11 HIV REV 77 A ILWQVDRM 8 HIV VIF 9 A KLGSLQYL 8 HIV VIF 146 A KVGSLQYV 8 HIV VIF 146 A TLHDLCQAV 9 HPV E6 11 A TLQDIVLHL 9 HPV E7 7 TLGPGPGHL 9 HPV E7 7 A TLQGPGPGL 9 HPV E7 7 A TLSFVCPWCV 10 HPV E7 94 A TLSFVCPWCA 10 HPV18 E7 93 RTLHDLCQA 9 HPV33 E6 10 TLHDLCQAL 9 HPV33 E6 11 YLSGADLNL 9 Human GEA 605 A YLEPGPVTA 9 Human gp100 280 LLDGTATLRL 10 Human gp100 457 KVYGLSAFV 9 Human Her2/neu 369 A IISAVVAIL 9 Human Her2/neu 654 A ILSAVVGIL 9 Human Her2/neu 654 A IISAVVGFL 9 Human Her2/neu 654 A IISAVVGIV 9 Human Her2/neu 654 A KISAVVGIL 9 Human Her2/neu 369 A KIFAVVGIL 9 Human Her2/neu 369 A KIFASVAIL 9 Human Her2/neu 369 A ELVSEFSRV 9 Human Her2/neu 971 A VLVHPQWVV 9 Human Kallikrein2 53 A VLVHPQWVLTV 11 Human Kallikrein2 53 A DLMLLRLSEPV 11 Human Kallikrein2 120 A PLVCNGVLQGV 11 Human Kallikrein2 216 A VLVHPQWVLTV 11 Human Kallikrein2 53 A PLVGNGVLQGV 11 Human Kallikrein2 216 A QLGPGPLMEV 11 Human MAGE3 159 A QLVGPGPGMEV 11 Human MAGE3 159 A QLVFGPGIGEV 11 Human MAGE3 159 A QLVFGGPGPGV 11 Human MAGE3 159 A ALGIGILTV 9 Human MART1 27 A AMGIGILTV 9 Human MART1 27 A LLWQPIPV 8 Human PAP 136 LLGPGPGV 8 Human PAP 136 A VLAKELKFVTL 11 Human PAP 30 VLGPGPGFVTL 11 Human PAP 30 A VLAGPGPGVTL 11 Human PAP 30 A VLAKGPGPGTL 11 Human PAP 30 A VLAKEGPGPGL 11 Human PAP 30 A TLMSAMTNV 9 Human PAP 112 A ILYSAHDTTV 10 Human PAP 384 A IVYSAHDTTV 10 Human PAP 284 A VTAKELKFV 9 Human PAP 30 A ITYSAHDTTV 10 Human PAP 284 A SLSLGFLFV 9 Human PAP SLSLGFLFLV 10 Human PAP LLALFPPEGV 10 Human PAP LVALFPPEGV 10 Human PAP ALFPPEGVSV 10 Human PAP GLHGQDLFGV 10 Human PAP LLPPYASCHV 10 Human PAP LLWQPIPVHV 10 Human PAP MLLRLSEPV 9 Human PSA 118 A ALGTTCYV 8 Human PSA 143 A VLRLFVCFLI 10 Pf 2 FLIFHFFLFL 10 Pf 9 LIFHFFLFLL 10 Pf 10 FLFLLYILFL 10 Pf 15 RLPVIGSFLV 10 Pf 32 VICSFLVFLV 10 Pf 35 FLVFLVFSNV 10 Pf 39 MMIMIKFMGV 10 Pf 62 FLLYILFLV 9 Pf 17 VICSFLVFL 9 Pf 35 ATYGIIVPV 9 Pf 159 KIYKIIIWI 9 Pf 9 YMIKKLLKI 9 Pf 23 LMTLYQIQV 9 Pf 42 FMGVIYIMI 9 Pf 68 FMNRFYITT 9 Pf 312 YQDPQNYEL 9 Pf 22 KTWKPTWL 9 Pf 134 LLNESNIFL 9 Pf 142 FTHFFTWGT 9 Pf 220 VLFLQMMNV 9 Pf 180 NQMIFVSSI 9 Pf 251 MIFVSSIFI 9 Pf 253 SIFISFYLI 9 Pf 258 RLFEESLGI 9 Pf 293 ALWGFFPVL 9 Unknown A2 A allo- epitope SVYDFFVWL 9 TRP2 180 FAPGFFPYL 9 QLFEDKYAL 9 MLLSVPLLL 9

TABLE 14 HLA-A2 SUPERTYPE SEQ ID Sequence NO. A*0201 A*0202 A*0203 A*0206 A*6802 FPFKYAAAV 92 AMAKAAAAV 181 196 6.7 1485 177 AMAKAAAAL 413 123 3.7 18500 320 AMAKAAAAT 15143 12413 84 37000 >26666.67 AXAKAAAAL >50000 469 3300 37000 >11428.57 FVYGGSKTSL 296 ILGPGPGL 672 45 530 1262 56099 GILGFVFTL 1.0 10 236 2.1 1395 GLIYNRMGAV 317 VLMEWLKTRPI 464 FLPSDYFPSV 8.5 3.3 3.2 2.2 276 FLGPGPGPSV 17 0.80 2.5 55 286 FLPGPGPGSV 98 18 4.0 665 332 FLPSGPGPGV 21 1.2 3.4 64 40 WLGPGPGFV 171 4.1 2.2 530 293 WLSGPGPGV 220 2.5 12 885 24 GVLGWSPQV 22 157 389 28 9428 PVLPIFFCV 8.7 3136 14286 22 1814 VVQAGFFLV 440 79 2503 81 617 FLLAQFTSAI 65 1.9 4.8 148 533 YLLTLWKAGI 20 19 20 40 1388 YLGPGPGAGI 161 1.0 4.2 548 315 YLLGPGPGGI 180 12 3.3 89 2064 YLLTGPGPGI 42 15 59 60 5678 HVYSHPIIV 150 1923 14 1199 123 FVLSLGIHV 45 399 2817 131 112 YVDDVVLGV 18 14 70 16 354 IYRGTSFVYV 50000 5301 69 5398 1217 SLGPGPGIAV 1131 5.3 11 917 281 SLLGPGPGAV 95 17 2.6 642 795 SLLNGPGPGV 65 3.8 14 63 45 KITPLCVTL 461 36 528 59 883 KLTPLCVTM 340 3.6 143 197 6288 KLTPLCVPL 15 0.25 297 135 67 KLTPLCVSL 67 2.4 240 16 5947 KLTPLCITL 1.7 0.27 23 1.7 9155 QLTPLCVTL 64 1.5 57 368 933 KLTPRCVTL 597 150 20 1554 >63492.06 ELTPLCVTL 7190 38 231 1919 32 QMTFLCVQM 3153 40 1127 232 1297 KMTFLCVQM 1793 22 525 100 8744 KLTPLCVAL 209 2.3 54 11 13009 KLTPFCVTL 87 0.37 28 78 11814 SLYNTVATL 290 6573 68 37000 20000 VLAEAMSQT 290 2.2 0.65 236 447 VLAEAMSQA 24 1.1 0.30 9.6 271 VLAEAMSQI 71 0.15 0.87 70 207 ILAEAMSQV 38 1.1 1.1 101 34 VLAEAMSKV 230 1.8 1.4 93 329 VLAEAMSHA 149 1.7 1.2 121 431 ILAEAMSQA 29 1.0 1.1 8.6 253 VLAEAMSRA 127 0.88 1.0 20 229 VLAEAMATA 6.7 1.4 0.73 8.6 33 ILAEAMASA 22 0.72 0.82 6.8 343 MTHNPPIPV 167 119 1.4 158 1.4 MTNNPPVPV 86 18 0.42 287 309 MTSNPPIPV 53 16 0.39 250 3.8 MTSNPPVPV 22 29 0.80 81 1.1 MTSDPPIPV 107 13 0.45 587 2.5 MTGNPPIPV 125 11 0.74 79 7.8 MTGNPPVPV 2021 158 23 35 0.84 MTGNPAIPV 1200 24 10 213 0.48 MTGNPSIPV 16 1.1 0.43 257 0.57 MTANPPVPV 20 5.0 0.62 134 4.0 SLYNTVATL 367 79 19 15072 247113 QAHCNISRA 338 FLKEKGGV 13327 653 267 >14341.09 >19464.72 GLGAVSRDL 18679 436 1733 >10393.26 >16666.67 GLITSSNTA 5800 102 64 7865 >14311.27 ALEEEEVGFPV 2420 487 15744 2988 >13793.1 FLKEKGGLEGV 322 3.5 6.8 739 1252 FLKEKGGLDGV 332 3.7 11 3207 3807 GLIYSKKRQEV 8971 57 152 >8564.81 >14260.25 LLYSKKRQEI 80687 382 152 >9438.78 >15686.27 LLYSKKRQEIL >38167.94 282 1569 >8564.81 >14260.25 RLDILDLWV 43 615 1639 2635 >17777.78 EILDLWVYHV 496 569 1865 2229 163 ILDLWVTYHV 17 30 156 145 7414 ILDLWVYNV 40 30 201 135 5814 WLNYTPGPGT 547 124 231 >31623.93 11808 WQNYTPGPGV 1175 114 230 223 11993 WLNYTPGPGI 135 4.6 46 >31623.93 1196 YLPGPGIRYPL 1026 20 1583 3497 782 YTPGPGIRYPV 7764 1985 11126 1112 9.2 LLFGWCFKL 18 4.1 198 340 1084 LTFGWCFKV 15 33 1168 187 9.7 LLFGWCFKLV 658 84 114 1669 3276 FGVRPQVPL 321 FTVRPQVPL 13 FSVRPQVPL 52 YLKEPVHGV 54 0.65 1.9 212 63 FLKEPVHGV 44 0.28 1.9 140 135 PVPLQLPPV 10047 >7337.88 12595 81 >15625 LQLPPLERV 7951 7705 13517 203 1786 LLLPPLERLTL 34 2607 9010 45 >12779.55 LQLPPLERLTV 159 4545 6270 52 >61068.7 ILWQVDRM 1745 67 2998 11332 >19464.72 KLGSLQYL 1862 14 298 9010 >19464.72 KVGSLQYV 1650 441 703 1904 17480 TLHDLCQAV 331 17 15 10585 2809 TLQDIVLHL 22 4.4 46 781 5088 TLGPGPGHL 14974 35 66 12144 27910 TLQGPGPGL 6248 62 951 9121 3809 TLSFVGPWGV 786 123 370 4357 388 TLSFVCPWCA 1611 221 521 27321 13228 RTLHDLCQA 8121 34 678 96 61604 TLHDLCQAL 1404 2.7 40 2182 70390 YLSGAIDLNL 36 4.9 9.2 1605 51227 YLEPGPVTA 466 10 27 20720 >470588.24 LLDGTATLRL 180 1.9 201 841 >421052.63 KVYGLSAFV 33 1.8 11 69 110 IISAVVAIL 1127 8.0 45 1440 148 ILSAVVGLL 1464 1.9 21 2539 11854 IISAVVGFL 747 1.0 4.8 234 77 IISAVVGIV 712 15 20 958 390 KISAVVGIL 6238 42 60 1752 4952 KIFAVVGIL 3957 38 34 1539 6659 KIFASVAIL 1062 16 21 1068 363 ELVSEFSRV 8178 969 53 197 23 VLVHPQWVV 464 65 1988 3224 14606 VLVHPQWVLTV 11 1.7 3.0 13 3288 DLMLLRLSEPV 69 66 32 118 2078 PLVCNGVLQGV 91 424 36 212 3532 VLVHPQWVLTV 11 1.5 16 31 8889 PLVCNGVLQGV 26 126 19 264 4211 QLGPGPGLMEV 194 9.4 29 481 648 QLVGPGPGMEV 865 17 19 919 223 QLVFGPGPGEV 2944 106 50 4067 447 QLVFGGPGPGV 2153 96 242 3207 1318 ALGIGILTV 11 AMGIGILTV 15 LLWQPIPV 137 2445 9.9 4251 32939 LLGPGPGV 25 49 123 93 5620 VLAKELKFVTL 1298 23 194 5170 15664 VLGPGPGFVTL 1528 13 63 4766 42136 VLAGPGPGVTL 1118 2.4 94 7200 2645 VLAKGPGPGTL 11256 26 344 11450 >170212.77 VLAKEGPGPGL 1890 6.9 37 59024 50993 TLMSAMTNV 636 14 35 2188 484 ILYSAHDTTV 397 1.1 13 1480 6285 IVYSAHDTTV 7643 91 627 356 737 VTAKELKFV 7143 2688 40 137 26667 ITYSAHDTTV 4167 115 238 154 82 SLSLGFLFV 77 25 21 93 26667 SLSLGFLFLV 1.9 3.9 17 42 348 LLALFPPEGV 5.0 0.73 1.6 148 163 LVALFPPEGV 156 17 4.8 463 28 ALFPPEGVSV 15 1.1 18 119 4444 GLHGQDLFGV 12 2.3 3.1 18 >80000 LLPPYASCHV 88 15 16 97 5333 LLWQPIPVTIV 25 1.8 18 285 62 MLLRLSEPV 47 29 48 689 433 ALGTTGYV 93 6.7 12 292 28284 VLRLFVCFLI 2744 2112 299 68226 45639 FLIFHFFLFL 161 174 2087 288 475 LIFHFFLFLL 200 1468 3167 1562 460 FLFLLYILFL 2834 172 2012 2113 8248 RLPVICSFLV 12 2.5 33 19 9176 VICSFLVFLV 167 415 2916 197 1949 FLVFLVFSNV 269 212 35 232 5393 MMIMIKFMGV 123 19 25 109 39 FLLYILFLV 346 279 3091 1801 6981 VICSFLVFL 184 19 2331 236 4800 ATYGIIVPV 3.2 2.0 2.8 5.0 21 KIYKIIIWI 157 1179 638 101 2198 YMIKKLLKI 105 4.6 4.7 93 63127 LMTLYQIQV 14 1.6 20 615 1276 FMGVIYIMI 13 2.1 26 98 14501 FMNRFYITT 101 18 13 996 6543 YQDPQNYEL 79 18 441 52 166775 KTWKPTIFL 135 1242 7487 76 3617 LLNESNIFL 43 2.5 24 143 4484 FIHFFTWGT 80 4.7 64 60 383 VLFLQMMNV 31 1.8 2.7 9.5 323 NQMIFVSSI 250 21 3.6 14 198 MTFVSSIFI 85 18 83 114 5.2 SIFISFYLI 289 35 1416 43 18 RLFEESLGI 26 1.9 5.5 68 418 ALWGFFPVL 3.6 0.74 3.7 15 1503 SVYDFFVWL 36 169 226 10 0.86 FAPGFFPYL 48 0.85 44 2.3 7.6 QLFEDKYAL 646 1.8 380 2009 2982 MLLSVPLLL 9.0 79 41 8.4 24607

TABLE 15 HLA-A3 SUPERTYPE SEQ ID Sequence NO. AA Organism Protein Position Analog ALNAAAAAK 9 Artificial Poly sequence ALAAGAAAK 9 Artificial Poly sequence ALQAAAAAK 9 Artificial Poly sequence STGPGPGVVRR 11 HBV core 141 A STLGPGPGVRR 11 HBV core 141 A STLPGPGPGRR 11 HBV core 141 A STLPEGPGPGR 11 HBV core 141 A QAGFFLLTR 9 HBV ENV 179 RVHFASPLH 9 HBV POL 818 AAYAAQGYK 9 HCV II 1247 KSKFGYGAK 9 HGV II 2551 PAAYAAQGYK 10 HCV II 1246 RMYVGGVEH 9 HCV IV 635 SQLSAPSLK 9 HCV IV 2209 TSCGNTLTCY 10 HCV NS5 2740 VTGPGPGPVWK 11 HIV env 48 A VTVGPGPGVWK 11 HIV env 48 A VTVYGPGPGWK 11 HIV env 48 A VTVYYGPGPGK 11 HIV env 48 A PVRPQVPLR 9 HIV NEF 95 HGAITSSNTK 10 HIV NEF 61 A AVDLSFFLK 9 HIV NEF 111 A DVSHFLKEK 9 HIV NEF 113 A GVLDGLIYSK 10 HIV NEF 124 A GVDGLIYSK 9 HIV NEF 125 A EILDLWVYK 9 HIV NEF 185 A ILDLWVYK 8 HIV NEF 186 A RVPLTFGWCFK 11 HIV NEF 216 A QVYTPGPGTR 10 HIV NEF 205 A AVGPGPGLK 9 HIV nef 84 A AVDGPGPGK 9 HIV nef 84 A QMGPGPGNFK 10 HIV pol 1432 A QMAGPGPGFK 10 HIV pol 1432 A QMAVGPGPGK 10 HIV pol 1432 A TVGPGPGPEK 10 HIV pol 935 A TVQGPGPGEK 10 HIV pol 935 A TVQPGPGPGK 10 HIV pol 935 A VAIKIGGQLK 10 HIV Pol 98 A VTVKIGGQLK 10 HIV Pol 98 A VTIKVGGQLK 10 HIV Pol 98 A VTIRIGGQLK 10 HIV Pol 98 A VTVRIGGQLK 10 HIV Pol 98 A VTVKVGGQLK 10 HIV Pol 98 A VTIRVGGQLK 10 HIV Pol 98 A VTVRVGGQLK 10 HIV Pol 98 A VTVKIGGQLR 10 HIV Pol 98 A VTIRIGGQLR 10 HIV Pol 98 A VTIKLGGQIR 10 HIV Pol 98 A VSIKVGGQIK 10 HIV Pol 98 A VSIRVGGQIK 10 HIV Pol 98 A VTVKIEGQLK 10 HIV Pol 98 A VTIKIEGQLK 10 HIV Pol 98 A VTVKIEGQLR 10 HIV Pol 98 A VSIRVGGQTK 10 HIV Pol 98 A VSIRVGGQTR 10 HIV Pol 98 A VTVRIGGMQK 10 HIV Pol 98 A ITVKIGKEVR 10 HIV Pol 98 A GTRQARRNK 9 HIV REV 36 A GTRQARRNRK 10 HIV REV 36 A GTRQARRNRK 11 HIV REV 36 A GTRQTRKNRK 9 HIV REV 37 A GTRQTRKNRK 10 HIV REV 37 A GTRQTRKNRRK 11 HIV REV 37 A RVRRRRWRAR 10 HIV REV 43 A KVRRRRWRAR 10 HIV REV 43 A LTISYGRK 8 HIV TAT 46 A KTLGISYGR 9 HIV TAT 44 A LTISYGRKK 9 HIV TAT 46 A GTSYGRIKR 9 HIV TAT 47 A GTGISYGRK 9 HIV TAT 45 A KTLGISYGRK 10 HIV TAT 44 A LTISYGRKKR 10 HIV TAT 46 A KTLGISYGRKK 11 HIV TAT 44 A TVCNNCYGK 9 HIV TAT 23 A LVISYGRKKRR 11 HIV TAT 46 A ISYGRKKRRQK 11 HIV TAT 48 A ETGPSGQPCK 10 HIV TAT 101 A KVGPGGYPRR 10 HIV TAT 101 A KAGPGGYPRK 10 HIV TAT 101 A KVGPGGYPRRK 11 HIV TAT 101 A AVPGGYPRR 9 HIV TAT 102 A AVPGGYPRRK 10 HIV TAT 102 A KVGSLQYLK 9 HIV VIF 146 A ETVRHFPR 8 HIV VPR 29 A AACHKCIDFY 10 HPV E6 63 LLIRCLRGQK 10 HPV E6 101 KISEYRHYNY 10 HPV E6 72 AVCRVCLLFY 10 HPV E6 64 FAFTDLTIVY 10 HPV E6 45 FAFADLTVVY 10 HPV E6 45 RFLSKISEYR 10 HPV E6 68 ILIRCIIGQR 10 HPV E6 99 RTAMFQDPQER 11 HPV E6 5 AMFQDPQERPR 11 HPV E6 7 MFQDPQERPRK 11 HPV E6 8 DLLIRCINGQK 11 HPV E6 105 RFEDPTRRPYK 11 HPV E6 3 ELTEVFEFAFK 11 HPV E6 40 GLYNLLIRGLR 11 HPV E6 97 NLLIRCLRCQK 11 HPV E6 100 EVLEESVHEIR 11 HPV E6 17 EVYKFLFTDLR 11 HPV E6 41 FLFTDLRIVYR 11 HPV E6 45 EVLEIPLIDLR 11 HPV E6 20 DLRLSCVYCKK 11 HPV E6 28 EVYNFACTELK 11 HPV E6 44 RVCLLFYSKVR 11 HPV E6 67 LLFYSKVRKYR 11 HPV E6 70 QLCDLLIRCYR 11 HPV E6 98 TLEQTVKK 8 HPV E6 87 ATRDLCIVYR 10 HPV E6 53 A AFRDLCIVYK 10 HPV E6 53 A ATCDKCLKFY 10 HPV E6 68 A AVCDKCLKFR 10 HPV E6 68 A KLYSKISEYR 10 HPV E6 75 A KFYSKISEYK 10 HPV E6 75 A KESEYRHYCY 10 HPV E6 79 A KISEYRHYCR 10 HPV E6 79 A LFIRCINCQK 10 HPV E6 106 A LLIRCINCQR 10 HPV E6 106 A KVRFHNTRGR 10 HPV E6 129 A KQRFHNIRGK 10 HPV E6 129 A WFGRCMSCCR 10 HPV E6 139 A WTGRCMSCCK 10 HPV E6 139 A MTCCRSSRTR 10 HPV E6 144 A MSCCRSSRTK 10 HPV E6 144 A STCRSSRTRR 10 HPV E6 145 A SCCRSSRTRK 10 HPV E6 145 A DIEITCVYCR 10 HPV E6 27 A FTFKDLFVVY 10 HPV E6 47 A FAFKDLFVVK 10 HPV E6 47 A AVKDLFVVYR 10 HPV E6 48 A AFKDLFVVYK 10 HPV E6 48 A FVVYRDSIPK 10 HPV E6 53 A DTTPHAACHK 10 HPV E6 58 A DSIPHAACHR 10 HPV E6 58 A KFIDFYSRIR 10 HPV E6 67 A DTVYGDTLEK 10 HPV E6 83 A DSVYGDTLER 10 HPV E6 83 A LFIRCLRCQK 10 HPV E6 101 A LLIRCLRCQR 10 HPV E6 101 A RVHNIAGHYR 10 HPV E6 126 A RFHNIAGHYK 10 HPV E6 126 A RTQCHSCCNR 10 HPV E6 135 A RGQCHSCCNX 10 HPV E6 135 A ATTDLTIVYR 10 HPV E6 46 A AFTDLTIVYK 10 HPV E6 46 A RLYSKVSEFR 10 HPV E6 68 A RFYSKVSEFK 10 HPV E6 68 A KFSEFRWYRY 10 HPV E6 72 A KVSEFRWYRR 10 HPV E6 72 A YFVYGTTLEK 10 HPV E6 81 A YSVYGTTLER 10 HPV E6 81 A GTTLEKLTNR 10 HPV E6 85 A LVIRCITCQR 10 HPV E6 99 A LLIRCITCQK 10 HPV E6 99 A WVGRCIACWR 10 HPV E6 132 A WTGRCIACWK 10 HPV E6 132 A RTIACWRRPR 10 HPV E6 135 A RCIACWRRPK 10 HPV E6 135 A AVADLTVVYR 10 HPV E6 46 A AFADLTVVYK 10 HPV E6 46 A RVLSKISEYR 10 HPV E6 68 A RFLSKISEYK 10 HPV E6 68 A KFSEYRHYNY 10 HPV E6 72 A KISEYRHYNR 10 HPV E6 72 A ITIRCIICQR 10 HPV E6 99 A ILIRCIICQK 10 HPV E6 99 A WVGRCAACWR 10 HPV E6 132 A WAGRCAACWK 10 HPV E6 132 A CFACWRSRRR 10 HPV E6 136 A DTSIACVYCK 10 HPV E6 27 A DVSIACVYCR 10 HPV E6 27 A CVYCKATLEK 10 HPV E6 32 A RFEVYQFAFK 10 HPV E6 41 A RTEVYQFAFR 10 HPV E6 41 A AVKDLCIVYR 10 HPV E6 48 A AFKDLCIVYK 10 HPV E6 48 A ATCHKGIDFY 10 HPV E6 63 A AAGHKCIDFK 10 HPV E6 63 A NIVYGETLEK 10 HPV E6 83 A NSVYGETLER 10 HPV E6 83 A LSIRCLRGQK 10 HPV E6 101 A LLIRCLRCQY 10 HPV E6 101 A RVHSIAGQYR 10 HPV E6 126 A RFHSIAGQYK 10 HPV E6 126 A LVTDLRIVYR 10 HPV E6 46 A LFTDLRIVYK 10 HPV E6 46 A CTMGLRFLSK 10 HPV E6 63 A CIMCLRFLSR 10 HPV E6 63 A RLLSKISEYR 10 HPV E6 68 A RFLSKISEYY 10 HPV E6 68 A SFYGKTLEER 10 HPV E6 82 A SLYGKTLEEK 10 HPV E6 82 A WFGRCSECWR 10 HPV E6 132 A WTGRCSECWK 10 HPV E6 132 A AFGRVCLLFY 10 HPV E6 64 A AVCRVCLLFR 10 HPV E6 64 A CFLFYSKVRK 10 HPV E6 69 A CLLFYSKVRR 10 HPV E6 69 A LVYSKVRKYR 10 HPV E6 71 A LFYSKVRKYK 10 HPV E6 71 A GTTLESITKK 10 HPV E6 88 A WVGSCLGCWR 10 HPV E6 135 A WTGSCLGGWK 10 HPV E6 135 A VVADLRIVYR 10 HPV E6 46 A VFADLRIVYK 10 HPV E6 46 A RTLSKISEYR 10 HPV E6 68 A RLLSKISEYK 10 HPV E6 68 A KVSEYRHYNY 10 HPV E6 72 A KISEYRHYNK 10 HPV E6 72 A IVIRCIICQR 10 HPV E6 99 A WLGRCAVCWR 10 HPV E6 132 A WTGRCAVCWK 10 HPV E6 132 A YYVCDKCLK 9 HPV E6 67 A YAVCDKCLR 9 HPV E6 67 A SVCRSSRTR 9 HPV E6 145 A SCCRSSRTK 9 HPV E6 145 A SLPHAACHK 9 HPV E6 59 A SIPHAACHR 9 HPV E6 59 A FVDLTIVYR 9 HPV E6 47 A FTDLTIVYK 9 HPV E6 47 A SFYGTTLEK 9 HPV E6 82 A SVYGITLER 9 HPV E6 82 A TFLEKLTNK 9 HPV E6 86 A TFLEKLTNR 9 HPV E6 86 A ETNPFGIGK 9 HPV E6 56 A EGNPFGIGR 9 HPV E6 56 A NTLEQTVKR 9 HPV E6 86 A ALCWRSRRR 9 EPY E6 137 A AACWRSRRK 9 HPV E6 137 A VSIACVYCR 9 HPV E6 28 A SIACVYCKK 9 HPV E6 29 A ILYRDCIAY 9 HPV E6 54 A IVYRDGIAR 9 HPV E6 54 A GTAYAAGHK 9 HPV E6 59 A CIAYAACHR 9 HPV E6 59 A SEYGETLEK 9 HPV E6 84 A SVYGETLER 9 HPV E6 84 A LIRCLRCQR 9 HPV E6 102 A RTQCVQCKK 9 HPV E6 27 A RLQCVQCKR 9 HPV E6 27 A KFLEERVKK 9 HPV E6 86 A KTLEERVKR 9 HPV E6 86 A NVMGRWTGR 9 HPV E6 127 A NIMGRWTGK 9 HPV E6 127 A LTYRDDFPY 9 HPV E6 55 A LVYRDDFPK 9 HPV E6 55 A RFCLLFYSK 9 HPV E6 67 A RVCLLFYSR 9 HPV E6 67 A LTFYSKVRK 9 HPV E6 70 A LLFYSKVRR 9 HPV E6 70 A ATLESITKR 9 HPV E6 89 A KVLCDLLIR 9 HPV E6 97 A KQLCDLLIK 9 HPV E6 97 A TFVHEIELK 9 HPV E6 21 A TSVHEIELR 9 HPV E6 21 A YTFVFADLR 9 HPV E6 43 A DFLEQTLKK 9 HPV E6 86 A DTLEQTLKR 9 HPV E6 86 A LVRCIICQR 9 HPV E6 100 A LIRCIICQK 9 HPV E6 100 A RVAVGWRPR 9 HPV E6 135 A RCAVCWRPK 9 HPV E6 135 A AFCWRPRRR 9 HPV E6 137 A AVCWRPRRK 9 HPV E6 137 A LSFVCPWCA 9 HPV E7 94 TFCCKCDSTLR 11 HPV E7 56 LVVESSADDLR 11 HPV E7 74 TLQVVCPGCAR 11 HPV E7 88 YLIHVPGCECK 11 HPV E7 59 FVVQLDIQSTK 11 HPV E7 70 HTCNTTVR 8 HPV E7 59 GLVCPICSQK 10 HPV E7 88 A GFNIHQHLPAR 10 HPV E7 43 A GVNHQHLPAK 10 HPV E7 43 A NVVTFCGQCK 10 HPV E7 53 A NIVTFCCQGR 10 HPV E7 53 A GVSHAQLPAK 10 HPV E7 44 A LIHVPCGECR 10 HPV E7 60 A AVLQDIVLH 9 HPV E7 6 A ATLQDIVLK 9 HPV E7 6 A GVNHQHLPK 9 HPV E7 43 A HVMLGMGCK 9 HPV E7 59 A HTMLCMCGR 9 HPV E7 59 A LSFVCPWCR 9 HPV E7 94 A AQPATADYK 9 HPV E7 45 A VVHAQLPAR 9 HPV E7 45 A VSHAQLPAK 9 HPV E7 45 A QLARQAKQH 9 HPV E7 48 A KQHTCYLIR 9 HPV E7 54 A VTLDIQSTK 9 HPV E7 72 A VQLDIQSTR 9 HPV E7 72 A SLGPGPGTK 9 Human MAGE1 96 A SLFGPGPGK 9 Human MAGE1 96 A LVGPGPGK 8 Human MAGE2 116 A KMFLQLAK 8 Human p53 132 KMGPGPGK 8 Human p53 132 A KQENWYSLKX 10 Pf CSP 58 GVGPGPGLK 9 Pf LSA1 105 A GVSGPGPGK 9 Pf LSA1 105 A FLLYILFLVK 10 Pf 17 LVFSNVLCFR 10 Pf 43 SSFDIKSEVK 10 Pf 116 TLYQTQVMKR 10 Pf 44 KQVQMMIMIK 10 Pf 58 GVIYIMNSK 10 Pf 70 ELFDKDTFFK 10 Pf 158 ALERLLSLKK 10 Pf 50 KILIKITPVTK 10 Pf 109 RLPLLPKTWK 10 Pf 128 SQVSNSDSYK 10 Pf 161 QQNQESKIMK 10 Pf 197 IIALLIIPPK 10 Pf 249 SSPLFNNFYK 10 Pf 14 FLYLLNKIKNK 10 Pf 151 LQMMNVNLQK 10 Pf 183 LTNHLTNTPK 10 Pf 195 IFISFYLINK 10 Pf 259 RLFEESLGIR 10 Pf 293 LLYILFLVK 9 Pf 18 KSMLKELTK 9 Pf 129 PVLTSLFNK 9 Pf 166 KTMNNYMIK 9 Pf 18 LFDKDTFFK 9 Pf 159 YLFNQHLKK 9 Pf 287 MQSSFFMNR 9 Pf 307 RFYITTRYK 9 Pf 315 TTRYKYLNK 9 Pf 319 AVIFTPIYY 9 Pf 34 ALERLLSLK 9 Pf 50 SISGKYDIK 9 Pf 85 EQRLPLLPK 9 Pf 126 IALLIIPPK 9 Pf 250 PVVCSMEYK 9 Pf 270 VVCSMEYKK 9 Pf 271 FSYDLRLNK 9 Pf 308 HLNIPIGFK 9 Pf 323 PLFNNFYKR 9 Pf 16 YQNFQNADK 9 Pf 141 QMMNVNLQK 9 Pf 184 AVSEIQNNK 9 Pf 222 GTMYILLKK 9 Pf 236 FISFYLINK 9 Pf 260 YLINKHWQR 9 Pf 264 ALKISQLQK 9 Pf 273 KINSNFLLK 9 Pf 282 AAMXDPTTFK 10 Unknown Naturally A processed GTMTTSXYK 9 Unknown Naturally A processed SXXPAXFQK 9 Unknown Naturally A processed ATAGDGXXEXRK 12 Unknown Naturally A processed

TABLE 16 HLA-A3 SUPERTYPE Sequence A*0301 A*1101 A*3101 A*3301 A*6801 ALNAAAAAK 74 21 10954 >72500 80000 ALAAGAAAK 19 37 ALQAAAAAK 57 65 51962 >72500 >80000 STGPGPGVVRR 18695 367 95 5983 5.8 STLGPGPGVRR 892 19 42 670 3.8 STLPGPGPGRR 297 19 61 1893 25 STLPEGPGPGR 325 26 28 822 30 QAGFFLLTR 10138 1678 302 182 5.3 RVHFASPLH 12 60 572 >12288 1.36 7620 AAYAAQGYK 18 18 1175 14074 34 KSKFGYGAK 36 596 116 >122881.36 >7626.31 PAAYAAQGYK 950 456 20314 >110687.02 666 RMYVGGVEH 3.8 274 162 >122881.36 >28776.98 SQLSAPSLK 306 25 1276 >122881.36 3845 TSCGNTLTCY >36666.67 5.0 VTGPGPGPVWK 2900 24 12964 >102836.88 425 VTVGPGPGVWK 174 2.7 2731 75360 21 VTVYGPGPGWK 1151 18 >8995.5 >102836.88 206 VTVYYGPGPGK 310 24 9720 101830 30 PVRPQVPLR >10901.88 16112 332 3439 7012 HGAITSSNTK 2837 344 >16143.5 >22924.9 1235 AVDLSFFLK 226 23 6207 >27831.09 4038 DVSHFLKEK >9298.39 5645 >17839.44 232 135 GVLDGLIYSK 1080 21 6007 >25151.78 831 GVDGLIYSK 10089 47 >17664.38 >29652.35 5100 EILDLWVYK 1032 64 >5774.78 288 93 ILDLWVYK 1265 320 13680 30096 12092 RVPLTFGWGFK 69 30 102 26651 571 QVYTPGPGTR 1249 852 1764 3334 273 AVGPGPGLK 18 3.6 128 75754 444 AVDGPGPGK 179 19 36837 >112403.1 2132 QMGPGPGNFK 49 22 2682 100771 63 QMAGPGPGFK 9.4 6.2 667 4784 30 QMAVGPGPGK 33 16 5961 86676 22 TVGPGPGPEK 115 17 10140 98177 23 TVQGPGPGEK 218 3.4 9874 103379 195 TVQPGPGPGK 41 2.5 1335 68584 28 VAIKIGGQLK 2593 151 46875 51222 123 VTVKIGGQLK 296 61 24385 104757 147 VTIKVGGQLK 188 59 6061 47647 127 VTIRIGGQLK 51 14 4458 65764 25 VTVRIGGQLK 226 15 5380 40344 49 VTVKVGGQLK 206 54 21484 46182 104 VTIRVGGQLK 43 13 3591 86086 28 VTVRVGGQLK 216 19 8238 >72319.2 141 VTVKIGGQLR 19185 194 417 3833 52 VTIRIGGQLR 3192 23 61 1352 16 VTIKLGGQIIR 43252 219 590 12965 104 VSIKVGGQLK 1921 86 57069 >72319.2 2026 VSIRVGGQIK 642 91 50677 >61702.13 1960 VTVKTEGQLK 647 23 4616 64604 30 VTIKIEGQLK 361 69 5077 58024 27 VTVKIEGQLR 35612 143 394 4057 146 VSIRVGGQTK 341 21 29949 38958 290 VSIRVGGQTR 18531 241 466 8595 288 VTVRIGGMQK 54 13 2583 44425 155 ITVKIGKEVR >69182.39 12904 5057 24985 154 GTRQARRNK 67 749 9713 45966 59708 GTRQARRNRK 100 634 3800 >42335.77 7788 GTRQARRNRRK 404 2596 7774 >24308.47 9104 GTRQTRKNK 198 3104 13373 >29713.11 18657 GTRQTRKNRK 129 1082 2485 60183 5998 GTRQTRKNRRK 478 4184 4008 >24308.47 >17167.38 RVRRRRWRAR 2443 >16759.78 265 3758 >36866.36 KVRRRRWRAR 327 >20905.92 342 3243 15501 LTISYGRK 988 708 27068 38162 482 KTLGISYGR 53 9.8 21 502 36 LTISYGRKK 584 69 13918 59654 63 GTSYGRKKR 9965 5916 225 21588 5778 GTGISYGRK 480 77 58102 >43740.57 7407 KTLGISYGRK 36 79 841 42378 1629 LTISYGRKKR 7161 1229 71 2515 33 KTLGISYGRKK 52 285 91 23401 647 TVCNNCYGK 9920 267 8793 28481 876 LVISYGRKKRR >11702.13 8669 562 267 4662 ISYGRXKRRQK 48 2807 3147 >20000 4428 ETGPSGQPGK >14569.54 3501 >22500 >17813.27 50 KVGPGGYPRR 2268 487 250 7904 721 KAGPGGYPRK 62 43 10734 >17813.27 5555 KVGPGGYPRRK 70 87 775 >5063.73 921 AVPGGYPRR 3012 1215 1349 3453 109 AVPGGYPRRK 819 60 39974 >5570.5 846 KVGSLQYLK 482 70 2104 >43740.57 4200 ETVRHFPR >13513.51 4183 1000 81 86 AACHXCIDFY 18824 261 20643 >116465.86 32548 LLTRCLRCQK 437 170 6612 28936 78 KISEYRHYNY 42 112 1426 35341 25077 AVCRVGLLFY 77 21 1978 4520 1302 FAFTDLTIVY 40343 21161 42065 131202 346 FAFADLTVVY 18592 5866 23676 26768 402 RFLSKISEYR 1640 18468 33 436 172 ILIRCIICQR 8550 5012 377 2480 537 RTAMFQDPQER 1478 103 49 3459 19 AMFQDPQERPR 1718 886 45 1787 1478 MFQDPQERPRK 15493 8571 604 419 16729 DLLIRCINCQK 2923 935 4884 29 263 RFEDPTRRPYK 169 432 53 1758 7338 ELTEVFEFAFK 8966 582 25205 1733 15 GLYNLLIRCLR 1268 1568 250 401 1624 NLLIRGLRCQK 1565 854 3140 397 1480 EVLEESVHEIR >45643.15 >20202.02 31037 212 240 EVYKFLFTDLR 31240 602 759 4.3 11 FLFTDLRIVYR 672 227 58 21 1.4 EVLEIPLIDLR >47008.55 16638 36427 72 27 DLRLSCVYCKK 3644 1907 17023 109 3002 EVYNFACTELK 1622 117 484 5.9 2.7 RVCLLFYSKVR 771 190 221 1061 1267 LLFYSKVRKYR 28 94 7.0 11 15 QLCDLLIRGYR 1240 700 450 106 489 TLEQTVKK 4766 203 >100000 >75324.68 21400 ATRDLCIVYR 237 156 4.7 44 28 AFRDLCIVYK 31 15 10 132 57 ATGDKCLKFY 194 17 491 18080 4562 AVCDKCLKFR 77 15 11 45 34 KLYSKISEYR 5.4 168 6.4 28 91 KFYSKISEYK 7.6 674 27 329 208 KFSEYRHYCY 5092 7485 308 49397 14571 KISEYRHYCR 486 688 25 833 1488 LFIRCINCQK 2880 702 52 42 56 LLIRGINCQR 2818 686 30 50 14 KVRFHNIRGR 39 8632 27 4500 3979 KQRFHNIRGK 55 1953 573 35208 22879 WFGRCMSCCR 16071 10690 288 98 303 WTGRCMSCCK 6687 841 6496 15191 118 MTCCRSSRTR 3825 933 410 601 2.2 MSCGRSSRTK 352 169 2333 6916 12 STCRSSRTRR 2989 118 152 1020 312 SCCRSSRTRK 326 3272 5592 20916 8777 DIEITCVYCR 2014 826 3780 448 422 FTFKDLFVVY 14364 1208 10757 2725 62 FAFKDLFVVK 783 71 525 1066 3.6 AVKDLFVVYR 1728 91 3.1 9.1 3.3 AFKDLFVVYX 3256 211 32 93 576 FVVYRDSIPK 265 81 6216 146 30 DTIPHAACHK 2366 701 1763 9.3 23 DSIPHAACHR 2772 853 357 2.2 27 KFIDFYSRIR 8891 9008 3.3 677 2551 DTVYGDTLEK 50 15 28754 55090 31 DSVYGDTLER 292 23 485 891 28 LFIRCLRCQK 3390 1533 218 77 200 LLIRCLRCQR 3360 1396 28 75 13 RVHNIAGHYR 30 21 22 114 18 RFHNIAGHYK 25 22 2.6 80 23 RTQCHSCCNR 338 20 22 132 161 RGQCHSCCNK 6135 113 425 37669 20340 ATTDLTIVYR 247 10 34 1739 14 AFTDLTIVYK 701 112 3952 9380 215 RLYSKVSEFR 6.4 131 24 690 73 RFYSKVSEFK 27 521 30 4452 547 KFSEFRWYRY 4750 1595 34 856 12811 KVSEFRWYRR 266 16 2.8 159 30 YFVYGTTLEK 204 62 2167 15740 53 YSVYGTTLER 430 96 2136 6903 19 GTTLEKLTNR 3604 1720 382 706 2946 LVIRCITCQR 2222 255 54 135 14 LLIRCITCQK 291 120 3009 2165 40 WVGRGIACWR 6227 1391 85 13 9.7 WTGRCIACWK 2633 55 3078 169 24 RTLACWRRPR 40 63 3.2 95 51 RCIACWRRPK 1535 1476 292 176 1655 AVADLTVVYR 489 11 31 892 7.3 AFADLTVVYK 2365 107 1113 13557 50 RVLSKISEYR 34 84 24 197 136 RFLSKISEYK 31 287 42 10237 112 KFSEYRHYNY 5819 5521 286 18351 1798 KISEYRHYNR 58 140 17 161 1579 ITIRCIICQR 488 93 50 123 12 ILIRCIICQK 192 78 1383 1423 165 WVGRCAACWR 2757 3973 360 24 19 WAGRCAACWK 4662 583 23311 1491 50 CFACWRSRRR 23542 7164 578 165 10206 DTSIACVYCK 2936 89 5385 1968 216 DVSIACVYCR 2814 217 406 487 658 CVYCKATLEK 418 653 5307 17928 862 RFEVYQFAFK 38 611 179 2867 2443 RTEVYQFAFR 217 78 12 142 147 AVKDLCIVYR 841 66 7.3 8.0 6.5 AFKDLCIVYK 856 47 39 263 378 ATGHKCIDFY 133 7.4 1164 12691 1386 AAGHKCIDFK 118 20 437 53733 414 NLVYGETLEK 846 143 761 121 87 NSVYGETLER 150 25 163 1333 18 LSIRGLRGQK 245 14 100 1135 17 LLIRGLRCQY 727 452 2894 2430 254 RVHSIAGQYR 31 34 7.6 812 28 RFHSIAGQYK 17 43 1.3 629 83 LVTDLRIVYR 3869 648 20 150 6.8 LFTDLRIVYK 628 263 258 149 277 CTMCLRFLSK 1002 226 6274 3945 429 CIMCLRFLSR 41 101 167 83 155 RLLSKISEYR 5.2 662 7.7 108 21 RFLSKISEYY 1702 25535 14 41096 3999 SFYGKTLEER 642 205 17 66 42 SLYGKTLEEK 7.9 6.8 1044 6516 29 WFGRGSECWR 1788 1569 20 5.5 26 WTGRCSECWK 2492 26 3323 720 22 AFCRVCLLFY 509 272 1777 1202 173 AVCRVCLLFR 20 1.8 2.1 64 21 CFLFYSKVRK 125 96 81 315 172 CLLFYSKVRR 417 204 159 386 242 LVYSKVRKYR 320 619 17 49 31 LFYSKVRXYK 680 2582 18 30 1976 GTTLESITKK 622 108 85182 132509 10147 WVGSCLGCWR 48682 5520 20 15 9.3 WTGSCLGGWK 7705 6.9 18344 2980 3.7 VVADLRIVYR 513 18 41 101 16 VFADLRIVYK 2086 127 402 200 273 RTLSKISEYR 77 100 52 189 133 RLLSKISEYK 15 65 158 40019 429 KVSEYRTYNY 349 110 1791 70859 3498 KISEYRHYNK 29 18 397 24827 15565 IVIRCIICQR 984 217 52 529 28 WLGRCAVCWR 2330 3002 356 40 112 WTGRGAVGWK 1261 131 4176 3403 29 YVVCDKCLK 3282 643 8.5 165 1289 YAVCDKGLR 458 194 4261 26582 16034 SVCRSSRTR 323 97 249 547 17 SCCRSSRTK 21 3.9 51 5227 4.2 SLPHAACHK 32 66 219 1186 654 SIPHAACHR 1053 352 236 253 181 FVDLTIVYR 29674 5312 2384 430 138 FTDLTIVYK 557 16 24170 18477 143 SFYGTTLEK 34 15 517 3385 498 SVYGTTLER 28 6.4 133 454 21 TFLEKLTNK 6839 815 451 148 918 TTLEKLTNR 1993 817 42 37 101 ETNPFGICK 9585 100 29103 804 14 EGNPFGICR 11467 10372 5123 344 82 NTLEQTVKR 20380 1151 2273 18 8.6 ALGWRSRRR 959 9748 72 1289 7416 AACWRSRRK 75 770 3022 45341 12877 VSIACVYGR 3236 143 42 1347 185 SIACVYCKK 271 83 9114 19632 96 ILYRDCIAY 261 1832 53232 44670 >19607.84 IVYRDCIAR 465 106 27 325 64 CTAYAACHK 726 196 2956 771 167 CIAYAACHR 3625 1905 502 115 262 SEYGETLEK 288 108 947 885 1074 SVYGETLER 44 11 235 160 17 LIRCLRCQR 21335 12648 695 810 200 RTQCVQGKK 234 20 127 8147 3066 RLQCVQCKR 2535 6081 65 1829 11479 KFLEERVKK 5344 2229 30 9740 17674 KTLEERVKR 1957 159 37 1360 17685 NVMGRWTGR 3884 794 40 18 20 NIMGRWTGK 52 54 3274 86 173 LTYRDDFPY 8265 82 >71146.25 20186 1529 LVYRDDFPK 317 13 3009 1970 130 RFCLLFYSK 1156 484 83 450 232 RVCLLFYSR 439 111 51 2176 689 LTFYSKVRK 3.8 8.0 87 3382 13 LLFYSKVRR 56 73 38 276 11 ATLESITKR 1437 16 100 851 188 KVLCDLLIR 363 169 66 5896 9053 KQLCDLLIK 226 65 340 46426 11897 TFVHEIELK 4431 217 8412 4130 172 TSVHEIELR >64327.49 872 1039 5948 12 YTFVFADLR 3633 8.1 20 6.6 2.9 DFLEQTLKK >57591.62 18809 34365 174 14376 DTLEQTLKR 31347 12909 38127 9.2 110 LVRCIICQR 677 358 59 109 201 LTRCIICQK 445 252 639 834 285 RVAVGWRPR 5.3 8.5 7.0 102 33 RCAVCWRPK 285 340 382 131 1297 AFCWRPRRR 273 17907 60 75 1087 AVCWRPRRK 34 101 263 7950 1810 LSFVCPWCA 38337 10864 4289 4603 341 TFCCKGDSTLR 21772 8043 332 91 260 LVYESSADDLR >47008.55 2170 26410 5624 28 TLQVVCPGCAR 20997 1395 67 63 147 YLIHVPCCECK 1748 1534 33044 8066 177 FVVQLDIQSTK 3682 853 48593 31350 2.7 HTCNTIYR 4862 1792 726 4490 25 GLVCPICSQK 428 814 45293 70317 3568 GFNHQHLPAR >46610.17 27889 173 5572 34617 GVNHQHLPAK 42 11 3337 76239 9347 NVVTFCGQCK 790 303 4757 87 13 NIVTFGCQGR 1507 1070 2731 766 93 GVSHAQLPAK 42 12 36011 >74935.4 20590 LIHVPCGECR 5326 5925 385 387 228 AVLQDIVLH 1922 101 6307 25776 27035 ATLQDTVLK 37 8.6 65 17121 3231 GVNHQHLPK 26 7.7 353 15615 1192 HVMLCMCCK 282 79 772 825 99 HTMLCMCCR 405 92 11 14 24 LSFVCPWCR 31676 200 47 231 152 AQPATADYK 3500 109 10413 58871 24173 VVHAQLPAR 423 127 3.4 12 201 VSHAQLPAK 378 9.5 46 1401 13502 QLARQAKQH 8423 6862 945 1665 243 KQHTCYLIR 135 213 13 2275 12177 VTLDIQSTK 78 13 2046 1954 237 VQLDIQSTR 15105 2917 162 4588 10341 SLGPGPGTK 7.8 5.8 4392 152133 3517 SLFGPGPGK 3.4 2.3 1085 82275 36 LVGPGPGK 1004 291 23907 >125541.13 598 KMFLQLAK 45 62 677 >125541.13 8384 KMGPGPGK 84 242 1144 106362 4156 KQENWYSLKK 608 178 6327 >136150.23 4794 GVGPGPGLK 47 4.0 1367 >111538.46 3972 GVSGPGPGK 13 5.8 >11221.95 >111538.46 209 FLLYILFLVK 446 1431 54496 3254 2266 LVFSNVLCFR 120 19 33 19 7.7 SSFDIKSEVK 1900 19 19829 70344 31 TLYQIQVMKR 361 164 397 558 90 KQVQMMIMIK 264 112 4627 1231 2247 GVIYIMIISK 777 18 18811 1567 1134 ELFDKDTFFK 144 109 3676 13 3.6 ALERLLSLKK 147 822 33559 18255 22391 KILIKIPVTK 13 60 1661 24992 19571 RLPLLPKTWK 11 67 340 11392 2889 SQVSNSDSYK 1656 83 24559 >17448.86 1384 QQNQESKIMK 3469 77 28120 >17448.86 21310 HALLIIPPK 30 5.3 23822 8426 82 SSPLFNNFYK 100 0.7 1608 1728 6.3 FLYLLNKKNK 177 475 4313 780 155 LQMMNVNLQK 25 7.2 435 1113 320 LTNHLTNTPK 11 5.9 62 373 10 IFISEYLINK 1987 1056 462 394 363 RLFEESLGIR 64 1096 297 788 409 LLYILFLVK 13 207 90687 13261 5545 KSMLKELIK 189 151 450 >46548.96 >37037.04 PVLTSLFNK 1949 25 5107 18271 29928 KTMNNYMIK 17 5.5 24 12743 29 LFDKDTFFK 931 167 5706 1189 101 YLFNQHIKK 14 7.8 4919 7974 14 MQSSFFMNR 13 1.1 29 75 3.8 RFYITTRYK 1.9 67 15 98 17468 TTRYKYLNK 117 848 416 652 2565 AVIFTPIYY 25 9.5 42321 10068 1352 ALERLLSLK 233 369 3433 12786 13708 SISGKYDIK 2086 50 28249 12437 1745 EQRLPLLPK 1088 765 423 987 1911 IALLIIPPK 1241 108 2926 1404 1965 PVVCSMEYK 1940 80 330791 22608 414 VVCSMEYKK 443 54 891 14328 167 FSYDLRLNK 29 4.9 461 1264 15 HLNIPIGFK 2.3 1.3 183 97 2.8 PLFNNFYKR 2635 1890 520 1258 132 YONFQNADK 2712 177 44698 >18447.84 19830 QMMNVNLQK 20 7.0 504 6649 243 AVSEIQNNK 25 11 1429 25449 14 GTMYILLKK 2.2 1.2 29 8453 3.1 FISFYLINK 19 9.0 2192 1456 18 YLTNKHWQR 1034 676 4.4 7.7 3.7 ALKISQLQK 15 96 3203 23800 >54794.52 KIINSNFLLK 17 6.4 68 47740 2737 AAMXDPTTFK 50 7.2 GTMTTSXYK 4.0 4.5 SXXPAXFQK 14 2.0 ATAGDGXXEXRK 184 19

TABLE 17 HLA-A24 SUPERTYPE SEQ ID Sequence NO. AA Organism Protein Position Analog AYGPGPGKF 9 Artificial Consensus A sequence AYIGPGPGF 9 Artificial Consensus A sequence AYAAAAAAL 9 Artificial Poly sequence AYSSWMYSY 9 EBV EBNA3 176 DLLDTASALY 10 HBV Core 419 WFHISCLTF 9 HBV NUC 102 KYTSFPWL 8 HBV pol 745 FAAPFTQCGY 10 HBV pol 631 SYQHFRKLLL 10 HBV POL 4 LYSHPIILGF 10 HBV POL 492 MSTTDLEAY 9 HBV X 103 MYVGDLCGSVF 11 HCV E1 275 MYGPGPGGSVF 11 HCV E1 275 A MYVGPGPGSVF 11 HCV E1 275 A MYVGGPGPGVF 11 HCV E1 275 A MYVGDGPGPGF 11 HCV E1 275 A VMGSSYGF 8 HCV NS5 2639 EVDGVRLHRY 10 HCV NS5 2129 KYSKSSIVGW 10 HIV NEF 4 A KWSKSSIVGF 10 HIV NEF 4 A FFLKEKGGF 9 HIV NEF 116 A IYSKKRQEF 9 HIV NEF 175 A IYSKKRQEIF 10 HIV NEF 175 A LYVYHTQGYF 10 HIV NEF 190 A VYHTQGYFPDF 11 HIV NEF 192 A RYPLTFGW 8 HIV NEF 216 RYPLTFGF 8 HIV NEF 216 A RFPLTFGF 8 HIV NEF 216 A TYGWCFKL 8 HIV NEF 222 A TFGWCFKF 8 HIV NEF 222 A LYVYHTQGY 9 HIV NEF 190 A NYTPGPGIRF 10 HIV NEF 206 A QYPPLERLTL 10 HIV REV 78 A QLPPLERLTF 10 HIV REV 78 A KYGSLQYLAL 10 HIV VIF 146 A LSKISEYRHY 10 HPV E6 70 ISEYRHYNY 9 HPV E6 73 RFHNIRGRW 9 HPV E6 131 RFLSKISEY 9 HPV E6 68 RFHNISGRW 9 HPV E6 124 VYDFAFRDLCI 11 HPV E6 49 PYAVCDKCLKF 11 HPV E6 66 QYNKPLCDLLI 11 HPV E6 98 PFGICKLCLRF 11 HPV E6 59 VYQFAFKDLCI 11 HPV E6 44 AYAACHKCIDF 11 HPV E6 61 VYKFLFTDLRI 11 HPV E6 42 PYGVCIMCLRF 11 HPV E6 59 PYAVCRVCLLF 11 HPV E6 62 VYDFVFADLRI 11 HPV E6 42 QYNKPLGDLF 10 HPV E6 98 A VYEFAFKDLF 10 HPV E6 44 A FYSKVSEFRF 10 HPV E6 69 A VYREGNPFGF 10 HPV E6 53 A FYSRIRELRF 10 HPV E6 71 A PYAVCRVCLF 10 HPV E6 62 A FYSKVRKYRF 10 HPV E6 72 A LYGDTLEQTF 10 HPV E6 83 A VYDFAFRDF 9 HPV E6 49 A AYRDLCIVY 9 HPV E6 53 A AFRDLC1VF 9 HPV E6 53 A PYAVGDKCF 9 HPV E6 66 A KYYSKISEY 9 HPV E6 75 A KEYSKISEF 9 HPV E6 75 A CYSLYGTTF 9 HPV E6 87 A RYHNIRGRW 9 HPV E6 131 A RFHNIRGRF 9 HPV E6 131 A VYCKTVLEF 9 HPV E6 33 A AYKDLFVVY 9 HPV E6 48 A AFKDLFVVF 9 HPV E6 48 A LYVVYRDSI 9 HPV E6 52 A LFVVYRDSF 9 HPV E6 52 A RYHNIAGHY 9 HPV E6 126 A RFHNIAGHF 9 HPV E6 126 A VYGTFLEKF 9 HPV E6 83 A AYADLTVVY 9 HPV E6 46 A AFADLTVVF 9 HPV E6 46 A RYLSKISEY 9 HPV E6 68 A NYSVYGNTF 9 HPV E6 80 A RYHNISGRW 9 HPV E6 124 A AYKDLCIVY 9 HPV E6 48 A AFKDLCIVF 9 HPV E6 48 A AYAAGHKCF 9 HPV E6 61 A VYGETLEKF 9 HPV E6 85 A RYHSIAGQY 9 HPV E6 126 A RFHSIAGQF 9 HPV E6 126 A KYLFTDLRI 9 HPV E6 44 A KFLFTDLRF 9 HPV E6 44 A LYTDLRIVY 9 HPV E6 46 A LFTDLRIVF 9 HPV E6 46 A PYGVCIMCF 9 HPV E6 59 A RFLSKISEF 9 HPV E6 68 A EYRHYQYSF 9 HPV E6 75 A RYHNIMGRW 9 HPV E6 124 A RFHNIMGRF 9 HPV E6 124 A VYNFACTEF 9 HPV E6 45 A NYACTELKL 9 HPV E6 47 A NFACTELKF 9 HPV E6 47 A PYAVCRVCF 9 HPV E6 62 A LYYSKVRKY 9 HPV E6 71 A LFYSKVRKF 9 HPV E6 71 A VYDFVFADF 9 HPV E6 42 A VYADLRIVY 9 HPV E6 46 A VFADLRIVF 9 HPV E6 46 A NYSLYGDTF 9 HPV E6 80 A RFHNISGRF 9 HPV E6 124 A LYNLLIRCF 9 HPV E6 98 A FYSKYSEF 8 HPV E6 69 VYREGNPF 8 HPV E6 53 VFEFAFKDLF 10 HPV E6 44 EYRHYCYSLY 10 HPV E6 82 EYRHYNYSLY 10 HPV E6 75 ETRHYCYSLY 10 HPV E6 82 A EYDHYGYSLY 10 HPV E6 82 A KTRYYDYSVY 10 HPV E6 78 A KYDYYDYSVY 10 HPV E6 78 A ETRHYNYSLY 10 HPV E6 75 A EYDHYNYSLY 10 HPV E6 75 A TYCCKCDSTL 10 HPV E7 56 A TFCCKGDSTF 10 HPV E7 56 A TYCHSCDSTF 10 HPV E7 58 A CYTCGTTVRF 10 HPV E7 59 A LYPEPTDLF 9 HPV E7 15 A NYYIVTCCF 9 HPV E7 52 A LFLNTLSF 8 HPV E7 89 LFLSTLSF 8 HPV E7 90 RVLPPNATKY 9 Human 40s ribo 132 prot S13 RLAHEVGWKY 10 Human 60s ribo 139 prot L13A AYKKQFSQY 9 Human 60s ribo 217 prot L5 KTKDIVNGL 9 Human Factin 235 capping protein SLFVSNHAY 9 Human fructose 355 biphosphate- aldolase TYGPGPGSLSF 11 Human Her2/neu 63 A TYLGPGPGLSF 11 Human Her2/neu 63 A TYLPGPGPGSF 11 Human Her2/neu 63 A TYLPTGPGPGF 11 Human Her2/neu 63 A RWGLLLALL 9 Human Her2/neu 8 PYVSRLLGI 9 Human Her2/neu 780 TYLPTNASL 9 Human Her2/neu 63 IYGPGPGLIF 10 Human MAGE3 195 A IYPGPGPGIF 10 Human MAGE3 195 A IYPKGPGPGF 10 Human MAGE3 195 A RISGVDRYY 9 Human NADH 53 ubiqoxido- reductase LYSACFWWL 9 Human OA1 194 LYSACFWWF 9 Human OA1 194 A TYSVSFDSLF 10 Human PSM 624 TYGPGPGSLF 10 Human PSM 624 A TYSGPGPGLF 10 Human PSM 624 A TYSVGPGPGF 10 Human PSM 624 A AYPNVSAKI 9 Lysteria listerio- 196 lysin AYGPGPGKI 9 Lysteria listerio- 196 A lysin IMVLSFLF 8 Pf CSP 427 YYGKQENW 8 Pf CSP 55 VFNVVNSSI 9 Pf CSP 416 ALFQEYQCY 9 Pf CSP 18 LYNTEKGRHPF 11 Pf EXP 100 YFILVNLL 8 Pf LSA 10 KFFDKDKEL 9 Pf LSA 76 KFIKSLFHI 9 Pf LSA 1876 YFILVNLLIF 10 Pf LSA 10 FYFILVNLLIF 11 Pf LSA 9 SFYFILVNLLI 11 Pf LSA 8 VFLIFFDLF 9 Pf SSP2 13 LYLLMDCSGSI 11 Pf SSP2 49 KVSDEIWNY 9 Pf 182 SYKSSKRDKF 10 Pf 225 RYQDPQNYEL 10 Pf 21 DFFLKSKFNI 10 Pf 3 IFHFFLFLL 9 Pf 11 VFLVFSNVL 9 Pf 41 TYGIIVPVL 9 Pf 160 NYMKIMNHL 9 Pf 34 TYKKKNNHI 9 Pf 264 VYYNILIVL 9 Pf 277 LYYLFNQHI 9 Pf 285 SFFMNRFYI 9 Pf 310 FYITTRYKY 9 Pf 316 KYINFINFI 9 Pf 328 KYEALIKLL 9 Pf 380 IYYFDGNSW 9 Pf 40 VYRHCEYIL 9 Pf 94 TWKPTIFLL 9 Pf 135 SYKVNCINF 9 Pf 168 KYNYFIHEF 9 Pf 216 NYFIHFFTW 9 Pf 218 HEFTWGTMF 9 Pf 222 MFVPKYFEL 9 Pf 229 IYTIIQDQL 9 Pf 295 FFLKSKFNI 9 Pf 4 RMTSLKNEL 9 Pf 61 YYNNFNNNY 9 Pf 77 YYNKSTEKL 9 Pf 87 EYEPTANLL 9 Pf 109 VYXKHPVSX 9 Unknown Naturally A processed TYGNXTVTV 9 Unknown Naturally A processed KYPDRVVPX 9 Unknown Naturally A processed VYVXSXVTX 9 Unknown Naturally A processed DAQXXXNTX 9 Unknown Naturally A processed KYQAVTTTL 9 Unknown Tumor p198 197 KYGPGPGTTTL 11 Unknown Tumor p198 197 A KYQGPGPGTTL 11 Unknown Tumor p198 197 A

TABLE 18 HLA-A24 SUPERTYPE Sequence A*2402 A*2301 A*2902 A*3002 AYGPGPGKF 2.4 9.7 44854 3.2 AYIGPGPGF 217 12 15887 5728 AYAAAAAAL 443 AYSSWMYSY 21 4.9 DLLDTASAL 74 37 Y WFHISCLTF 204 11 95 75094 KYTSFPWL 208 177 >172413.79 346 FAAPFTQCG 461 1364 Y SYQHFRKLL 418 39 28 3768 L LYSHPIILG 2.6 5.4 109 1116 F MSTTDLEAY 2565 396 MYVGDLCGS 26 0.91 612 1460 VF MYGPGPGGS 35 5.4 48442 31980 VF MYVGPGPGS 35 4.4 1527 28177 VF MYVGGPGPG 381 85 89 2870 VF MYVGDGPGP 90 11 8656 39608 GF VMGSSYGF 36 159 145 41967 EVDGVRLHR 14940 113 Y KYSKSSIVG 4061 491 >69444.44 >34482.76 W KWSKSSIVG 1674 84 >56179.78 30367 F FFLKIEKGG 3456 655 3015 141 F IYSKKRQEP 306 421 29353 727 IYSKKRQEI 238 360 >131578.95 21001 F LYVYHTQGY 38 23 1696 1222 F VYHTQGYFP 149 68 14923 >22556.39 DF RYPLTFGW 127 3836 13889 6251 RYPLTFGF 3.3 6.4 9704 6328 RFPLTFGF 178 124 12759 13472 TYGWCFKL 2181 333 25658 >8042.9 TFGWCFKF 3424 462 4449 >10135.14 LYVYHTQGY 7140 6088 216 258 NYTPGPGIR 483 37 8334 >9646.3 F QYPPLERLT 211 22 >11520.74 >9646.3 L QLPPLERLT 2507 338 >37313.43 >36585.37 F KYGSLQYLA 2800 147 >69444.44 6957 L LSKISEYRH >93023.26 >23671.5 55190 186 Y ISEYRHYNY 125794 >23557.69 1329 32 RFHNIIRGR 53237 11416 18 58 W RFLSKISEY 472 121 34623 23 RFRNISGRW >80536.91 22871 174 37 VYDFAFRDL 44 8.9 62242 35724 CI PYAVCDKCL 99 8.1 118249 >60000 KF QYNKPLCDL 303 36 >166666.67 6680 LI PFGICKLCL 137 19 1249 32803 RF VYQFAFKDL 30 1.9 49276 3477 CI AYAACHKCI 91 14 1264 4699 DF VYKFLFTDL 37 14 30216 1865 RI PYGVCLMCL 380 100 69 43722 RF PYAVCRVCL 226 150 2711 53351 LF VYDFVFADL 47 8.0 8904 7585 RI QYNKPLCDL 115 21 7658 525 F VYEFAFKDL 15 1.7 1973 2038 F FYSKVSEFR 7.1 2.2 79 18453 F VYREGNPFG 197 91 11120 21947 F FYSRIRELR 11 1.6 83 12598 F PYAVCRVCL 12 4.5 407 5226 F FYSKVRKYR 18 13 3042 1232 F LYGDTLEQT 91 24 40871 42025 F YYIDFAFRD 9.6 19 47381 8490 F AYRDLCIVY 2094 1479 7117 66 AFRDLCIVF 1005 369 6722 3305 PYAVCDKCF 216 183 122025 9884 KYYSKISEY 10951 2165 702 1.3 KEYSKISEF 174 138 73339 306 CYSLYGTTF 28 11 2088 7823 RYHNIRGRW 145 14 122644 15 RFHNIRGRF 29 2.4 346 0.69 VYCKTVLEF 50 4.7 610 1139 AYKDLFVVY 1549 905 639 1.3 AFKDLFVVF 294 6.8 3051 829 LYVVYRDSI 982 242 148359 3483 LFVVYRDSF 268 134 919 18 RYITNIAGH 1227 195 138 0.93 Y RFHNIAGIT 37 17 635 1.4 F VYGTTLEKF 19 13 75267 220 AYADLTVVY 369 1384 136 9.3 AFADLTVVF 203 30 779 137 RYLSKISEY 142 98 4247 1.1 NYSVYGNTF 28 29 9121 2559 RYHNISGRW 47 15 104884 13 AYKDLCLVY 33798 3036 5205 29 AFKDLCIVF 284 16 5846 2305 AYAACHKCF 200 159 10972 3393 VYGETLEKE 45 14 91902 20009 RYHSIAGQY 3170 1904 544 1.4 RFHSIAGQF 28 2.9 481 1.2 KYLFTDLRI 108 1.9 78575 339 KFLFTDLRF 12 0.74 44 152 LYTDLRIVY 1986 1216 4.8 2.1 LFTDLRIVF 169 2.6 164 2649 PYGVCIMCF 190 147 144402 38850 RFLSKISEF 58 2.5 40103 201 EYRHYQYSF 21 2.3 13707 430 RYHNIMGRW 29 12 106990 7.1 RFHNIMGRF 39 2.6 174 1.3 VYNFACTEF 14 2.1 774 784 NYACTELKL 1741 131 77844 49107 NFACTELKF 211 13 46 6826 PYAVCRVCF 429 257 5602 316 LYYSKVRKY 21942 2735 1452 28 LFYSKVRKF 2008 277 11172 632 VYDFVFADF 9.9 2.2 1230 3961 VYADLRIVY 28 122 8.2 8.3 VFADLRIVF 23 2.5 87 24062 NYSLYGDTF 6.4 142 20945 64 RFHNISGRF 34 5.5 572 2.8 LYNLLIIRC 47 15 17958 2255 F FYSKVSEF 21 18 3774 66667 VYREQNPE 554 147 10001 65970 VFEFAFKDL 400 F EYRHYCYSL 198 3.7 Y EYRIIYNYS 956 12 LY ETRHYCYSL 755 10 Y EYDHYCYSL 799 77 Y KTRYYDYSV 87841 0.71 Y KYDYYDYSV 5749 11 Y ETRHYNYSL 5464 29 Y EYDHYNYSL 777 93 Y TYCCKCDST 206 30 145803 16588 L TFCCKCDST 25 14 501 1167 F TYCHSCDST 14 2.9 5236 3580 F CYTCGTTVR 41 18 7744 38331 F LYPEPTDLF 38 17 1150 30732 NYYIVTCCF 27 12 2675 8398 LFLNTLSF 587 104 1013 118217 LFLSTLSF 2283 160 1034 >75000 RVLPPNWKY >49000 3.0 RLAHEVGWK 4631 3.8 Y AYKKQFSQY 10669 5.3 KTKDIVNGL >49000 164 SLFVSNHAY 30295 1.1 TYGPGPGSL 7.1 1.7 9853 47246 SF TYLGPGPGL 23 0.65 600 26889 SF TYLPGPGPG 8.8 2.2 56183 7275 SF TYLPTGPGP 39 8.6 56574 32985 GF RWGLLLALL 106 100 61253 300 PYVSRLLGI 11 18 200160 65465 TYLPTNASL 141 7.8 106153 8244 IYGPGPGLI 7.4 8.0 58 6845 IF IYPGPGPGI 58 12 18659 17959 F IYPKGPGPG 7.5 4.9 53603 61283 F RISGVDRYY >49000 3.0 LYSACFWWL 28 LYSACFWWF 28 TYSVSFDSL 10 12 521 5218 F TYGPGPGSL 3.9 8.7 7228 10871 F TYSGPGPGL 50 92 7726 3461 F TYSVGPGPG 332 340 120913 55200 F AYPNVSAKI 14 45 56905 4456 AYGPGPGKI 36 169 >156250 5427 IMVLSFLF 469 7.5 111 30000 YYGKQENW 85 951 >50000 >30000 VFNVVNSSI 403 35 24001 15737 ALFQEYQCY 149 1032 LYNTEKGRH 175 1947 >50000 >30000 PF YFILVNLL 96 82 4050 30000 KLFFDKDKE 269 >49000 >50000 3012 L KIFIKSLFH 4.1 2.0 >50000 3495 I YFILVNLLI 577 12 764 3388 IF FYFILVNLL 599 50 902 9826 IF SFYFILVNL 229 35 3066 2096 LI VFLTFFDLF 40 12 1510 13554 LYLLMDCSG 154 10 5893 1469 SI KVSDETWNY 52169 >11980.44 230 1.9 SYKSSKRDK 256 797 12594 88 F RYQDPQNYE 212 124 79717 189 L DFFLKSKFN 1648 304 47714 491 I IIFHFFLFL 208 80 1405 837 L VFLVFSNVL 26 4.9 33675 37689 TYGIIVPVL 248 20 30056 1519 NYMKIMNIH 16 1.7 45443 110 L TYIKKKNNH 30 81 21642 162 I VYYNILIVL 265 52 >192307.69 1127 LYYLFNQHI 33 1.4 20130 11035 SFFMNKFYI 172 11 200 1022 FYITTRYKY 350 11 9.6 7.5 KYINFIINF 11 0.72 25475 55 I KYEALIIKL 2856 484 17296 16098 L IYYFDGNSW 80 6.1 3101 3025 VYRHCEYIL 2200 64 117851 3326 TWKPTIIFL 148 11 21155 306 L SYKVNCINF 27 15 2535 572 KYNYFIHFF 2.5 0.49 319 2.7 NYFIHFFTW 9.3 1.3 9774 3020 HFFTWGTMF 83 5.7 4.0 220 MFVPKYFEL 266 11 2560 8560 IYTIIQDQL 72 45 >37313.43 14124 FFLKSKFNI 1434 49 43105 >83333.33 RMTSLKINE 12711 1807 40270 14 L YYNNFNNNY 817 126 19 34 YYNKSTEKL 109 106 55636 21751 EYEPTANLL 127 44 >37313.43 >26086.96 VYXKITPVS 4.3 X TYGNXTVTV 26 KYPDRVVPX 224 VYVXSXVTX 5.3 DAQXXXNTX 5.9 KYQAVTTTL 22 16 >156250 625 KYGPGPGTT 103 130 9180 7056 TL KYQGPGPGT 543 438 74453 5999 TL

TABLE 19 HLA-B7 SUPERTYPE SEQ Sequence ID NO. AA Organism Protein Position Analog APGPGPGLL 9 Artificial Consensus A sequence APRGPGPGL 9 Artificial Consensus A sequence QPRAPIRPI 9 EBNA 881 YPLHEQHGM 9 EBNA 458 CPTVQASKL 9 HBV NUC 14 SPTYKAFL 8 HBV pol 659 SPGPGFGL 8 HBV pol 659 A TPAGPGPGVF 10 HBV pol 354 A TPARGPGPGF 10 HBV pol 354 A TPTGWGLM 9 HBV POL 691 APCNFFTSA 9 HBV X 146 GPGHKARVI 9 HIV GAG 390 A RPQVPLRPMTI 11 HIV NEF 98 A FPVRPQVPI 9 HIV NEF 94 A RPQVPLRPI 9 HIV NEF 98 A RPQVPLRPMTI 11 HIV NEF 98 A YPLTFGWCI 9 HIV NEF 217 A FPLTFGWCI 9 HIV NEF 217 A FPLTFGWCFKI 11 HIV NEF 217 A FPVRPQVPL 9 HIV nef 94 FPGPGPGPL 9 HIV nef 94 A FPVGPGPGL 9 HIV nef 94 A GPKVKQWPI 9 HIV POL 197 A LPPLERLTI 9 HIV REV 79 A CPEEKQRHL 9 HPV E6 118 VPGPGPGL 8 Human Her2/neu 884 A RPGPGPGVSEF 11 Human Her2/neu 966 A RIPRGPGPGSEF 11 Human Her2/neu 966 A RPRFGPGPGEF 11 Human Her2/neu 966 A RPRFRGPGPGF 11 Human Her2/neu 966 A APGPGPGAAPA 11 Human p53 76 A APAGPGPGAPA 11 Human p53 76 A APAAGPGPGPA 11 Human p53 76 A APAAPGPGPGA 11 Human p53 76 A RPRGDNFAV 9 Pf SSP2 305 RPGPGPGAV 9 Pf SSP2 305 A RPRGPGPGV 9 Pf SSP2 305 A APRTVALTAL 10 Unknown Naturally procesed APGPGPGTAL 10 Unknown Naturally A procesed APRGPGPGAL 10 Unknown Naturally A procesed APRTGPGPGL 10 Unknown Naturally A procesed XVXDNATEY 9 Unknown Naturally A procesed LGFVFTLTV 9 unknown

TABLE 20 HLA-B7 SUPERTYPE SEQ Sequence ID NO. B*0702 B*3501 B*5101 B*5301 B*5401 APGPGPGLL 299 7481 1614 18117 15613 APRGPGPGL 4.9 974 633 19779 1120 QPRAPIRPI 6770 >72000 >55000 12 >100000 YPLHEQHGM >55000 20785 >55000 10 >100000 CPTVQASKL 3247 645 448 1861 21643 SPTYKAFL 109 31169 4665 54879 58651 SPGPGPGL 173 2337 3535 25607 53272 TPAGPGPGVF 334 374 296 2629 351 TPAIRGPGPGF 144 1678 2418 2742 31768 TPTGWGLAI 76 5145 103 1343 172 APCNFFTSA 43 8087 1045 >22409.64 0.61 GPGHKARVI 1686 >72000 >55000 2.2 >50000 RPQVPLRPMTI 47009 >18997.36 8081 21518 129 FPVRPQVPI 94 124 39 222 9.1 RPQVPLRPI 367 >23225.81 >9001.64 85335 1215 RPQVPLRPMTI 140 10455 5045 21538 >15128.59 YPLTFGWCI 54283 1378 153 154 79 FPLTFGWCI 47951 164 63 36 14 FPLTFGWCFKI 52567 4991 590 188 105 FPVRPQVPL 17 3.8 18 49 21 FPGPGPGPL 1584 426 2330 21036 29900 FPVGPGPGL 106 14 138 32 246 GPKVKQWPI 5500 >72000 >55000 2.3 >50000 LPPLERLTI 24398 13399 359 2624 11243 CPEEKQRHL 10 >52554.74 >35483.87 >109411.76 >76923.08 VPGPGPGL 1517 447 537 4094 46405 RPGPGPGVSEF 119 18115 16774 20988 3360 RPRGPGPGSEF 11 24871 >14824.8 19336 2745 RPRFGPGPGEF 14 >30901.29 >14824.8 76844 15470 RPRFRGPGPGF 9.7 >30901.29 >14824.8 49682 60095 APGPGPGAAPA 1112 1252 1317 4366 361 APAGPGPGAPA 161 >28915.66 11947 >39743.59 43 APAAGPGPGPA 173 12845 12470 28574 204 APAAPGPGPGA 811 3484 15814 >39240.51 158 RPRGDNFAV 12 20386 1681 >46268.66 212 RPGPGPGAV 23 48487 2899 >46268.66 1891 RPRGPGPGV 11 2368 52 34831 47 APRTVALTAL 12 4351 14601 61596 16804 APGPGPGTAL 81 16315 16462 >43661.97 35965 APRGPGPGAL 11 23381 12732 >43661.97 1665 APRTGPGPGL 15 1414 1559 22012 2043 XVXDNATEY >55000 444 >100000 LGFVFTLTV 849 >72000 27500 >93000 464

TABLE 21 HLA-B44 SUPERTYPE SEQ ID Sequence NO. AA Organism Protein Position Analog SEAAYAKKI 9 Artificial pool A sequence consensus GEFPYKAAA 9 Artificial pool A sequence consensus SEAPYKAIL 9 Artificial pool A sequence consensus SEAPKYAIL 9 Artificial pool A sequence consensus AIEFKYIAAV 9 Artificial pool A sequence consensus AEIPYLAKY 9 Artificial pool A sequence consensus AEIPKLAYF 9 Artificial pool A sequence consensus FPFDYAAAF 9 Artificial A sequence FPFKYKAAF 9 Artificial A sequence FPFKYAKAF 9 Artificial A sequence FPFKYAAAF 9 Artificial A sequence FAFKYAAAF 9 Artificial A sequence FQFKYAAAF 9 Artificial A sequence FDFKYAAAF 9 Artificial A sequence SENDRYRLL 9 EBV BZLF1 209 A IEDPPYNSL 9 EBV lmp2 200 A YEANGNLI 8 Flu HA 259 A YBDLRVLSF 9 Flu NP 338 A SDYEGRLI 8 Flu NP 50 GEISPYPSL 9 Flu NS1 158 A MDIDPYKEF 9 HBV NUC 30 LDKGIKPY 8 HBV POL 125 ADLMGYIPL 9 HCV core 131 LDPYARVAI 9 HCV NS5b 2663 A AENLWVTVY 9 HIV gp120 1 KBNLWVTVY 9 HIV gp120 1 A AEKLWVTVY 9 HIV gp120 1 A AENKWVTVY 9 HIV gp120 1 A AENLKVTVY 9 HIV gp120 1 A AENLWKTVY 9 HIV gp120 1 A AENLWVKVY 9 HIV gp120 1 A AENLWVTKY 9 HIV gp120 1 A AENLWVTYK 9 HIV gp120 1 A FENLWVTVY 9 HIV gp120 1 A VENLWVTVY 9 HIV gp120 1 A PENLWVTVY 9 HIV gp120 1 A NENLWVTVY 9 HIV gp120 1 A DENLWYTVY 9 HIV gp120 1 A TENLWVTVY 9 HIV gp120 1 A YENLWVTVY 9 HIV gp120 1 A ATNLWVTVY 9 HIV gp120 1 A AEFLWVTVY 9 HIV gp120 1 A AEVLWVTVY 9 HIV gp120 1 A AEPLWVTVY 9 HIV gp120 1 A ABDLWVTVY 9 HIV gp120 1 A AENLWVTVY 9 HIV gp120 1 AETLWVTVY 9 HIV gp120 1 A AENFWVTVY 9 HIV gp120 1 A ABNVWVTVY 9 HIV gp120 1 A AENPWVTVY 9 HIV gp120 1 A AENDWVTVY 9 HIV gp120 1 A AENNWVTVY 9 HIV gp120 1 A AENTWVTVY 9 HIV gp120 1 A AENLFVTVY 9 HIV gp120 1 A ABNLVVTVY 9 HIV gp120 1 A AENLPVTVY 9 HIV gp120 1 A AENLDVTVY 9 HIV gp120 1 A AENLNVTVY 9 HIV gp120 1 A AENLTVTVY 9 HIV gp120 1 A AENLWFTVY 9 HIV gp120 1 A AENLWLTVY 9 HIV gp120 1 A AENLWPTVY 9 HIV gp120 1 A AENLWDTVY 9 HIV gp120 1 A AENLWNTVY 9 HIV gp120 1 A AENLWTTVY 9 HIV gp120 1 A AENLWVFVY 9 HIV gp120 1 A AENLWVVVY 9 HIV gp120 1 A AENLWVPVY 9 HIV gp120 1 A AENLWVDVY 9 HIV gp120 1 A AENLWVNVY 9 HIV gp120 1 A AENLWVSVY 9 HIV gp120 1 A AENLWVTFY 9 HIV gp120 1 A AENLWVTLY 9 HIV gp120 1 A AENLWVTPY 9 HIV gp120 1 A AENLWVTDY 9 HIV gp120 1 A AENLWVTNY 9 HIV gp120 1 A ABNLWVTTY 9 HIV gp120 1 A AENLWVTVA 9 HIV gp120 1 A AENLWVTVG 9 HIV gp120 1 A AENLWVTVE 9 HIV gp120 1 A AENLWVTVF 9 HIV gp120 1 A AENLWVTVG 9 HIV gp120 1 A AENLWVTVH 9 HIV gp120 1 A AENLWVTVI 9 HIV gp120 1 A AENLWVTVL 9 HIV gp120 1 A AENLWVTVM 9 HIV gp120 1 A AENLWVTVN 9 HIV gp120 1 A AENLWVTVP 9 HIV gp120 1 A AENLWVTVQ 9 HIV gp120 1 A AENLWVTVR 9 HIV gp120 1 A AENLWVTVS 9 HIV gp120 1 A AENLWVTVT 9 HIV gp120 1 A AENLWVTVV 9 HIV gp120 1 A AENLWVTVW 9 HIV gp120 1 A AENLWVTVY 9 HIV gp120 1 ABNLYVTVF 9 HIV gp120 1 A TEPAAVGVGAV 11 HIV NEF 33 AEPAAEGV 8 HIV NEF 34 AEPAAEGVGA 10 HIV NEF 34 ABPAAEGVGAV 11 HIV NEF 34 QEEEEVGFPV 10 HIV NEF 84 EEEEVGFPV 9 HIV NEF 86 EEEVGFPV 8 HIV NEF 87 EEVGFPVRPQV 11 HIV NEF 88 DEEVGFPV 8 HIV NEF 89 KBKGGLDGL 9 HIV NEF 120 KBKGGLDGLI 10 HIV NEF 120 QEILDLWV 8 HIV NEF 184 QEILDLWVY 9 HIV NEF 184 AETFYYDGA 9 HIV POL 629 EEKPRTLHDL 10 HPV E6 6 NEILIRCII 9 HPV E6 97 QEKKRHVDL 9 HPV E6 113 AEGKEVLL 8 Human CEA 46 QELFIPNL 8 Human CEA 282 QELFISNI 8 Human CEA 460 TEKNSGLY 8 Human CEA 468 AELPKPSI 8 Human CEA 498 PEAQNTTY 8 Human CEA 525 IESTPFNVA 9 Human CEA 38 AEGKEVLLL 9 Human CEA 46 EEATGQFRV 9 Human CEA 132 VEDKDAVAF 9 Human CEA 157 CEPETQDAT 9 Human CEA 167 PETQDATYL 9 Human CEA 169 CETQNPVSA 9 Human CEA 215 QELFIIPNIT 9 Human GEA 282 AEPPKPFIT 9 Human CEA 320 VEDEDAVAL 9 Human CEA 335 CEPEIQNTT 9 Human CEA 345 PEIQNTTYL 9 Human CEA 347 YECGIQNEL 9 Human CEA 391 QELFISNIT 9 Human CEA 460 TEKNSQLYT 9 Human CEA 468 AEGKIEVLLLV 10 Human CEA 46 KEVLLLVHNL 10 Human CEA 49 GERVDGNRQI 10 Human CEA 70 REIIYPNASL 10 Human CEA 98 NEEATGQFRV 10 Human CEA 131 EEATGQFRVY 10 Human CEA 132 GENLNLSCHA 10 Human CEA 252 QELFIIPNITV 10 Human CEA 282 CEPEIQNTTY 10 Human CEA 345 PEIQNTIFYLW 10 Human CEA 347 CEPEAQNTTY 10 Human CEA 523 PEAQNTTYLW 10 Human CEA 525 MESPSAPPHRW 11 Human CEA 1 IESTPFNVAEG 11 Human CEA 38 GERVDGNRQII 11 Human CEA 70 REIIYPNASLL 11 Human CEA 98 NEEATGQFRVY 11 Human CEA 131 CEPETQDATYL 11 Human CEA 167 GENLNLSCHAA 11 Human CEA 252 CEPEIQNTTYL 11 Human CEA 345 PEIQNTTYLWW 11 Human CEA 347 YECGIQNELSV 11 Human CEA 391 NELSVDHSDPV 11 Human CEA 397 GEPEAQNTTYL 11 Human CEA 523 PEAQNTTYLWW 11 Human CEA 525 PEIQNTTYLWWV 12 Human CEA 347 PEAQNTTYLWWV 12 Human CEA 525 CEPEIQNTTYLWW 13 Human CEA 345 AEMGKGSFKY 10 Human elong. 48 Factor Tu SEDCQSL 7 Human Her2/neu 209 REVRAVT 7 Human Her2/neu 351 FETLEEI 7 Human Her2/neu 400 TELVEPL 7 Human Her2/neu 694 SECRPRF 7 Human Her2/neu 963 PETHLDML 8 Human Her2/neu 39 QEVQGYVL 8 Human Her2/neu 78 RELQLRSL 8 Human Her2/neu 138 CELHCPAL 8 Human Her2/neu 264 LEEITGYL 8 Human Her2/neu 403 EEITGYLY 8 Human Her2/neu 404 DECVGEGL 8 Human Her2/neu 502 AEQRASPL 8 Human Her2/neu 644 KBILDEAY 8 Human Her2/neu 765 EEAPRSPL 8 Human Her2/neu 1068 SEDPTVPL 8 Human Her2/neu 1113 MELAALCRW 9 Human Her2/neu 1 QEVQGYVLI 9 Human Her2/neu 78 FEDNYALAV 9 Human Her2/neu 108 RELQLRSLT 9 Human Her2/neu 138 TEILKGGVL 9 Human Her2/neu 146 HEQCAAGCT 9 Human Her2/neu 237 GELHCPALV 9 Human Her2/neu 264 FESMPNPEG 9 Human Her2/neu 279 QEVTAEDGT 9 Human Her2/neu 320 CEKCSKPCA 9 Human Her2/neu 331 MEHLREVRA 9 Human Her2/neu 347 REVRAVTSA 9 Human Her2/neu 351 QEFAGCKKI 9 Human Her2/neu 362 EEITGYLYI 9 Human Her2/neu 404 RELGSGLAL 9 Human Her2/neu 459 GEGLACHQL 9 Human Her2/neu 506 QEGVEECRV 9 Human Her2/neu 538 VEECRVLQG 9 Human Her2/neu 541 EECRVLQGL 9 Human Her2/neu 542 AEQRASPLT 9 Human Her2/neu 644 QETELVEPL 9 Human Her2/neu 692 VEPLTPSGA 9 Human Her2/neu 697 TELRKVKVL 9 Human Her2/neu 718 GENVKIPVA 9 Human Her2/neu 743 KBILDEAYV 9 Human Her2/neu 765 DEAYVMAGV 9 Human Her2/neu 769 DETEYHADG 9 Human Her2/neu 873 LESILRRRF 9 Human Her2/neu 891 GERLPQPPI 9 Human Her2/neu 938 LEDDDMGDL 9 Human Her2/neu 1009 EEYLVPQQG 9 Human Her2/neu 1021 EEEAPRSPL 9 Human Her2/neu 1067 EEAPRSPLA 9 Human Her2/neu 1068 SEQAGSDVF 9 Human Her2/neu 1078 PEYVNQPDV 9 Human Her2/neu 1137 PEYLTPQGG 9 Human Her2/neu 1194 PERGAPPST 9 Human Her2/neu 1228 ABNPEYLGL 9 Human Her2/neu 1243 MELAALCRWG 10 Human Her2/neu 1 LELTYLPTNA 10 Human Her2/neu 60 QEVQGYVLIA 10 Human Her2/neu 78 FEDNYALAVL 10 Human Her2/neu 108 TEILKGGVLI 10 Human Her2/neu 146 GESSEDCQSL 10 Human Her2/neu 206 SEDCQSLTRT 10 Human Her2/neu 209 CELHCPALVT 10 Human Her2/neu 264 MEHLREVRAV 10 Human Her2/neu 347 QEFAGCKKIF 10 Human Her2/neu 362 FETLEEITGY 10 Human Her2/neu 400 LEEITGYLYI 10 Human Her2/neu 403 RELGSGLALI 10 Human Her2/neu 459 PEDECVGEGL 10 Human Her2/neu 500 QEGVEECRVL 10 Human Her2/neu 538 YEECRVLQGL 10 Human Her2/neu 541 REYVNARHCL 10 Human Her2/neu 552 PECQPQNGSV 10 Human Her2/neu 565 EEGACQPCPI 10 Human Her2/neu 619 QETELVIEPLT 10 Human Her2/neu 692 VEPLTPSGAM 10 Human Her2/neu 697 KBTELRKVKV 10 Human Her2/neu 716 TELRKVKVLG 10 Human Her2/neu 718 GENVKIPVAI 10 Human Her2/neu 743 KEILDEAYVM 10 Human Her2/neu 765 DEAYVMAGVG 10 Human Her2/neu 769 DETEYHADGG 10 Human Her2/neu 873 TEYHADGGKV 10 Human Her2/neu 875 LESILRRRFT 10 Human Her2/neu 891 REIPDLLEKG 10 Human Her2/neu 929 SECRPRFREL 10 Human Her2/neu 963 RELVSEFSRM 10 Human Her2/neu 970 NEDLGPASPL 10 Human Her2/neu 991 AEEYLVPQQG 10 Human Her2/neu 1020 EEYLVPQQGF 10 Human Her2/neu 1021 SEEEAPRSPL 10 Human Her2/neu 1066 EEEAPRSPLA 10 Human Her2/neu 1067 SETDGYVAPL 10 Human Her2/neu 1122 PERGAPPSTF 10 Human Her2/neu 1228 PEYLGLDVPV 10 Human Her2/neu 1246 MELAALCRWGL 11 Human Her2/neu 1 PETHLDMLRHL 11 Human Her2/neu 39 RELQLRSLTEI 11 Human Her2/neu 138 GESSEDCQSLT 11 Human Her2/neu 206 SEDCQSLTRTV 11 Human Her2/neu 209 GELHCPALVTY 11 Human Her2/neu 264 FESMPNPEGRY 11 Human Her2/neu 279 CEKCSKPCARV 11 Human Her2/neu 331 MEHLREVRAVT 11 Human Her2/neu 347 REVRAVTSANI 11 Human Her2/neu 351 QEFAGCKKIFG 11 Human Her2/neu 362 FEThEEITGYL 11 Human Her2/neu 400 EEITGYLYISA 11 Human Her2/neu 404 GEGLACHQLCA 11 Human Her2/neu 506 DEEGACQPCPI 11 Human Her2/neu 618 AEQRASPLTSI 11 Human Her2/neu 644 TELVEPLTPSG 11 Human Her2/neu 694 KBTELRKVKVL 11 Human Her2/neu 716 KEILDEAYVMA 11 Human Her2/neu 765 LEDVRLVHRDL 11 Human Her2/neu 836 WELMTFGAKPY 11 Human Her2/neu 913 GERLPQPPICT 11 Human Her2/neu 938 SEGRPRFRBLV 11 Human Her2/neu 963 RELVSEFSRMA 11 Human Her2/neu 970 AEEYLVPQQGF 11 Human Her2/neu 1020 EEYLVPQQGFF 11 Human Her2/neu 1021 SEEEAPRSPLA 11 Human Her2/neu 1066 SEGAGSDVFDG 11 Human Her2/neu 1078 SETDGYVAPLT 11 Human Her2/neu 1122 REGPLPAARPA 11 Human Her2/neu 1153 VENPEYLTPQG 11 Human Her2/neu 1191 PEYLTPQGGAA 11 Human Her2/neu 1194 AENPEYLGLDV 11 Human Her2/neu 1243 LELTYLPTNASL 12 Human Her2/neu 60 RELQLRSLTEIL 12 Human Her2/neu 138 PEGRYTFGASCV 12 Human Her2/neu 285 LEEITGYLYISA 12 Human Her2/neu 403 EEITGYLYISAW 12 Human Her2/neu 404 PEADQCVACAHY 12 Human Her2/neu 579 TELVEPLTPSGA 12 Human Her2/neu 694 TEYHADGGKVPI 12 Human Her2/neu 875 GERLPQPPIGTI 12 Human Her2/neu 938 AEEYLVPQQGFF 12 Human Her2/neu 1020 PEGRYTFGASCVT 13 Human Her2/neu 285 CEKCSKPCARVCY 13 Human Her2/neu 331 MEHLREVRAVTSA 13 Human Her2/neu 347 DECVGEGLAGHQL 13 Human Her2/neu 502 PECQPQNGSVTCF 13 Human Her2/neu 565 RBNTSPKANKEIL 13 Human Her2/neu 756 REIPDLLEKGERL 13 Human Her2/neu 929 SEFSRMARDPQRF 13 Human Her2/neu 974 SEGAGSDVFDGDL 13 Human Her2/neu 1078 GEFGGYGSV 9 Human Histactranf 127 A LWQLNGRLEYTLKDR 15 Human IFN-B 21 A SEFQAAI 7 Human MAGE2 103 SEYLQLV 7 Human MAGE2 155 WEELSML 7 Human MAGE2 222 GEPHISY 7 Human MAGE2 295 LEARGEAL 8 Human MAGE2 16 QEEEGPRM 8 Human MAGE2 90 EEEGPRMF 8 Human MAGE2 91 VELVEELL 8 Human MAGE2 114 AEMLESVL 8 Human MAGE2 133 SEYLQLVF 8 Human MAGE2 155 EEKIWEEL 8 Human MAGE2 218 LEARGEALG 9 Human MAGE2 16 GEALGLVGA 9 Human MAGE2 20 QEEEGPRMF 9 Human MAGE2 90 VELVHFLLL 9 Human MAGE2 114 REPVTKAEM 9 Human MAGE2 127 SEYLQLVFG 9 Human MAGE2 155 PEEKIWEEL 9 Human MAGE2 217 EELSMLEVF 9 Human MAGE2 223 FEGREDSVF 9 Human MAGE2 231 YEFLWGPRA 9 Human MAGE2 269 EEGLEARGEA 10 Human MAGE2 13 LEARGEALGL 10 Human MAGE2 16 VEVTLGEVPA 10 Human MAGE2 46 EEGPRMFPDL 10 Human MAGE2 92 REPVTKAEML 10 Human MAGE2 127 SEYLQLVFGI 10 Human MAGE2 155 VEVVPISHLY 10 Human MAGE2 167 EEKIWEELSM 10 Human MAGE2 218 WEELSMLEVF 10 Human MAGE2 222 FEGREDSVFA 10 Human MAGE2 231 QENYLEYRQV 10 Human MAGE2 252 YEFLWGPRAL 10 Human MAGE2 269 GEPHISYPPL 10 Human MAGE2 295 EEGLEARGEAL 11 Human MAGE2 13 LEARGEALGLV 11 Human MAGE2 16 GEALGLVGAQA 11 Human MAGE2 20 EEQQTASSSST 11 Human MAGE2 34 VEVTLGEVPAA 11 Human MAGE2 46 EEEGPRMFPDL 11 Human MAGE2 91 SEFQAAISRKM 11 Human MAGE2 103 VELVHFLLLKY 11 Human MAGE2 114 LESVLRNCQDF 11 Human MAGE2 136 VEVVPISHLYI 11 Human MAGE2 167 IEGDCAPEEKI 11 Human MAGE2 211 EEKIWEELSML 11 Human MAGE2 218 EELSMLEVFEG 11 Human MAGE2 223 LEVEEGREDSV 11 Human MAGE2 228 YEFLWGPRALI 11 Human MAGE2 269 EEQQTASSSSTL 12 Human MAGE2 34 QEEEGPRMFPDL 12 Human MAGE2 90 SEFQAAISRKMV 12 Human MAGE2 103 LESVLRNCQDFF 12 Human MAGE2 136 VEVYPISHLYIL 12 Human MAGE2 167 EEGLEARGEALGL 13 Human MAGE2 13 LEARGEALGLVGA 13 Human MAGE2 16 LESEFQAAISRKM 13 Human MAGE2 101 REPVTKAEMLESV 13 Human MAGE2 127 SEYLQLVFGIEVV 13 Human MAGE2 155 IEVVEVVPISHLY 13 Human MAGE2 164 VEVVPISHLYILV 13 Human MAGE2 167 MEVDPIGHLY 10 Human MAGE3 167 EEEGPSTF 8 Human MAGE3 91 AELVHFLL 8 Human MAGE3 114 FEGREDSI 8 Human MAGE3 231 QEAASSSST 9 Human MAGE3 36 AELVHFLLL 9 Human MAGE3 114 AEMLGSVVG 9 Human MAGE3 133 EELSVLEVF 9 Human MAGE3 223 FEGREDSIL 9 Human MAGE3 231 QEAASSSSTL 10 Human MAGE3 36 EEGPSTFPDL 10 Human MAGE3 92 IELMEVDPIG 10 Human MAGE3 164 MEVDPIGHLY 10 Human MAGE3 167 EEKIWEELSV 10 Human MAGE3 218 WEELSVLEVF 10 Human MAGE3 222 FEGREDSILG 10 Human MAGE3 231 EEEGPSTFPDL 11 Human MAGE3 91 AELVHFLLLKY 11 Human MAGE3 114 MEVDPIGHLYI 11 Human MAGE3 167 REGDCAPEEKI 11 Human MAGE3 211 EEKIWEELSVL 11 Human MAGE3 218 LEVFEGREDSI 11 Human MAGE3 228 RERFEMF 7 Human p53 335 LEDSSGNL 8 Human p53 257 GEYFTLQI 8 Human p53 325 VEPPLSQET 9 Human p53 10 PENNVLSPL 9 Human p53 27 DEAPRMPEA 9 Human p53 61 HBRCSDSDG 9 Human p53 179 VEGNLRVEY 9 Human p53 197 VEYLDDRNT 9 Human p53 203 LEDSSGNLL 9 Human p53 257 RELNEALEL 9 Human p53 342 NEALELKDA 9 Human p53 345 LELKDAQAG 9 Human p53 348 MEEIPQSDPSV 10 Human p53 1 VEPPLSQETF 10 Human p53 10 QETFSDLWKL 10 Human p53 16 IEQWFTEDPG 10 Human p53 50 DEAPRMPEAA 10 Human p53 61 HERCSDSDGL 10 Human p53 179 VEGNLRVEYL 10 Human p53 197 VEYLDDRNTF 10 Human p53 203 PEVGSDCTTI 10 Human p53 223 LEDSSGNLLG 10 Human p53 257 FEVRVCAGPG 10 Human p53 270 TEEENLRXKG 10 Human p53 284 GEPHHELPPG 10 Human p53 293 GEYETLQIRG 10 Human p53 325 RERFEMFREL 10 Human p53 335 FEMFRELNEA 10 Human p53 338 QETFSDLWKLL 11 Human p53 16 HERCSDSDGLA 11 Human p53 179 YEPPEVGSDCT 11 Human p53 220 HELPPGSTKRA 11 Human p53 297 FEMFRELNEAL 11 Human p53 338 NEALELKDAQA 11 Human p53 345 TEDPGPDEAPRM 12 Human p53 55 GEPHHELPPGST 12 Human p53 293 DEAPRMPEAAPPV 13 Human p53 61 VVPPEVGSDCTTI 13 Human p53 220 RERRDNYV 8 Human unknown SEIDLILGY 9 Human unknown AEIPTRVNY 9 Human unknown AEMGKFKFSY 10 Human unknown DEIGVIDLY 9 Human unknown AEMGKFKYSF 10 Human unknown A SEAIHTFQY 9 Human unknown SEAIYTFQF 9 Human unknown A AEGIVTGQY 9 Human unknown HETTYNSI 8 Mouse beta actin 275 A GELSYLNV 8 Mouse cathepsin D 255 YEDTGKTI 8 Mouse p40 phox RNA 245 YENDIEKKI 9 Pf CSP 375

TABLE 22 HLA-B44 SUPERTYPE SEQ ID Sequence NO. B*1801 B*4001 B*4002 B*4402 B*4403 B*4501 SEAAYAKKI 8609 308 129 1685 61 287 GEFPYKAAA 286 170 3.9 746 2537 11 SEAPYKAIL 2258 29 8.8 440 170 262 SEAPKYAIL 2263 113 7.8 762 2260 479 AEFKY1AAV 48 2.8 6.5 28 21 4.9 AEIPYLAKY 116 7258 3159 44 30 668 AEIPKLAYF 1641 57 5.6 229 57 608 FPFDYAAAF 141 FPFKYKAAF 155 FPFKYAKAF 86 FPFKYAAAF 16 FAFKYAAAF 95 FQFKYAAAF 22 FDFKYAAAF 187 SENDRYRIL 18281 271 23 183 164 1073 IEDPPYNSL 35457 16 688 15833 40075 18697 YEANGNLI 191 7.9 7.0 516 3085 10342 YEDLRVLSF 20 67 71 24 212 18697 SDYEGRLI >24800 27150 86 851 228 10469 GEISPYPSL 19361 24 1.8 3564 293 115 MDIDPYKEF 169477 3700 382 21744 1949 2615 LDKGIKPY >100000 17884 468 >43192.49 19311 23609 ADLMGYIPL >7616.71 959 4.7 >21395.35 10292 >49000 LDPYARVAI >24409.45 >88888.89 372 >41628.96 >39766.08 >49000 AENLWVTVY 155 1053 547 522 284 200 KENLWVTVY 184 2738 373 308 306 6215 AEKLWVTVY 286 18278 306 168 287 219 AENKWVTVY 781 11303 534 294 540 297 AENLKVTVY 138 7746 1075 253 487 9624 AENLWKTVY 913 850 406 139 383 245 AENLWVKVY 2735 1482 1696 708 105 132 AENLWVTKY 511 1010 1998 355 1064 201 AENLWVTVK 29464 853 2004 6305 2133 186 FENLWVTVY 59 943 1336 4179 1312 21403 VENLWVTVY 25 5499 5586 13454 4856 15654 PENLWVTVY 190 >72727.27 >154545.45 >167272.73 >425000 >49000 NENLWVTVY 38 >72727.27 11774 453 224 1668 DENLWVTVY 26 >72727.27 41098 4589 988 49000 TENLWVTVY 14 14040 1415 291 364 5296 YENLWVTVY 29 552 324 640 369 10701 ATNLWVTVY 17615 487 >154545.45 8912 >43037.97 >49000 AEFLWVTVY 131 183 240 1013 156 472 AEVLWVTVY 142 1549 436 1520 390 1244 AEPLWVTVY 310 1727 2484 1322 96 1384 AEDLWVTVY 354 423 3521 2329 469 1845 AENLWVTVY 122 1581 552 308 132 301 AETLWVTVY 199 1052 198 501 221 774 AENFWVTVY 182 1394 542 171 268 289 AENVWVTVY 262 2238 386 1112 744 737 AENPWVTVY 27 843 224 18 53 202 AENDWVTVY 324 954 742 96 165 365 AENNWVTVY 167 1161 357 214 162 99 AENTWVTVY 213 1451 1793 386 166 442 AENLFVTVY 29 970 334 357 125 232 AENLVVTVY 62 876 1344 1030 203 718 AENLPVTVY 20 205 566 356 126 246 AENLDVTVY 517 220 12081 673 340 1291 AENLNVTVY 198 564 3544 447 358 2445 AENLTVTVY 153 689 1269 327 208 793 AENLWFTVY 360 699 668 227 62 90 AENLWLTVY 666 1702 884 647 226 227 ABNLWPTVY 661 690 688 157 50 116 AENLWDTVY 775 1145 2090 414 68 263 AENLWNTVY 336 1338 957 66 81 257 AENLWTTVY 196 246 625 51 50 118 AENLWVFVY 242 857 375 348 310 237 ABNLWVVVY 326 2728 1688 599 632 468 ABNLWVPVY 303 175 183 96 47 106 AENLWVDVY 415 700 3440 334 92 242 AENLWVNVY 317 1156 952 159 76 266 AENLWVSVY 232 1251 1347 351 178 292 AENLWVTFY 1299 1201 295 124 222 347 AENLWVTLY 392 463 731 199 119 349 AENLWVTPY 41 274 189 127 44 122 AENLWVTDY 1001 930 1208 191 103 328 AENLWVTNY 730 865 948 149 74 215 AENLWVTTY 28 280 191 37 26 48 ABNLWVTVA 9689 557 4.8 1543 296 9.1 AENLWVTVC 178026 157 1425 5593 2267 146 AENLWVTVE >258333.33 3888 1362 8910 2573 246 AENLWVTVF 365 162 20 346 162 262 AENLWVTVG 39743 861 47 1812 245 35 AENLWVTVH 16516 493 151 966 387 120 AENLWVTVI 11224 14 7.3 237 88 54 AENLWVTVL 6198 14 13 68 208 114 AENLWVTVM 508 13 6.1 195 35 50 AENLWVTVN 129167 6701 481 2623 414 169 AENLWVTVP 38441 9711 339 7715 2473 187 AENLWVTVQ 49640 522 85 1223 188 100 AENLWVTVR 32979 1246 1744 4857 1474 233 AENLWVTVS 25726 2163 103 4221 417 34 AENLWVTVT 12331 947 7.8 2696 343 10 AENLWVTVV 10709 84 19 5757 1432 35 AENLWVTVW 22610 1304 135 423 324 204 AENLWVTVY 51 1358 90 66 43 68 AENLYVTVF 61 17 3.1 39 47 69 TEPAAVGVGAV >8115.18 930 391 1938 459 8235 ABPAAEGV >8115.18 2070 2675 >22604.42 402 6590 AEPAAEGVGA >8115.18 4116 1655 >22604.42 >11447.81 104 AEPAAEGVGAV >8611.11 20364 242 >23896.1 >11447.81 1499 QEEEEVGFPV >8611.11 13117 2596 15203 >11447.81 86 EEEEVGFPV 3691 3340 417 7440 10313 37 EEEVGFPV 427 9578 2605 6372 >10461.54 227 EEVGFPVRPQV >22794.12 9905 108 23777 6553 808 DEEVGFPV 7.1 >32000 4260 9305 >10461.54 916 KEKGGLDGL >22794.12 55 174 >81415.93 >10461.54 9926 KEKGGLDGLI >22794.12 843 233 14726 3626 9986 QEILDLWV >22794.12 142 1717 >81415.93 5919 5504 QEILDLWVY 52 740 4522 264 172 6261 AETFYVDGA >6709.96 21630 1923 >21198.16 6924 38 EEKPRTLHDL >81578.95 36208 34027 15236 30010 419 NEILIRCII 5672 291 59 2722 258 3248 QEKKRHVDL 7.3 15984 63093 443 211 12613 AEGKEVLL 11455 1311 5303 17268 129 14165 QELFIPNI 127 5815 147 752 8.5 1319 QELFISNI 889 6396 1175 2282 70 1172 TEKNSGLY 211 9851 7117 1868 605 10248 AELPKPSI 7423 6697 131 1164 19 2608 PEAQNTTY 149 2594 2437 2204 76 3255 IESTPFNVA 69 1234 66 18749 0.97 15 AEGKEVLLL 1080 72 147 178 1.7 199 EEATGQFRV 805 5563 470 1691 95 18 VEDKDAVAF 94 121 1583 1661 1443 21204 CEPETQDAT 4009 3646 410 23421 50 97 PETQDATYL 9473 1240 33745 >34586.47 301 13430 CETQNPVSA 73 7016 261 20023 10.0 15 QELFIPNIT 125 4361 172 1217 3.0 18 AEPPKPFIT 12850 7067 7170 >34586.47 232 1813 VEDEDAVAL 840 11 2665 30667 51 27810 CEPEIQNTT 6889 5709 3081 31834 120 2732 PEIQNTTYL 923 138 2786 16816 231 1825 YECGIQNEL 82 71 53 452 5.3 855 QELFISNIT 530 6571 58 2334 3.9 80 TEKNSGLYT 1113 7522 3195 10097 101 1963 AEGKEVLLLV 5135 1019 408 479 8.6 994 KEVLLLVHNL 893 3.1 4.4 414 2.3 2512 GERVDGNRQI 9395 1933 369 3900 13 19464 REIIYPNASL 741 2.3 7.5 374 1.7 954 NEEATGQFRV 998 29086 22678 4365 471 405 EEATGQFRVY 64 >33333.33 55956 29 1041 1374 GENLNLSCHA 14373 1341 357 8610 5.3 271 QELFIPNITV 81 121 27 93 2.6 14 CEPEIQNTTY 1459 >10322.58 35697 49 14596 43739 PEIQNTTYLW 819 3301 9423 13 6173 10011 CEPEAQNTTY 9525 >12903.23 >48571.43 61 >4268.68 17330 PEAQNTTYLW 17082 >9248.55 >12592.59 27 21243 >28654.97 MESPSAPPHRW 12 943 1915 5.3 41 359 IESTPFNVAEG 87 1074 352 89 8.7 84 GERVDGNRQII 764 278 18 871 1.3 27084 REIIYPNASLL 1788 2.4 12 57 0.38 1777 NEEATGQFRVY 7.7 3252 999 9.6 69 3986 CEPETQDATYL 831 311 3388 398 807 62150 GENLNLSCHAA 7838 4557 63 1907 9.0 32 CEPEIQNITYL 129 287 1603 1245 60 11981 PEIQNTTYLWW 172 749 1045 17 227 1365 YECGIQNELSV 9.2 33 26 1714 0.46 155 NELSVDHSDPV 49 2554 1128 1615 38 78 CEPEAQNTTYL 962 2184 11723 3419 131 2450 PEAQNTTYLWW 147 2096 3090 121 79 2005 PBIQNTTYLWWV 644 1808 1539 481 93 994 PEAQNTTYLWWV 20 1694 646 5.1 3.3 CEPEIQNTTYLWW 84 858 3168 7.9 409 1243 AEMGKGSFKY 1618 6427 3820 112 90 305 SEDCQSL 18245 2691 14258 8248 431 19225 REVRAVT 8564 3136 725 31615 29 23544 FETLEBI 1518 7621 2110 42991 69 67957 TELVEPL 162 14164 1258 8854 66 >148484.85 SECRPRF 926 18181 1157 852 48 8856 PETHLDML 1954 8387 6118 >17523.81 83 20257 QEVQGYVL 3.4 28 5.0 1210 0.92 33 RELQLRSL 42 49 5.9 2025 0.62 1372 CELHCPAL 150 871 259 4361 39 30089 LEEITGYL 242 830 1805 5913 403 35502 EEITGYLY 20 5713 1223 11 83 238 DEGVGEGL 49 4864 481 938 34 14244 AEQRASPL 16 73 13 211 0.38 120 KEILDEAY 82 921 430 1081 74 2646 EEAPRSPL 1191 3489 1611 1593 171 1926 SEDPTVPL 103 71 161 12267 2.0 308 MELAALCRW 7.0 4833 138 16 9.9 1183 QEVQGYVLI 77 206 39 30 0.50 96 FEDNYALAV 12 34 5.1 13470 0.17 131 RELQLRSLT 638 316 13 465 0.20 162 TEILKGGVL 125 30 14 1377 0.28 2480 HEQCAAGCT 1995 42164 7377 19048 178 2974 CELHCPALV 136 4805 319 2308 52 1110 FESMPNPEG 6068 30237 59 16458 14 155 QEVTAEDGT 5207 31081 3122 7886 66 1843 CEKCSKPCA 3740 27386 2703 19957 342 8007 MEHLREVRA 233 44754 386 38 3.2 19 REVRAVTSA 626 427 0.71 3160 0.18 9.3 QEFAGCKKI 1120 736 131 81 44 2684 EEITGYLYI 86 906 916 12 121 94 RELGSGLAL 359 3.7 0.85 457 0.97 2262 GEGLACHQL 13766 187 88 112 11 340 QECVEECRV 15799 8755 1664 7150 210 4542 VEECRVLQG 1528 8947 7622 14202 305 20142 EEGRVLQGL 890 7076 2029 717 434 1185 AEQRASPLT 346 874 183 103 1.8 10 QETELVEPL 12 62 85 681 3.5 1232 VEPLTPSGA 7321 >9638.55 11 8516 191 17037 TELRKVKVL 1514 4698 54 2128 2.5 14147 GENVKIPVA 10755 14510 7.5 20309 2.7 7.0 KEILDEAYV 1358 62 146 6466 8.4 42 DEAYVMAGV 58 5327 1245 8006 138 161 DETEYHADG 159 >11940.3 >65384.62 >24403.18 1397 13353 LESILRRRF 29 >11940.3 3475 4.7 101 12918 GBRLPQPPI 62 71 15 63 1.1 15 LEDDDMGDL 191 556 351 947 900 6251 EEYLVPQQG 66 10344 136 651 126 131 EEEAPRSPL 902 4490 2881 342 362 307 EBAPRSPLA 486 10707 4900 180 294 4.5 SEGAGSDVF 74 5627 6525 69 192 6960 PEYVNQPDV 831 3437 1581 1109 48 2536 PEYLTPQGG 1456 18951 13860 6532 284 18990 PERGAPPST 385 4744 7679 1116 178 7767 AENPEYLGL 17 81 271 44 2.5 155 MELAALCRWG 102 8684 1840 5.7 135 408 LELTYLPTNA 332 325 10.4 6428 3.1 24 QEVQGYVL1A 61 772 64 1871 15 11 FEDNYALAVL 321 6.2 48 2844 3.8 3095 TEILKGGVLI 1021 241 294 24 21 7600 GESSEDCQSL 138636 8.1 23 427 5.1 2491 SEDGQSLTRT 335 8550 11529 518 2857 4726 GELHCPALVT 80 >9248.55 65 933 18 477 MEHLREVRAV 72 20684 160 180 13 140 QEFAGCKKIF 53 3686 12 4.0 3.6 115 FETLEEITGY 671 53363 36302 262 1679 >28488.37 LEEITGYLYI 143 914 2996 222 143 1488 RELGSGLALI 4810 22 4.4 32 0.78 173 PEDECVGEQL 1257 278 257 6331 49 24019 QECVEECRVL 315 444 399 606 22 2863 VEEGRVLQGL 270 227 5815 237 189 16094 REYVNARHCL 1327 39 4.8 106 0.97 126 PECQPQNGSV 7962 35957 20374 12964 472 >28488.37 EEGACQPCPI 119 40113 340 52 80 401 QETELVEPLT 15 293 338 1619 13 288 VEPLTPSGAM 4649 1667 584 4368 108 20167 KETELRKVKV 11925 26700 68 2936 4.5 1603 TELRKVKVLG 721 20312 601 3650 14 12816 GENVKIPVAI 563 314 28 230 6.7 198 KEILDEAYVM 0.14 10 153 35 7.5 234 DEAYVMAGVG 122 203 154 4033 4102 218 DETEYHADGG 613 45291 16801 3891 269 29025 TEYHADGGKV 239 5246 2003 2911 15 1571 LESILRRRFT 82 28476 1189 34 87 2251 REIPDLLEKG 649 4493 814 1270 13 1977 SEGRPRFREL 80 307 18 11 0.20 25 RELVSEFSRM 9.1 28 4.3 33 0.12 1726 NEDLGPASPL 107 281 150 40 6.0 231 AEEYLVPQQG 723 66699 24424 417 479 127 EEYLVPQQGF 2.1 26569 2551 6.9 11 73 SEEEAPRSPL 151 155 217 37 8.4 84 EEEAPRSPLA 6611 49549 38943 425 960 14 SETDGYVAPL 94 214 184 386 2.4 302 PERGAPPSTF 1062 14884 3437 6871 208 15700 PEYLGLDVPV 613 352 35 1371 1.7 610 MELAALCRWGL 6.4 24 30 17 0.92 116 PETHLDMLRHL 1322 700 2971 11534 70 4329 RELQLRSLTEI 261 2.8 3.7 125 0.99 269 GESSEDCQSLT 742 48 180 14386 40 2158 SEDCQSLTRTV 101 4322 311 943 21 10 CELHCPALVTY 12 3469 3198 140 89 2779 FESMPNPEGRY 74 3666 3533 59 70 1394 CEKCSKPCARV 1167 4103 2079 9594 101 1561 MEHLREVRAVT 1064 3614 2207 795 111 74 REVRAVTSANI 4491 17 30 1680 1.8 421 QEFAGCKKIFG 211 314 477 37 2.1 138 FETLEEITGYL 133 78 649 7490 42 2200 EEITGYLYISA 0.94 1440 52 4.5 2.1 0.9 GBGLACHQLCA 62 39 97 159 2.7 196 DEEGACQPCPI 451 5517 7293 968 438 1323 AEQRASPLTSI 467 19 58 5.1 2.5 11 TELVEPLTPSG 601 2978 3703 >21052.63 269 14079 KETELRKVKVL 9529 2973 1868 7136 71 12237 KEILDEAYVMA 731 252 95 11514 64 123 LEDVRLVHRDL 729 325 641 818 59 2382 WELMTFGAKPY 13 509 778 24 75 1216 GERLPQPPICT 12486 24270 23 9094 3.9 15 SECRPRFRBLV 1996 3673 121 927 18 118 RELVSEFSRMA 168 389 143 2613 3.5 32 AEEYLVPQQGF 125 584 1831 21 99 268 EEYLVPQQGFF 94 4291 1695 78 168 154 SEEEAPRSPLA 1318 3604 5110 8550 158 27 SEGAGSDVFDG 928 3751 5695 374 286 3008 SETDGYVAPLT 66 125 224 1225 2.2 45 REGPLPAARIPA 157 543 78 32906 4.2 347 VENPEYLTPQG 8386 56393 42593 17337 11 4188 PEYLTPQGGAA 1724 41026 200 >17829.46 354 1382 AENPEYLGLDV 11934 28 139 69 3.0 24 LELTYLPTNASL 12 25 102 386 6.8 11 RELQLRSLTEIL 5954 151 600 3778 1.1 1371 PEGRYTFGASCV 4071 2.9 4.4 778 116 LEEITGYLYISA 209 28 31 263 18 694 EEITGYLYISAW 746 478 1800 252 1492 PEADQCVACAHY 901 4050 5127 213 463 TELVEPLTPSGA 236 2059 59 2132 206 TEYHADGGKVPI 680 22 4.4 2177 61 GERLPQPPICTI 17769 162 3.9 292 2.5 AEEYLVPQQGFF 144 228 45 16 13 PEGRYTFGASCVT 5228 3793 737 1419 267 673 CEKCSKPCARVCY 701 >53333.33 406 302 44 1315 MEHLREVRAVTSA 70 669 72 144 18 12 DECVGEGLACHQL 464 2635 3668 2544 212 2063 PECQPQNGSVTGF 6293 381 5338 3564 375 >22374.43 RENTSPKANKEIL 7750 3.7 77 >2540.03 3.9 1510 REIPDLLEKGERL 7636 40 136 3050 16 2710 SEFSRMARDPQRF 61 350 57 23 12 247 SEGAGSDVFDGDL 5172 45 2059 1303 711 2458 GEFGGYGSV 307 112 6.4 2335 534 40 LWQLNGRLEYTLKDR 0.11 SEFQAAI 181 6830 779 2660 33 9597 SEYLQLV 1375 7777 658 733 21 930 WEELSML 1288 781 740 >28482.97 151 82009 GEPHISY 8833 12272 6716 36116 272 >33333.33 LEARGEAL 163 99 65 29495 2.9 31463 QEEEGPRM 298 11598 1608 19255 118 6730 EEEGPRMF 723 12281 32093 2406 213 943 VELVHFLL 5.0 69 31 3322 1.2 2427 AEMLESVL 968 14 31 327 0.88 302 SEYLQLVF 0.97 765 6.0 284 0.70 122 EEKIWEEL 753 9084 2599 98976 104 171 LEARGEALG 155 1161 3006 11018 24 2688 GEALOLYGA 9529 2832 34 6134 2.2 17 QEEEGPRMF 414 918 7747 237 409 2171 VELVHFLLL 71 79 31 579 3.1 1129 REPVTKAEM 60 373 284 896 4.5 832 SEYLQLVFG 18 8890 421 271 19 113 PEEKIWEEL 577 19449 3908 1029 235 17345 EELSMLEVF 1.4 16436 252 22 2.8 1013 FEGREDSVF 9.8 2366 348 221 13 3339 YEFLWGPRA 5.3 249 5.2 2355 1.1 241 EEGLEARGEA 1077 3434 3227 216 302 30 LEARGEALGL 81 184 277 2275 4.1 964 VEVTLGEVPA 14 371 31 3801 0.52 15 EEGPRMFPDL 128 4438 486 95 13 42 REPVTKAEML 88 23 264 84 41 917 SEYLQLVFGI 2.2 20 6.1 3.7 0.84 4.4 VEVVPISHLY 20 11522 4385 13 1225 4885 EEKIWEELSM 17 21450 477 46 19 107 WEELSMLEVF 0.14 463 30 15 15 290 FEGRLEDSVFA 178 >10062.89 4775 6879 192 503 QENYLEYRQV 118 493 102 17 16 27 YEFLWGPRAL 8.5 0.97 130 0.72 753 GEPHISYPPL 2612 7.0 2.9 1200 0.71 380 EEGLEARGEAL 179 300 578 2630 19 1812 LEARGEALGLV 158 198 345 >17829.46 13 1912 GEALGLVGAQA 877 4293 52 3575 1.4 28 EEQQTASSSST 752 4040 41162 5910 1552 134 VEVTLGEVPAA 124 25216 919 >23469.39 44 1583 EEEGPRMFPDL 1011 2646 3470 3273 131 209 SEFQAAISRKM 7.0 345 107 88 1.2 161 VELVHFLLLKY 52 550 294 1551 49 1790 LESVLRNCQDF 64 5409 3458 209 76 15241 VEVVPISHLYI 97 135 146 335 7.2 3788 IEGDCAPEEKI 844 27827 32058 2627 486 183 EEKIWEELSML 1641 4978 20625 1862 375 181 EELSMLEVFEG 1.5 24061 294 4.6 23 163 LEVFEGRBDSV 639 2624 367 >21296.3 46 29449 YEFLWGPRALI 5.2 4.1 2.8 92 0.59 450 EEQQTASSSSTL 7259 166 526 57 981 15 QEEEGPRMFPDL 3595 394 1330 1643 120 SEFQAAISRKMV 43 161 29 25 21 LESVLRNCQDFF 56 55 356 184 24 1993 VEVVPISHLYIL 266 3.4 16 486 4.0 1182 EEGLEARGEALGL 10416 1769 5143 196 118 1673 LEARGEALGLVGA 347 20 48 2575 2.2 116 LESEFQAAISRKM 49 310 72 242 14 22 REPVTKAEMLESV 5531 337 411 4546 21 1507 SEYLQLVFGIEVV 9.7 23 4.5 144 5.4 6.6 IEVVEVVPTSHLY 79 162 245 52 125 106 VEVVPISHLYILV 92 93 47 270 51 112 MEVDPIGHLY 13 209 334 13 28 228 EEEGPSTF 216 1008 435 3933 27 1819 AELVHFLL 120 71 6.8 1074 0.16 452 FEGREDSI 927 718 127 7708 13 2291 QEAASSSST 1422 23469 1480 9593 41 110 AELVHFLLL 160 25 3.1 33 0.94 141 AEMLGSVVG 96 1899 109 27 1.6 11 EELSVLEVF 7.3 10215 3314 61 12 2120 FEGREDSIL 1091 51 439 1925 11 >27071.82 QEAASSSSTL 171 49 47 56 13 287 EEGPSTFPDL 158 655 591 198 127 128 IELMEVDPIG 194 6592 5325 222 >16306.95 7604 MEVDPIGHLY 15 617 625 11 99 169 EEKIWEELSV 73 8947 79 396 17 17 WEELSVLEVF 1.7 75 37 14 13 1701 FEGREDSILG 229 940 4361 8534 172 20261 EEEGPSTFPDL 935 431 2120 2685 102 158 AELVHFLLLKY 153 32 39 178 1.6 670 MEVDPIGHLYI 9.8 34 16 64 0.91 95 REGDCAPEEKI 973 2418 830 4038 42 146 EEKIWEELSVL 133 152 1255 1416 58 218 LEVFEGREDSI 4745 206 512 20963 69 >31012.66 RERFEME 180 4079 1907 25488 108 20048 LEDSSGNL 17736 782 362 42791 211 15946 GEYFTLQI 7774 112 60 3511 1.0 261 VEPPLSQET 8302 17052 20508 3186 236 29270 PENNVLSPL 1150 1261 718 11174 8.8 >27071.82 DEAPRMPEA 84 9092 4577 6448 98 10.0 HERCSDSDG 1118 2367 38636 19328 208 13390 VEGNLRVEY 832 12752 67730 142 2583 39059 VEYLDDRNT 1442 36833 35854 10071 157 13503 LEDSSGNLL 1140 43 2771 4656 43 26134 RELNEALEL 3000 15 30 525 1.1 3337 NEALELKDA 1925 3887 27585 4270 1582 129 LELKDAQAG 451 18706 3659 17293 30 1989 MEEPQSDPSV 12157 3802 16536 1927 816 175 VEPPLSQETF 814 >37209.3 21732 406 525 >24019.61 QETFSDLWKL 736 199 255 39 14 901 IEQWFTEDPG 151 1250 2114 5595 142 197 DEAPRMPEAA 121 3941 8444 2594 1037 100 HERCSDSDGL 139 171 61 1468 6.0 1723 VEGNLRVEYL 104 481 2565 1963 22 15189 VEYLDDRNTF 0.94 501 37 32 1.4 3601 PEVGSDCTTI 611 4552 248 2293 2046 22487 LEDSSGNLLG 103 531 697 7905 153 19256 FEVRVCACPG 64 2043 4.9 180 0.76 1872 TEEENLRKKG 74966 >37209.3 11858 >23589.74 315 30635 GEPHHELPPG 108 3323 1888 11728 4.4 20 GEYFTLQIRG 108 88 19 2452 3.9 157 RERFEMFREL 83 29 17 17 0.34 422 FEMFRELNEA 127 3207 223 952 2.0 208 QETFSDLWKLL 4158 3366 740 631 168 1218 HERCSDSDGLA 1408 4879 1915 >20956.72 96 186 YEPPEVGSDCT 16872 4529 125 13349 12712 16034 HELPPGSTKRA 6034 3974 3255 47077 189 1472 FEMFRELNEAL 475 17 8.8 748 1.1 1352 NEALELKDAQA 742 6235 5071 >20956.72 949 53 TEDPGPDEAPRM 888 327 893 2053 161 1676 GEPHHELPPGST 6822 24342 4631 6581 252 169 DEAPRMPEAAPPV 427 >48484.85 7258 >2762.76 1376 19 YEPPEVGSDCTTI 8796 2699 1540 >2740.54 253 >20000 RERPDNYV >73809.52 71554 62 >67647.06 >34517.77 34648 SEIDLILGY 3.0 285 140 4.8 8.5 397 AEIPTRVNY 1691 7826 5443 333 23 1286 AEMGKFKFSY 1517 2941 622 146 28 283 DEIGVIDLY 11 >114285.71 >77272.73 707 212 >49000 AEMGKFKYSF 155 113 3.8 18 31 186 SEAIHTFQY 25 2895 1802 18 16 1078 SEAIYTFQF 5.7 967 39 4.8 20 293 AEGIVTGQY 7176 6462 1528 255 12 418 HETTYNSI 1644 251 336 616 23959 6608 GELSYLNV >24800 4856 100 19013 23735 784 YEDTGKTI 13997 794 83 7911 2177 49000 YENDIEKKI 30992 1156 145 1725 371

TABLE 23 HLA-DQ SUPERTYPES SEQ ID Sequence NO. AA Organism Protein Position Analog AAAKAAAAAAYAA 13 Artificial A sequence (44)YAAAAAAKAAA 13 Artificial A sequence AAFAAAKTAAAFA 13 Artificial A sequence YAAFAAAKTAAAFA 14 Artificial A sequence YAAFAAAKTAAAFA 14 Artificial sequence AHAAHAAHAAHAAHAA 16 HA A VLERYLLEAKEAENI 15 Human EPO 11 VPDTKVNFYAWKRMB 15 Human EPO 41 WKRMEVGQQAVEVWQ 15 Human EPO 51 VGQQAVEVWQGLALL 15 Human EPO 56 VEVWQGLALLSEAVL 15 Human EPO 61 GLALLSEAVLRGQAL 15 Human EPO 66 SEAVLRGQALLVNSS 15 Human EPO 71 RGQALLVNSSQPWEP 15 Human EPO 76 LQLHVDKAVSGLRSL 15 Human EPO 91 KEAISPPDAASAAPL 15 Human EPO 116 PPDAASAAPLRTITA 15 Human EPO 121 SAAPLRTITADTFRK 15 Human EPO 126 EAENITTGTAEHTSL 15 Human EPO 21 A RLFDNASLRAHRLHQ 15 Human Growth 8 hormone QLAFDTYQEFEEAYI 15 Human Growth 22 hormone ISLLLIQSWLEPVQF 15 Human Growth 78 hormone NSLVYGASDSNVYDL 15 Human Growth 99 hormone SDSNVYDLLKDLEEG 15 Human Growth 106 hormone KIFGSLAFLPESFDGDPA 18 Human Her2/neu 369 CLKDRRNFDIPEEIK 15 Human IFN-B 31 QLQQFQKEDAAVTIY 15 Human IFN-B 46 QKEDAAVTIYEMLQN 15 Human IFN-B 51 STGWNETIVENILLAN 15 Human IFN-B 76 ETIVENLLANVYHQR 15 Human IFN-B 81 KEDSHCAWTIVRVEI 15 Human IFN-B 136 MSYNLLGFLQRSSNT 15 Human IFN-B 1 A QHLCGSHLVEALYLV 15 Human Insulin 4 beta chain GSHLVEALYLVGGER 15 Human Insulin 8 beta chain GSDLVEALYLVCGER 15 Human Insulin 8 A beta chain VEALYLVGGERGFLY 15 Human Insulin 12 A beta chain VEALYLVTGERGFFY 15 Human Insulin 12 A beta chain IDVWLGGLAENFLPY 15 Human thyroid 632 perox IDVWLGGLAYNFLPY 15 Human thyroid 632 A perox IDVWLGGLALNFLPY 15 Human thyroid 632 A perox IDVWLGGLASNFLPY 15 Human thyroid 632 A perox IDVWLGGLAKNFLPY 15 Human thyroid 632 A perox IDVWLGGLADNFLPY 15 Human thyroid 632 A perox IDVYLGGLAENFLPY 15 Human thyroid 632 A perox IDVLLGGLAENFLPY 15 Human thyroid 632 A perox IDVSLGGLAENFLPY 15 Human thyroid 632 A perox IDVKLGGLAENFLPY 15 Human thyroid 632 A perox IDVDLGGLAENFLPY 15 Human thyroid 632 A perox IDVWLGGLAENYLPY 15 Human thyroid 632 A perox IDVWLGGLAENVLPY 15 Human thyroid 632 A perox IDVWLGGLAENSLPY 15 Human thyroid 632 A perox IDVWLGGLAENKLPY 15 Human thyroid 632 A perox IDVWLGGLAENDLPY 15 Human thyroid 632 A perox IYVWLGGLABNFLPY 15 Human thyroid 632 A perox ILVWLGGLAENFLPY 15 Human thyroid 632 A perox ISVWLGGLAENFLPY 15 Human thyroid 632 A perox IKVWLGGLAENFLPY 15 Human thyroid 632 A perox IEVWLGGLAENFLPY 15 Human thyroid 632 A perox IDVWLGGLABNFLPE 15 Human thyroid 632 A perox IDVWLGGLAENFLPL 15 Human thyroid 632 A perox IDVWLGGLAENFLPS 15 Human thyroid 632 A perox IDVWVLGGLAENFLPK 15 Human thyroid 632 A perox TDVWLGGLAENFLPD 15 Human thyroid 632 A perox IDVWLGGLAENFYPY 15 Human thyroid 632 A perox IDVWLGGLAENFVPY 15 Human thyroid 632 A perox IDVWLGGLAENFSPY 15 Human thyroid 632 A perox IDVWLGGLAENFKPY 15 Human thyroid 632 A perox IDVWLGGLAENFDPY 15 Human thyroid 632 A perox IDVWLGGLAEYFLPY 15 Human thyroid 632 A perox IDVWLGGLAELFLPY 15 Human thyroid 632 A perox 1DVWLGGLAESFLPY 15 Human thyroid 632 A perox IDVWLGGLAEKFLPY 15 Human thyroid 632 A perox IDVWLGGLAEDFLPY 15 Human thyroid 632 A perox IDVWLGGLAEQFLPY 15 Human thyroid 632 A perox IDVWLGGLYENFLPY 15 Human thyroid 632 A perox IDVWLGGLLENFLPY 15 Human thyroid 632 A perox IDVWLGGLSENFLPY 15 Human thyroid 632 A perox IDVWLGGLKENFLPY 15 Human thyroid 632 A perox IDVWLGGLDENFLPY 15 Human thyroid 632 A perox IDVWLGGYAENFLPY 15 Human thyroid 632 A perox IDVWLGGVAENFLPY 15 Human thyroid 632 A perox IDVWLGGSABNFLPY 15 Human thyroid 632 A perox IDVWLGGKAENFLPY 15 Human thyroid 632 A perox IDVWLGGDAENFLPY 15 Human thyroid 632 A perox IDVWLGYLAENFLPY 15 Human thyroid 632 A perox IDVWLGLLAENFLPY 15 Human thyroid 632 A perox IDVWLGSLAENFLPY 15 Human thyroid 632 A perox IDVWLGKLAENFLPY 15 Human thyroid 632 A perox IDVWLGDLABNFLPY 15 Human thyroid 632 A perox IDVWLYGLAENFLPY 15 Human thyroid 632 A perox IDVWLLGLAENFLPY 15 Human thyroid 632 A perox IDVWLSGLAENFLPY 15 Human thyroid 632 A perox TDVWLKGLAENFLPY 15 Human thyroid 632 A perox TDVWLDGLAENFLPY 15 Human thyroid 632 A perox IDVWYGGLAENFLPY 15 Human thyroid 632 A perox IDVWVGGLAENFLPY 15 Human thyroid 632 A perox IDVWSGGLAENFLPY 15 Human thyroid 632 A perox IDVWKGGLAENFLPY 15 Human thyroid 632 A perox IDVWDGGLAENFLPY 15 Human thyroid 632 A perox IDYWLGGLAENFLPY 15 Human thyroid 632 A perox IDLWLGGLAENFLPY 15 Human thyroid 632 A perox IDSWLGGLAENFLPY 15 Human thyroid 632 A perox IDKWLGGLABNFLPY 15 Human thyroid 632 A perox IDDWLGGLAENFLPY 15 Human thyroid 632 A perox IDVWLGGLABNFLYY 15 Human thyroid 632 A perox IDVWLGGLAENFLLY 15 Human thyroid 632 A perox IDVWLGGLAENFLSY 15 Human thyroid 632 A perox IDVWLGGLAENFLKY 15 Human thyroid 632 A perox IDVWLGGLAENFLDY 15 Human thyroid 632 A perox YDVWLGGLAENFLPY 15 Human thyroid 632 A perox LDVWLGGLAENFLPY 15 Human thyroid 632 A perox SDVWLGGLAENFLPY 15 Human thyroid 632 A perox KDVWLGGLAENFLPY 15 Human thyroid 632 A perox DDVWLGGLAENFLPY 15 Human thyroid 632 A perox

TABLE 24 HLA-DQ SUPERTYPES SEQ ID DQB1*030 DQB1*030 DQB1*020 Sequence NO. 1 2 1 AAAKAAAAAAYAA 424 (44)YAAAAAAKAAA 26 AAFAAAKTAAAFA 49 YAAFAAAKTAAAFA 36 YAAFAAAKTAAAFA 39 AHAAHAAHAAHAAHAA 58 VLERYLLEAKRAENI 10932 309 5389 VPDTKVNFYAWKRME 730 >46666.67 >147058.82 WKRMEVGQQAVEVWQ 13666 12146 159 VGQQAVEVWQGLALL 1807 4407 838 VEVWQGLALLSEAVL 19 14 98 GLALLSEAVLRGQAL 107 16963 6742 SEAVLRGQALLVNSS 55 36395 9755 RGQALLVNSSQPWEP 302 14393 13362 LQLHVDKAVSGLRSL 88 7842 7590 KEAISPPDAASAAPL 458 960 7287 PPDAASAAPLRTITA 20 3869 3631 SAAPLRTITADTFRK 301 >46666.67 1100 EAENITTGTAEHTSL 316 8300 RLFDNASLRAHRLHQ 996 >36206.9 11766 QLAFDTYQEFEEAYI >89285.71 673 35 ISLLLIQSWLEPVQF >89285.71 562 5234 NSLVYGASDSNVYDL 14164 8337 731 SDSNYYDLLKDLEEG >89285.71 4136 503 KIFGSLAFLPESFDG 320 DPA CLKDRRNFDIIPEEIK 19365 208 774 QLQQFQKEDAAVTIY 26205 579 2145 QKEDAAVTIYIEMLQN 515 153 1685 STGWNRTIVENLLAN 47081 5041 322 ETIVENLLANVYHQR >92592.59 >75000 344 KEDSHCAWTWRVEI 4102 2123 465 MSYNLLGFLQRSSNT 724 >51219.51 QHLCGSHLVEALYLV 2553 8413 359 GSHLVEALYLVCGER >89285.71 2491 677 GSDLVEALYLVCGER >89285.71 806 VEALYLVCGERGFLY 27334 514 VEALYLVTGERGFFY 20021 564 IDVWLGGLAENFLPY 204 138 13 IDVWLGGLAYNFLPY 85 358 63 IDVWLGGLALNFLPY 49 457 52 IDVWLGGLASNFLPY 175 1251 40 IDVWLGGLAKNFLPY 170 10247 >4166.67 IDVWLGGLADNFLPY 296 1762 12 IDVYLGGLAENFLPY 161 186 30 IDVLLGGLAENFLPY 166 437 27 IDVSLGGLAENFLPY 188 277 48 IDVKLGGLAENFLPY 724 5511 41 IDWDLGGLAENFLPY 218 73 17 IDVWLGGLAENYLPY 223 110 19 IDVWLGGLAENVLPY 84 82 15 IDVWLGGLAENSLPY 116 125 25 IDVWLGGLAENKIPY 353 5189 51 IDVWLGGLAENDLPY 240 60 22 IYVWLGGLAENFLPY 170 237 13 ILVWLGGLAENFLPY 216 147 10.0 ISVWLGGLAENFLPY 132 286 18 IKVWLGGLAENFLPY 180 220 37 IEVWLGGLAENFLPY 158 145 23 IDVWLGGLAENFLPF 111 177 3.6 IDVWLGGLAENFLPL 182 114 17 IDVWLGGLAENFLPS 134 249 27 IDVWLGGLAENFLPK 261 231 23 IDVWLGGLAENFLPD 115 91 20 IDVWLGGLAENFYPY 324 203 37 IDVWLGGLAENFVPY 346 272 12 IDVWLGGLAENFSPY 131 193 47 IDVWLGGLAENFKPY 195 262 310 IDVWLGGLAENFDPY 364 90 32 IDVWLGGLAEYFLPY 151 88 14 IDVWLGGLAELFLPY 107 81 22 IDVWLGGLAESFLPY 60 64 49 IDVWLGGLAEKFLPY 68 112 66 IDVWLGGLAEDFLPY 357 120 23 IDVWLGGLAEQFLPY 167 123 9.7 IDVWLGGLYENFLPY 912 697 6.4 IDVWLGGLLENFLPY 810 1734 58 IDVWLGGLSENFLPY 242 1348 37 IDVWLGGLKENFLPY 15907 >2800 25 IDVWLGGLDENFLPY >19230.77 637 18 IDVWLGGYAENFLPY 900 492 39 IDVWLGGVAENFLPY 982 327 75 IDVWLGGSAENFLPY 427 755 166 IDVWLGGKAENFLPY 517 633 398 IDVWLGGDABNFLPY 11114 2074 11 IDVWLGYLAENFLPY 15215 1121 31 IDVWLGLLAENFLPY 2986 180 39 IDVWLGSLAENFLPY 654 278 72 IDVWLGKLAENFLPY 2333 20023 81 IDVWLGDLAENFLPY >44642.86 370 18 IDVWLYGLAENFLPY 2171 442 18 IDVWLLGLAENFLPY 4903 455 47 IDVWLSGLAENFLPY 3043 373 98 IDVWLKGLAENFLPY 41667 1115 55 IDVWLDGLAENFLPY 13325 357 43 IDVWYGGLAENFLPY 375 224 43 IDVWVGGLAENFLPY 128 158 14 IDVWSGGLAENFLPY 451 128 15 IDVWKGGLAENFLPY 256 346 41 IDVWDGGLAENFLPY 2086 299 112 IDYWLGGLAENFLPY 503 342 49 IDLWLGGLAENFLPY 1292 661 25 IDSWLGGLAENFLPY 508 276 35 IDKWLGGLAENFLPY 579 534 62 IDDWLGGLAENFLPY 219 101 85 IDVWLGGLAENFLYY 341 387 154 IDVWLGGLAENFLLY 649 491 52 IDVWLGGLAENFLSY 425 676 54 IDVWLGGLAENFLKY 2266 995 111 IDVWLGGLAENFLDY 371 149 49 YDVWLGGLAENFLPY 482 214 59 LDVWLGGLAENFLPY 180 216 29 SDVWLGGLAENFLPY 154 232 19 KDVWLGGLAENFLPY 348 254 54 DDVWLGGLAEKFLPY 241 158 48

TABLE 25 HLA-DR SUPERTYPE SEQ ID Sequence NO. AA Organism Protein Position Analog AC- 18 A2 MHC Unknown NPTKHKWEAAHVAE derived QLAA DDYVKQYTKQYTKQ 19 Artificial NTLKK sequence AAAKAAAAAAYAA 13 Artificial A sequence AC- 13 Artificial A AAAKAAAAAAYAA sequence (20)AYA(20)A(20)A(20) 13 Artificial A K(20)A(20) sequence AC- 13 Artificial A AAAKATAAAAYAA sequence AC- 13 Artificial A AAAKAAAAAAFAA sequence AC- 13 Artificial A AAAKATAAAA(10)AA sequence AC- 13 Artificial A AAAKATAAAA(23)AA sequence AAKAAAAAAA(10)AA 13 Artificial A sequence AAYAAAATAKAAA 13 Artificial A sequence AALAAAAAAKAAA 13 Artificial A sequence AAEAAAATAKAAA 13 Artificial A sequence AAYIIAAAAKAAA 13 Artificial A sequence AAYAAAAIIKAAA 13 Artificial A sequence AFLRAAAAAAFAA 13 Artificial A sequence AFLRQAAAAAFAAY 14 Artificial A sequence AAFAAAKTAAAFA 13 Artificial A sequence YAAFAAAKTAAAFA 14 Artificial A sequence AALKATAAAAAAA 13 Artificial A sequence YAR(15)ASQTTLKAKT 14 Artificial sequence YARF(33)QTTLKAKT 14 Artificial sequence PKYFKQRILKFAT 13 Artificial A sequence PKYFKQGFLKGAT 13 Artificial A Sequence PKYGKQIDLKGAT 13 Artificial A sequence AAFFFFFGGGGGA 13 Artificial sequence AADFFFFFFFFDA 13 Artificial sequence AAKGIKIGFGIFA 13 Artificial sequence AAFIFIGGGKIKA 13 Artificial sequence AAKIFIGFFIDGA 13 Artificial sequence AAFIGFGKIKFIA 13 Artificial sequence AAKIGFGIKIGFA 13 Artificial sequence AAFKIGKFGIFFA 13 Artificial sequence AADDDDDDDDDDA 13 Artificial sequence (43)AAIGFFFFKKGIA 14 Artificial sequence (43)AAFFGIFKIGKFA 14 Artificial sequence (43)AADFGIFIDFIIA 14 Artificial sequence (43)AAIGGIFIFKKDA 14 Artificial sequence (43)AAFIGFGKIKFIA 13 Artificial sequence (43)AAKIGFGIKIGFA 13 Artificial sequence (43)AAFKIGKFGIFFA 13 Artificial sequence AAAKAAAAAAAAF 13 Artificial sequence AAAKAAAAAAAFA 13 Artificial sequence AAAKAAAAAAFAA 13 Artificial sequence AAAKAAAAPAAAA 13 Artificial sequence FAAAAAAAAAAAA 13 Artificial sequence AAAAAAAAAAAAN 13 Artificial sequence AAAAAAAAAAANA 13 Artificial sequence AAANAAAAAAAAA 13 Artificial sequence AAAAAAAAAAAAS 13 Artificial sequence AAAAASAAAAAAA 13 Artificial sequence ASAAAAAAAAAAA 13 Artificial sequence AFAAAKTAA 9 Artificial sequence YARFLALTTLRARA 14 Artificial A sequence YAR(15A)SQTTLKAKT 14 Artificial A sequence YAR(15A)RQTTLKAAA 14 Artificial A sequence (15A)RQTTLKAAA 11 Artificial A sequence (16A)RQTTLKAAA 11 Artificial A sequence (46)AAKTAAAFA 10 Artificial sequence (39)AAAATKAAA 10 Artificial sequence (52)AAAATKAAAA 11 Artificial sequence (55)AAAATKAAAA 11 Artificial sequence A(14)AAAKTAAA 10 Artificial sequence AA(14)A(35)ATKAAAA 12 Artificial sequence AA(14)AA(36)TKAAAA 12 Artificial sequence AFAAAKTAA(72) 10 Artificial sequence (49)AAAKT(64)AAA 10 Artificial sequence (49)AAAKTA(64)AA 10 Artificial sequence HQAISPRTLNGPGPGS 20 Artificial PAIF sequence YAAFAAAKTAAAFA 14 Artificial sequence TBGRCLHYTVDKSKPK 16 Bee Venom 103 AWVAWRNRCK 0 Chicken HEL 107 IVSDGNGMNAWVAWRNRC 18 Chicken HEL 98 PHHTALRQAILSWGE 20 DPw4 binder LMTLA WMYYHGQRHSDEHHH 15 EBV LMP 183 YIVMSDWTGGA 15 EBV LMP 41 AHAAHAAHAAHAAHAA 16 HA A MDIDPYKEFGATVEL 25 HBV core LSFLPSDFFP GMLPVCPLIPGSSTTS 19 HBV env 102 TGP LGFFPDHQLDPAFRANT 17 HBV env 11 GYKVLVLNPSV 11 HCV NS3 1248 LMAFTAAVTS 10 HCV NS4 1790 TFALWRVSAEEY 12 HCV NS5 2079 ALWRVSAEEY 10 HCV NS5 2081 EEYVEIRQVGDFH 13 HCV NS5 2088 VGGVYLLPRRGPRLGV 16 HCV VGGAYLLPRRGPRLGV 16 HCV A VGGVALLPRIRGPRLGV 16 HCV A VGGVYALPRRGPRLGV 16 HCV A VGGVYLAPRRGPRLGV 16 HCV A VGGVYLLARRGPRLGV 16 HCV A VGGVYLLPARGPRLGV 16 HCV A VGGVYLLRRAGPRLGV 16 HCV A GAPLGGAARALAHGV 15 HCV GAALGGAARALAHGV 15 HCV A GAPLAGAARALAHGV 15 HCV A GAPLGAAARALAHGV 15 HCV A GAPLGGLARALAHGV 15 HCV A GAPLGGALRALAHGV 15 HCV A GAPLGGAAAALAHGV 15 HCV A GAPLGGAARLLAHGV 15 HCV A GAPLGGAARAAAHGV 15 HCV A GAPLGGAARALAAGV 15 HCV A FPDWQNYTPGPGTRY 15 HIV NEF 200 RFPLTFGWCFKLVPV 15 HIV NEF 216 RQDILDLWVYHTQGY 15 HIV NEF 182 RQEILDLWVYHTQGF 15 HIV NEF 182 LSHFLKEKGGLBGLI 15 HIV NEF 114 LSFFLKEKGGLDGLI 15 HIV NEF 114 LEPWNHPGSQPKTACT 16 HIV TAT 11 QVCFITKGLGISYGR 15 HIV TAT 38 QLGFLKKGLGISYGR 15 HIV TAT 38 PPEESFRFGEEKTRPS 16 HIV1 gp 81 CIVYRDGNPYAVCDK 15 HPV E6 58 HYCYSLYGTTLEQQY 15 HPV E6 85 CYSLYGTTLEQQYNK 15 HPV E6 87 NTSLQDIEITCVYCK 15 HPV E6 22 VFEFAFKDLFVVYRD 15 HPV E6 44 EFAFKDLFVVYRDSI 15 HPV E6 46 DLFVVYRDSIPHAAC 15 HPV E6 51 FVVYRDSTPHAACHK 15 HPV E6 53 NTGLYNLLIRCLRCQ 15 HPV E6 95 IRCLRCQKPLNPAEK 15 HPV E6 103 PRKLHELSSALEIPY 15 HPV E6 9 EIPYDELRLNCVYCK 15 HPV E6 20 TEVLDFAFTDLTIVY 15 HPV E6 40 VLDFAFTDLTIVYRD 15 HPV E6 42 DFAFTDLTIVYRDDT 15 HPV E6 44 TIVYRDDTPHGVCTK 15 HPV E6 51 WYRYSVYGTTLEKLT 15 HPV E6 78 ETTIHNIELQCVECK 15 HPV E6 20 SEVYDFAFADLTVVY 15 HPV E6 40 VYDFAFADLTVVYRE 15 HPV E6 42 DFAFADLTVVYREGN 15 HPV E6 44 TVVYREGNPFGICKL 15 HPV E6 51 GNPFGICKLCLRFLS 15 HPV E6 57 NYSVYGNThEQTVKK 15 HPV E6 80 KKPLNEILIRCIIGQ 15 HPV E6 93 NEILIRCIIGQRPLC 15 HPV E6 97 IRCIICQRPLCPQEK 15 HPV E6 101 CIVYRDCIAYAACHK 15 HPV E6 53 NTELYNLLIRCLRCQ 15 HPV E6 95 IRCLRCQKPLNPAEK 15 HPV E6 103 REVYKFLFTDLRIVY 15 HPV E6 40 RIVYRDNNPYGVCIM 15 HPV E6 51 NNPYGVCIMCLRFLS 15 HPV E6 57 EERVKKPLSEITIRC 15 HPV E6 89 IRCIICQTPLCPEEK 15 HPV E6 101 EIPLIDLRLSCVYCK 15 HPV E6 23 SCVYGKKELTRAEVY 15 HPV E6 32 VCLLFYSKVRKYRYY 15 HPV E6 68 YYDYSVYGATLESIT 15 HPV E6 81 IRCYRCQSPLTPEEK 15 HPV E6 104 VYDFVFADLRIVYRD 15 HPV E6 42 DFVFADLRIVYRDGN 15 HPV E6 44 RIVYRDGNPFAVCKV 15 HPV E6 51 GNPFAVGKVCLRLLS 15 HPV E6 57 KKCLNEILIRCIICQ 15 HPV E6 93 NEILIRCIICQRPLC 15 HPV E6 97 RTAMFQDPQERPRKL 15 HPV E6 5 LFVVYRDSIPHAACH 15 HPV E6 52 LTIVYRDDTPHGVGT 15 HPV E6 50 LCIVYRDGIAYAACH 15 HPV E6 52 YKFLFTDLRIVYRDN 15 HPV E6 43 YNFACTELKLVYRDD 15 HPV E6 46 LKLVYRDDFPYAVCR 15 HPV E6 53 YDFVFADLRIVYRDG 15 HPV E6 43 LRIVYRDGNPFAVCK 15 HPV B6 50 HEYMLDLQPETTDLY 15 HPV E7 9 TLRLCVQSTHVDIRT 15 HPV E7 64 IRTLEDLLMGTLGIV 15 HPV E7 76 LEDLLMGTLGIVCPT 15 HPV E7 79 DLLMGTLGIVCPICS 15 HPV E7 81 KATLQDIVLHLEPQN 15 HPV E7 5 IDGVNHQHLPARRAE 15 HPV E7 41 LRAFQQLFLNTLSFV 15 HPV E7 83 FQQLFLNTLSFVCPW 15 HPV E7 86 QDYVLDLQPEATDLH 15 HPV E7 9 DIRILQELLMGSFGI 15 HPV E7 75 IRILQELLMGSFGIV 15 HPV E7 76 ELLMGSFGIVCPNCS 15 HPV E7 81 KBYVLDLYPEPTDLY 15 HPV E7 9 LRTIQQLLMGTVNIV 15 HPV E7 76 IQQLLMGTVNIVCPT 15 HPV E7 79 QLLMGTVNIVCPTCA 15 HPV E7 81 RETLQEIVLHLEPQN 15 HPV E7 5 LRTLQQLFLSTLSFV 15 HPV E7 84 LQQLFLSTLSFVCPW 15 HPV E7 87 KDYILDLQPETTDLH 15 HPV E7 9 LRTLQQMLLGTLQVV 15 HPV E7 78 LQQMLLGTLQVVCPG 15 HPV E7 81 QMLLGTTQVVCPGCA 15 HPV E7 83 VPTLQDVVLELTPQT 15 HPV E7 5 LQDVVLELTPQTEID 15 HPV E7 8 QDVVLELTPQTEIDL 15 HPV E7 9 CKFVVQLDIQSTKED 15 HPV E7 68 VVQLDIQSTKEDLRV 15 HPV E7 71 DLRVVQQLLMGALTV 15 HPV E7 82 LRVVQQLLMGALTVT 15 HPV E7 83 VQQLLMGALTVTCPL 15 HPV E7 86 QQLLMGALTVTCPLC 15 HPV E7 87 QLLMGALTVTCPLCA 15 HPV E7 88 REYILDLHPEPTDLF 15 HPV E7 9 TCCYTCGTTVRICIN 15 HPV E7 57 VRTLQQLLMGTCTIV 15 HPV E7 77 LQQLLMGTCTIVCPS 15 HPV E7 80 MLDLQPETTDLYCYE 15 HPV E7 12 VLDLYPEPTDLYCYE 15 HPV E7 12 LREYILDLHPEPTDL 15 HPV E7 8 HIEFTPTRTDTYACRV 16 Human B2-μglobulin 67 LWWVNNESLPVSPRL 15 Human CEA 177 A YEEYVRFDSDVGE 13 Human DRB and CD4 peptide EEYVRFDSDVGE 12 Human DRB and CD4 peptide APPRLICDSRVLERY 15 Human EPO 1 ICDSRVLERYLLEAK 15 Human EPO 6 VLERYLLEAICEAENI 15 Human EPO 11 EHCSLNENITVPDTK 15 Human EPO 31 NENITVPDTKVNFYA 15 Human EPO 36 VPDTKVNFYAWKRME 15 Human EPO 41 XFNFYAWKRMEVGQQA 15 Human EPO 46 WKRMEVGQQAVEVWQ 15 Human EPO 51 VGQQAVEVWQGLALL 15 Human EPO 56 VEVWQGLALLSEAVL 15 Human EPO 61 GLALLSEAVLRGQAL 15 Human EPO 66 SEAVLRGQALLVNSS 15 Human EPO 71 RGQALLVNSSQPWEP 15 Human EPO 76 LVNSSQPWEPLQLHV 15 Human EPO 81 QPWEPLQLHVDKAVS 15 Human EPO 86 LQLHVDKAVSGLRSL 15 Human EPO 91 DKAVSGLRSLTTLLR 15 Human EPO 96 GLRSLTTLLRALGAQ 15 Human EPO 101 TTLLRALGAQKEAIS 15 Human EPO 106 ALGAQKEAISPPDAA 15 Human EPO 111 KEAISPPDAASAAPL 15 Human EPO 116 PPDAASAAPLRTITA 15 Human EPO 121 SAAPLRTITADTFRK 15 Human EPO 126 RTITADTFRKLFRVY 15 Human EPO 131 DTFRKLFRVYSNFLR 15 Human EPO 136 LFRVYSNFLRGKLKL 15 Human EPO 141 SNFLRGKLKLYTGEA 15 Human EPO 146 KLKLYTGEACRTGDR 15 Human EPO 152 APPRLITDSRVLERY 15 Human EPO 1 A ITDSRVLERYLLEAX 15 Human EPO 6 A EHTSLNENITVPDTK 15 Human EPO 31 A KLKLYTGEATRTGDR 15 Human EPO 152 A PQPFRPQQPYPQ 12 Human gliadin PFRPQQPYPQ 10 Human gliadin PQPFRPQQPYP 11 Human gliadin PQPFRPQQP 9 Human gliadin KQPFRPQQPYPQ 12 Human gliadin PKPFRPQQPYPQ 12 Human gliadin PQPFKPQQPYPQ 12 Human gliadin PQPFRKQQPYPQ 12 Human gliadin PQPFRPQKPYPQ 12 Human gliadin PQPFRPQQPKPQ 12 Human gliadin PQPFRPQQPYKQ 12 Human gliadin PQPFRPQQPYPK 12 Human gliadin QFLGQQQPFPPQ 12 Human gliadin FLGQQQPFPPQ 11 Human gliadin LGQQQPFPPQ 10 Human gliadin QFLGQQQPFPP 11 Human gliadin QFLGQQQPF 9 Human gliadin IRNLALQTLPAMGNVY 16 Human gliadin NLALQTLPAMCNVY 14 Human gliadin LALQTLPAMCNVY 13 Human gliadin IRNLALQTLPAM 12 Human gliadin IRNLALQTLP 10 Human gliadin EGDAFELTVSGQGGLPK 17 Human gp100 506 ESTGMTPEKVPVSEVMGT 18 Human gp100 370 FPTIPLSRLFDNASL 15 Human Growth hormone RLFDNASLRAHRLHQ 15 Human Growth 8 hormone LRAHRLHQLAFDTYQ 15 Human Growth 15 hormone QLAFDTYQEFEEAYI 15 Human Growth 22 hormone QEFEEAYIPKEQKYS 15 Human Growth 29 hormone IPKEQKYSFLQNPQT 15 Human Growth 36 hormone SFLQNPQTSLCFSES 15 Human Growth 43 hormone TSLCFSESIPTPSNR 15 Human Growth 50 hormone REETQQKSNLELLRI 15 Human Growth 64 hormone SNLELLRISLLLIQS 15 Human Growth 71 hormone ISLLLIQSWLEPVQF 15 Human Growth 78 hormone SWLEPVQFLRSVFAN 15 Human Growth 85 hormone FLRSVFANSLVYGAS 15 Human Growth 92 hormone NSLVYGASDSNVYDL 15 Human Growth 99 hormone SDSNVYDLLKDLEEG 15 Human Growth 106 hormone GIQTLMGRLEDGSPR 15 Human Growth 120 hormone RLEDGSPRTGQIFKQ 15 Human Growth 127 hormone RTGQIFKQTYSKFDT 15 Human Growth 134 hormone QTYSKFDTNSHNDDA 15 Human Growth 141 hormone TNSHNDDALLKNYGL 15 Human Growth 148 hormone ALLKNYGLLYCFRKD 15 Human Growth 155 hormone DMDKVETFLRIVQCR 15 Human Growth 169 hormone FLRIVQCRSVEGSCGF 16 Human Growth 176 hormone FPTIPLSRLFDNAML 15 Human Growth 1 A hormone RLFDNAMLRAHRLHQ 15 Human Growth 8 A hormone QLAFDTYQEFEQNPQ 15 Human Growth 22 A hormone SFLQNPQTSLCCFRK 15 Human Growth 43 A hormone SNLELL,RIGLLLIQS 15 Human Growth 71 A hormone ICLLLIQSWLEPVQF 15 Human Growth 78 A hormone NSLVYGASDSNIYDL 15 Human Growth 99 A hormone SDSNIYDLLKDLEEG 15 Human Growth 106 A hormone DKVETFLRIVQCCGF 15 Human Growth 169 A hormone SFLQNPQTSLTFSES 15 Human Growth 43 A hormone TSLTFSESIPTPSNR 15 Human Growth 50 A hormone ALLKNYGLLYTFRIKD 15 Human Growth 155 A hormone LLYTFRKDMDKVETF 15 Human Growth 162 A hormone DMDKVETFLRIVQTR 15 Human Growth 169 A hormone FLRIVQTRSVEGSTGF 16 Human Growth 176 A hormone HLDMLRIILYQGCQVV 15 Human Her2/neu 42 RLRIVRGTQLFEDNYAL 17 Human Her2/neu 98 GVGSPYVSRLLGICL 15 Human Her2/neu 776 TLERPKTLSPGKNGV 15 Human Her2/neu 1166 KIFGSLAFLPESFDGDPA 18 Human Her2/neu 369 ELVSBFSRMARDPQ 14 Human Her2/neu 971 GEALSTLVLNRLKVG 15 Human HSP60 280 AYVLLSEKKISSIQS 15 Human HSP60 242 VASLLTTAEVVVTEI 15 Human HSP60 535 KCEFQDAYVILLSEKK 16 Human HSP60 236 ALSTLVLNRLKVGLQ 15 Human HSP60 282 MSYNLLGFLQRSSNG 15 Human IFN-B 1 LGFLQRSSNCQCQKL 15 Human IFN-B 6 RSSNCQCQKLLWQLN 15 Human IFN-B 11 QCQKLLWQLNGRLEY 15 Human IFN-B 16 LWQLNGRLEYCLKDR 15 Human IFN-B 21 GRLEYCLKDRRITFDI 15 Human IFN-B 26 RNFDIPEBIKQLQQF 15 Human IFN-B 36 PEEIKQLQQFQKEDA 15 Human IFN-B 41 QLQQFQKEDAAVTIY 15 Human IFN-B 46 QKEDAAVTIYEMLQN 15 Human IFN-B 51 AVTIYEMLQNIFAIF 15 Human IFN-B 56 EMLQNIFAIFRQDSS 15 Human IFN-B 61 IFAIFRQDSSSTGWN 15 Human IFN-B 66 RQDSSSTGWNETIVE 15 Human IFN-B 71 STGWNETIVENLLAN 15 Human IFN-B 76 ETIVENLLANVYHQR 15 Human IFN-B 81 NLLANVYHQRNHLKT 15 Human IFN-B 86 VYHQRNHLKTVLEEK 15 Human IFN-B 91 LEKEDFTRGKPMSSL 15 Human IFN-B 106 FTRGKRMSSLHLKRY 15 Human IFN-B 111 RMSSLHLKRYYGRIL 15 Human IFN-B 116 HLKRYYGRILHYLKA 15 Human IFN-B 121 YGRILHYLKAKEDSH 15 Human IFN-B 126 HYLKAKEDSHCAWTI 15 Human IFN-B 131 KEDSHCAWTIVRVEI 15 Human IFN-B 136 CAWTIVRVEILRNEY 15 Human IFN-B 141 VRVEILRNEYVINRL 15 Human IFN-B 146 RNFYVINRLTGYLEN 15 Human IFN-B 152 MSYNLLGFLQRSSNT 15 Human IFN-B 1 A LGFLQRSSNTQTQKL 15 Human IFN-B 6 A RSSNTQTQKLLWQLN 15 Human IFN-B 11 A QTQKLLWQLNGRLEY 15 Human IFN-B 16 A LWQLNGRLEYTLKDR 15 Human IFN-B 21 A GRLBYTLKDRRNFDI 15 Human IFN-B 26 A HYLKAKEDSHTAWTI 15 Human IFN-B 131 A KEDSHTAWTIVRVEI 15 Human IFN-B 136 A TAWTIVRVEILRNFY 15 Human IFN-B 141 A LGFLQRSSNCQSQKI 15 Human IFN-B 6 A RSSNCQSQKLLWQLN 15 Human IFN-B 11 A QSQKLLWQLNGRLEY 15 Human IFN-B 16 A GIVEQCGTSICSLYQ 15 Human Insulin alpha 1 chain TSICSLYQLENYCN 14 Human Insulin alpha 8 chain GILEQCCTSICSLYQ 15 Human Insulin alpha 1 A chain GIVEQTTTSITSLYQ 15 Human Insulin alpha 1 A chain EQTTTSITSLYQLEN 15 Human Insulin alpha 4 A chain TSICSLYQLENYCG 14 Human Insulin alpha 8 A chain TSITSLYQLENYTN 14 Human Insulin alpha 8 A chain TSITSLYQLENYTG 14 Human Insulin alpha 8 A chain GIVEQCGCGSHLVEA 15 Human Insulin alpha- A beta SLYQLENYCCGERGF 15 Human Insulin alpha- A beta CCTSICSLYQLENYCC 16 Human Insulin alpha- A beta GSHLVEALYLVCCN 14 Human Insulin alpha- A beta CCGSHLVEALYLVCC 15 Human Insulin alpha- A beta FVNQHLCGSHLVEAL 15 Human Insulin beta chain QHLCGSHLVEALYLV 15 Human Insulin beta 4 chain GSHLVEALYLVGGER 15 Human Insulin beta 8 chain VEALYLVGGERGFFY 15 Human Insulin beta 12 chain YLVCGERGFFYTPKT 15 Human Insulin beta 16 chain FVNQHLCGSDLVEAL 15 Human Insulin beta 1 A chain FVNQHLTGSHLVEAL 15 Human Insulin beta 1 A chain QHLTGSHLVEALYLV 15 Human Insulin beta 4 A chain GSHLVEALYLVTGER 15 Human Insulin beta 8 A chain VEALYLVCGERGSFY 15 Human Insulin beta 12 A chain VEALYLVCGERCIFLY 15 Human Insulin beta 12 A chain VEALYLVTGERGFFY 15 Human Insulin beta 12 A chain YLVCGERGFLYTPKT 15 Human Insulin beta 16 A chain YLVCGERGFFYTDKT 15 Human Insulin beta 16 A chain YLVCGERGFFYTKPT 15 Human Insulin beta 16 A chain YLVTGERGFFYTPKT 15 Human Insulin beta 16 A chain YLVTGERGFFYTDKT 15 Human Insulin beta 16 A chain YLVTGERGFFYTKPT 15 Human Insulin beta 16 A chain VCGERGFFYTPKTRR 15 Human Insulin beta 18 A chain VTGERGFFYTPKTRP 15 Human Insulin beta 18 A chain MWDLVLSIALSVGCT 15 Human Kallikrein2 1 DLVLSIALSVGCTGA 15 Human Kallikrein2 3 HPQWVLTAAHCLKKN 15 Human Kallikrein2 56 QWVLTAAHCLKKNSQ 15 Human Kallikrein2 58 GQRVPVSHSFPHYLY 15 Human Kallikrein2 87 RVPVSHSFPHPLYNM 15 Human Kallikrein2 89 PHPLYNMSLLKHQSL 15 Human Kallikrein2 97 HPLYNMSLLKHQSLR 15 Human Kallikrein2 98 NMSLLKHQSLRPDED 15 Human Kallikrein2 102 SHDLMLLRLSEPAKI 15 Human Kallikrein2 118 HDLMLLRLSEPAKIT 15 Human Kallikrein2 119 PEEFLRPRSLQCVSL 15 Human Kallikrein2 162 PRSLQCVSLHLLSND 15 Human Kallikrein2 168 NGVLQGITSWGPEPC 15 Human Kallikrein2 220 KPAVYTKVVHYRKWI 15 Human Kallikrein2 239 LHLLSNDMCARAYSE 15 Human Kallikrein2 176 VGNWQYFFPVIFSKA 15 Human MAGE3 140 ESEFQAALSRKVAKL 15 Human MAGE6 102 IGHLYIFATCLGLSYDGL 18 Human MAGE6 172 VGNWQYFFPVIFSKAS 31 Human MAGE6 140 DSLQLVFGIELMEVD PAYEKLSAEQSPPPY 15 Human MART1 102 RNGYRALMDKSLHV 23 Human MART1 51 GTQCALTRR FFKNIVTFFKNIVT 14 Human MBP A YKSAHKGFKGVDAQ 20 Human MBP 134 GTLSKI VDAQGTLSKIFKLGG 20 Human MBP 144 RDSRS AC- 23 Human MBP 1 ASQKRPSQRHGSKYL ATAST ENPVVHFFKNIVTPR 15 Human MBP 85 ENPVVAFFKNIVTPR 15 Human MBP 85 SAAS ENPVVHAFKNIVTPR 15 Human MBP 85 SAAS ENPVVHFFANIVTPR 15 Human MBP 85 SAAS ENPVVHFFKNIVTPA 15 Human MBP 85 SAAS NPVVHFFKNIVT 12 Human MBP 86 HFFKNIVTPRTPPY 14 Human MBP 90 NPVVHFFKNIVTPR 14 Human MBP 86 LPVPGVLLKEFTVSGN 20 Human NY-ESO-1 116 ILTI WITQCFLPVFLAQPPS 20 Human NY-ESO-1 161 GQRR DHRQLQLSISSCLQQL 20 Human NY-ESO-1 141 SLLM YLAMPFATPMEAELA 20 Human NY-ESO-1 91 RRSLA AAPLLLARAASLSLG 15 Human PAP 3 APLLLARAASLSLGF 15 Human PAP 4 PLLLARAASLSLGFL 15 Human PAP 5 SLSLGFLFLLFFWLD 15 Human PAP 13 LLFFWLDRSVLAKEL 15 Human PAP 21 DRSVLAKELKFVTLV 15 Human PAP 27 AKELKFVTLVFRHGD 15 Human PAP 32 RSPIDTFPTDPIKES 15 Human PAP 47 FGQLTQLGMEQHYEL 15 Human PAP 67 DRTLMSAMTNLAALF 15 Human PAP 110 MSAMTNLAALFPPEG 15 Human PAP 114 MTNLAALFPPEGVSI 15 Human PAP 117 PEGVSIWNPILLWQP 15 Human PAP 126 GVSIWNPILLWQPIP 15 Human PAP 128 WNPILLWQPIPVHTV 15 Human PAP 132 NPILLWQPIPVHTVP 15 Human PAP 133 PILLWQPIPVHTVPL 15 Human PAP 134 ILLWQPLPVHTVPLS 15 Human PAP 135 WQPIPVHTVPLSEDQ 15 Human PAP 138 LSGLHGQDLFGIWSK 15 Human PAP 194 YDPLYCESVHNFTLP 15 Human PAP 210 LPSWATEDTMTKLRE 15 Human PAP 223 LRELSELSLLSLYGI 15 Human PAP 235 LSELSLLSLYGIHKQ 15 Human PAP 238 LSLLSLYGIHKQKEK 15 Human PAP 241 KSRLQGGVLVNEILN 15 Human PAP 255 GGVLVNEILNHMKRA 15 Human PAP 260 IPSYKKLIMYSAHDT 15 Human PAP 277 YKKLIMYSAHDTTVS 15 Human PAP 280 LIMYSAHDTIWSGLQ 15 Human PAP 283 DTTVSGLQMALDVYN 15 Human PAP 290 ALDVYNGLLPPYASC 15 Human PAP 299 LDVYNGLLPPYASCH 15 Human PAP 300 YNGLLPPYASCHLTE 15 Human PAP 303 FAELVGPVIPQDWST 15 Human PAP 356 TVPLSEDQLLYLPFR 15 Human PAP 145 LTELYFEKGEYFVEM 15 Human PAP 315 GPVIPQDWSTECM1T 15 Human PAP 361 QAHSLERVCHCLGKW 21 Human PLP 130 LGHPDK WTTCQSIAFPSKTSASI 20 Human PLP 181 GSL QKGRGYRGQHQAHS 20 Human PLP 121 LERVGH AATYNFAVLKLMGR 18 Human PLP 260 GTKF VATGLGFFGVALFCG 20 Human PLP 21 GGHEA FLYGALLLAEGFYTT 20 Human PLP 81 GAVRQ SAVPVYIYFNTWTTC 20 Human PLP 171 QSIAF TLSVTWIGAAPLILS 15 Human PSA 5 SVTWIGAAPLILSRI 15 Human PSA 7 VTWIGAAPLILSRIV 15 Human PSA 8 SQPWQVLVASRGRAV 15 Human PSA 31 GRAVCGGVLVHPQWV 15 Human PSA 42 GVLVHPQWVLTAAHC 15 Human PSA 48 HPQWVLTAAHCIRNK 15 Human PSA 52 QWVLTAAHCIRNKSV 15 Human PSA 54 AHCIRNKSVILLGRH 15 Human PSA 60 SVILLGRHSLFHPED 15 Human PSA 67 VILLGRHSLFHPEDT 15 Human PSA 68 GQVFQVSHSFPHPLY 15 Human PSA 83 VFQVSHSFPHPLYDM 15 Human PSA 85 PHPLYDMSLLKNRFL 15 Human PSA 93 SHDLMLLRLSEPAEL 15 Human PSA 114 HDLMLLRLSEPAELT 15 Human PSA 115 TDAVKVMDLPTQEPA 15 Human PSA 129 LHVISNDVCAQVHPQ 15 Human PSA 172 CAQVHPQKVTKFMLC 15 Human PSA 180 GGPLVCNGVLQGITS 15 Human PSA 210 GPLVCNGVLQGITSW 15 Human PSA 211 NGVLQGITSWGSEPC 15 Human PSA 216 RPSLYTKVVHYRKWI 15 Human PSA 235 HSLFHPEDTGQVFQV 15 Human PSA 74 PRWLCAGALVLAGGF 15 Human PSM 18 LGFLFGWFIKSSNEA 15 Human PSM 35 LDELKAENIKKFLYN 15 Human PSM 62 TKKFLYNFTQIPHLA 15 Human PSM 70 KFLYNFTQIPHLAGT 15 Human PSM 72 WKEFGLDSVELAHYD 15 Human PSM 100 LAHYDVLLSYPNKTH 15 Human PSM 110 GNEIFNTSLFEPPPP 15 Human PSM 135 GKVFRGNKVKNAQLA 15 Human PSM 206 GNKVKNAQLAGAKGV 15 Human PSM 211 EYAYRRGIAEAVGLP 15 Human PSM 276 AEAVGLPSIPVHPIG 15 Human PSM 284 AVGLPSIPVHPIGYY 15 Human PSM 286 IGYYDAQKLLEKMGG 15 Human PSM 297 TGNFSTQKVKMHIHS 15 Human PSM 334 TRIYNVIGTLRGAVE 15 Human PSM 353 ERGVAYINADSSIEG 15 Human PSM 444 GVAYINADSSIEGNY 15 Human PSM 446 DSSIEGNYTLRVDCT 15 Human PSM 453 NYTLRVDCTPLMYSL 15 Human PSM 459 CrPLMYSLVHNLTKE 15 Human PSM 466 DFEVFFQRLGIASGR 15 Human PSM 520 EVFFQRLGIASGRAR 15 Human PSM 522 TNKFSGYPLYHSVYE 15 Human PSM 543 YDPMFKYHLTVAQVR 15 Human PSM 566 DPMFKYHLTVAQVRG 15 Human PSM 567 MFKYHLTVAQVRGGM 15 Human PSM 569 KYHLTVAQVRGGMVF 15 Human PSM 571 VAQVRGGMVFELANS 15 Human PSM 576 RGGMVFELANSIVLP 15 Human PSM 580 GMVFELANSIVLPFD 15 Human PSM 582 VFELANSIVLPFDCR 15 Human PSM 584 ADKIYSISMKHPQEM 15 Human PSM 608 IYSISMKHPQEMKTY 15 Human PSM 611 PQEMKTYSVSFDSLF 15 Human PSM 619 TYSVSFDSLFSAVKN 15 Human PSM 624 VLRMMNDQLMFLERA 15 Human PSM 660 LRMMNDQLMFLERAF 15 Human PSM 661 RHVIYAPSSHNKYAG 15 Human PSM 688 RQIYVAAFTVQAAAE 15 Human PSM 730 QIYVAAFTVQAAAET 15 Human PSM 731 VAAFTVQAAAETLSE 15 Human PSM 734 YISIINEDGNEIFNT 15 Human PSM 127 ISIINEDGNEIFNTS 15 Human PSM 128 EDFFKLERDMKINGS 15 Human PSM 183 FFKLERDMKINCSGK 15 Human PSM 185 GVILYSDPADYFAPG 15 Human PSM 224 GAAVVHEIVRSFGTL 15 Human PSM 391 NSRLLQERGVAYINA 15 Human PSM 438 VAYINADSSIEGNYT 15 Human PSM 447 DQLMFLERAFIDPLG 15 Human PSM 666 KSNFLNCYVSGFHPSD 16 Human B2- 19 μglobulin AC- 18 IEd MHC Unknown NPDAENWNSQFEILE derived DAA EYLILSARDVLAVVS 15 M. leprae 85 YKTIAYDEEARR 12 MT 3 GEALSTLVVNKIRGT 15 Mycobacteria HSP60 254 PYILLVSSKVSTVKD 15 Mycobacteria HSP60 216 EAVLEDPYILLVSSK 15 Mycobacteria HSP60 210 IAGLFLTTEAVVADK 15 Mycobacteria HSP60 507 ALSTLVVNKIRGTFK 15 Mycobacteria HSP60 256 MKHTLYISFYFILVN 15 Pf LSA1 1 KSLLSTNLPYGRTNL Pf SSP2 116 HFFLFLLYILFLVKM 15 Pf 13 LFLLYLFLVKMINAL 15 Pf 16 ILFLVKMNALRRLPV 15 Pf 21 MNALRRLPVICSFLV 15 Pf 27 SAFLESQSMNKIGDD 15 Pf 79 LKELIKVGLPSFENL 15 Pf 132 FENLVAENVKPPKVD 15 Pf 143 PATYGIIVPVLTSLF 15 Pf 158 YGIIVPVLTSLFNKV 15 Pf 161 LLKIWKNYMKIMNHL 15 Pf 28 MTLYQIQVMKRNQKQ 15 Pf 43 QKQVQMMIMIKFMGV 15 Pf 57 MIMIKFMGVIYIMII 15 Pf 63 GVIYIMIISKKMMRK 15 Pf 70 LYYLFNQHIKKELYH 15 Pf 285 HFNMLKNKMQSSFFM 15 Pf 299 LDIYQKLYIKQEEQK 15 Pf 353 QKKYIYNLIMNTQNK 15 Pf 366 YEALIKLLPFSKRIR 15 Pf 381 ENEYATGAVRPFQAA 15 Pf 2 NYELSKKAVIFTPIY 15 Pf 27 QKILIKIPVTKNIIT 15 Pf 108 KCLVISQVSNSDSYK 15 Pf 156 SKIMKLPKLPISNGK 15 Pf 202 FIHFFTWGTMFVPKY 15 Pf 220 LCNFKKNIIALLIIP 15 Pf 242 KKNIIALLIIPPKIH 15 Pf 246 ALLIIPPKIHISIEL 15 Pf 251 SMEYKKDFLITARKP 15 Pf 274 KSKFNILSSPLFNNF 15 Pf 7 FKKLKNHVLFLQMMN 15 Pf 173 KNHVLFLQMMNVNLQ 15 Pf 177 VLFLQMMNVNLQKQL 15 Pf 180 NVNLQKQLLTNHLIN 15 Pf 187 QKQLLTNHLINTPKI 15 Pf 191 NHLINTPKIMPHHII 15 Pf 197 YILLKKILSSRFNQM 15 Pf 239 FNQMIFVSSIFISFY 15 Pf 250 KVSCKGSGYTFTAYQMH 17 Rheumatiod Variable vector region IAKVPPGPNITAEYGD 20 Rye grass Lolp1 1 KWLD TAEYGDKWLDAKST 20 Rye grass Lolp1 11 WYGKPT AKSTWYGKPTGAGPK 20 Rye grass Lolp1 21 DNGGA GAGPKDNGGAGGYK 20 Rye grass Lolp1 31 DVDKAP FNGMTGCGNTPIFKD 20 Rye grass Lolp1 51 GRGCG PIFKDGRGCGSCFEIK 20 Rye grass Lolp1 61 CTKP SCFEIKCTKPESCSGE 20 Rye grass Lolp1 AVTV AFGSMAKKGEEQNVR 20 Rye grass LoIp1 111 SAGEL TPDKLTGPFTVRYTTE 20 Rye grass Lolp1 201 GGTK VRYTTEGGTKSEVED 20 Rye grass Lolp1 211 VIPEG TCVLGKLSQELHKLQ 15 Salmon Calcitonin 6 KLSQELHKLQTYPRT 15 Salmon Calcitonin 11 LHKLQTYPRTNTGSG 15 Salmon Calcitonin 16 KLQTYPRTNTGSGTP 15 Salmon Calcitonin 18 CCVLGKLSQELHKLQ 15 Salmon Calcitonin 7 A CSNLSTCVLGKLSQE 15 Salmon Calcitonin 1 A TSNLSTTVLGKLSQE 15 Salmon Calcitonin 1 A TTVLGKLSQELHKLQ 15 Salmon Calcitonin 6 A DIAAKYKELGY 11 Sperm Myoglobin 141 whale ALVRQGLAKVA 11 Staph. Nase 102 PATLIKAIDGDTVKLM 20 Staph. Nase 11 YKGQ TPETKHPKKGVEKYG 20 Staph. Nase 41 PEASA VEKYGPEASAFTKKM 20 Staph. Nase 51 VENAK FTKKMVENAKKIEVE 20 Staph. Nase 61 FDKGQ YIYADGKMVNEALVR 20 Staph. Nase 91 QGLAK HEQHLRKSEAQAKKE 20 Staph. Nase 121 KLNIW QAKKEKLNIWSEDNA 19 Staph. Nase 131 DSGQ YFNNFTVSFWLRVPK 15 TetTox 947 FSYFPSI 7 TetTox 593 A YSFFPSI 7 TetTox 593 A YSYFPSIR 8 TetTox 593 A DPNANPNVDPNANPN 117 Unknown (MAP)= VNANPNANPNANP(X4) (T1B)4 QKWAAVVVPS 10 Unknown ClassI A2 242 TWQLNGEELIQDMEL 22 Unknown ClassI Kb 216 VETRPAG 216-237 PEFLEQRRAAVDTYC 15 Unknown IEBs2 STORKUSP33 Unknown RAGE DYSYLQDSDPDSFQD 15 Unknown Tyrosinase 448 DFSYLQDSDPDSFQD 15 Unknown Tyrosinase 448 SAAS QNILFSNAPLGPQFP 15 Unknown Tyrosinase 56 SAAS QNILLSNAPLVPQFP 15 Unknown Tyrosinase 56 SAAS DYSYLQDSDPDSFQD 15 Unknown Tyrosinase 448 KYVKQNTLKLAT 11 unknown P(X)KQNTLKLAT 13 unknown A EEDIEIIPIQEEEY 14 CD20 249 A HQAISPRTLNSPAIF 15 YTDVFSLDPTFTIETT 16 YAGIRiRDGLLLRLVD 15 A LFFYRKSVWSKLQSI 15 RPIVNMDYVVGARTF 20 RREKR RPGLLGASVLGLDDI 15 LYFVKVDVTGAYDTI 15 FAGIRRDGLLLRLVD 15 AKTFLRTLVRGVPEY 15 YGAVVNLRKTVVNFP 15 GTAFVQMPAHGLFPW 15 WAGLLLDTRTLEVQS 15 RTSIRASLTFNRGFK 15 RVIKNSIRLTL 11 PVIKNSIKLRL 11 ATSTKKLHKEPATLIK 21 AIDG

TABLE 26 HLA-DR SUPERTYPE DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 DRB1 Sequence *0101 *0301 *0401 *0404 *0405 *0701 *0802 *0901 ACNPTKHKWEA >900000 500000 25000 AHVAEQLAA DDYVKQYTKQY 50000 160 500000 12500 TKQNTLKK AAAKAAAAAAY 833 >900000 229 500000 12500 AA ACAAAKAAAAA 625 348 AYAA (20)AYA(20) 50000 250 500000 8333 A(20)A (20)K(20)A (20) ACAAAKATAAA 50000 381 AYAA ACAAAKAAAAA 50000 421 AFAA ACAAAKATAAA 5000 444 500000 A(10)AA ACAAAKATAAA 1250 286 25000 A(23)AA AAKAAAAAAA 2500 >888.89 (10)AA AAYAAAATAKA 3.9 0.54 2778 AA AALAAAAAAKA 1.9 12 152 1316 AA AAEAAAATAKA 2500 667 500000 AA AAEAAAATAKA 50000 533 500000 AA AAYAAAAJJKA 1250 308 500000 AA AFLRAAAAAAF 50000 400 500000 AA AFLRQAAAAAF 2500 1000 25000 AAY AAFAAAKTAAA 1.3 1063 0.19 6.2 67 FA YAAFAAAKTAA 0.74 0.13 5.0 34 AFA AALKATAAAAA 50000 800 500000 AA YAR(15)ASQT 1.5 0.46 5.2 1196 TLKAKT YARF(33)QTT 50000 889 16667 LKAKT PKYFKQRLLKF 1667 400 1042 AT PKYFKQGFLKG 50000 800 500000 AT PKYGKQIDLKG 50000 444 500000 AT AAFFFFFGGGG 50000 800 500000 GA AADFFFFFFFF 1250 286 500000 DA AAKGIKIGFGI 50000 471 500000 FA AAFIFIGGGKI 50000 195 500000 KA AAKIFIGFFID 1250 200 25000 GA AAFIGFGKIKF 50000 242 500000 IA AAKIGFGIKIG 50000 889 500000 FA AAFKIGKFGIF 50000 615 500000 FA AADDDDDDDDD 50000 667 500000 DA (43)AAIGFFF 50000 258 500000 FKKGIA (43)AAFFGIF 50000 381 500000 KIGKFA (43)AADFGIF 50000 235 500000 IDFHA (43)AAIGGIF 50000 800 500000 IFKKDA (43)AAFIGFG 50000 1000 500000 KIKFIA (43)AAKIGFG 50000 1000 500000 IKIGFA (43)AAFKIGK 50000 276 500000 FGIFFA AAAKAAAAAAA >1666.67 >347.83 12500 AF AAAKAAAAAAA 50000 727 500000 FA AAAKAAAAAAF 50000 235 25000 AA AAAKAAAAFAA 50000 533 500000 AA FAAAAAAAAAA 1667 200 8333 AA AAAAAAAAAAA 50000 500 500000 AN AAAAAAAAAAA 50000 1000 500000 NA AAANAAAAAAA 50000 615 500000 AA AAAAAAAAAAA 50000 533 500000 AS AAAAASAAAAA 50000 235 500000 AA ASAAAAAAAAA 50000 364 500000 AA AFAAAKTAA 50000 571 500000 YARFLALTTLR 0.98 0.28 3.4 ARA YAR(15A)SQT 2.4 0.78 5.2 1786 TLKAKT YAR(15A)RQT 1.6 0.35 3.8 8333 TLKA (15A)RQTTLK 4.2 0.31 4.3 250000 AAA (16A)RQTTLK 455 1.3 37 250000 AAA (46)AAKTAAA 5000 571 1852 FA (39)AAAATKA 3333 727 500000 AA (52)AAAATKA 2000 242 2632 AAA (55)AAAATKA 2500 667 5556 AAA A(14)AAAKTA 39 0.45 54 96 AA AA(14)A(35) 50000 >500 500000 ATKAAAA AA(14)AA 50000 667 25000 (36)TKAAAA AFAAAKTAA 5000 533 500000 (72) (49)AAAKT 50000 667 500000 (64)AAA (49)AAAKTA 50000 533 500000 (64)AA HQAISPRTLNG 1555 728464 12089 2056 3107 5081 PGPGSPAIF YAAFAAAKTAA 1.9 0.82 7.0 AFA TEGRCLHYTVD 1667 200 500000 >250000 KSKPK AWVAWRNRCK 50000 667 500000 >12500 TVSDGNGMNAW 1250 18371 1000 8333 >8333.33 VAWRNRC PHHTALRQAIL 1250 166 1773 14434 SWGELMTLA WMYYHGQRHSD 50000 >900000 727 500000 >250000 EHHH YIVMSDWTGGA 50000 13416 222 500000 12500 AHAAHAAHAAH 263 80000 500000 >250000 AAHAA MDIDPYKEFGA 1563 170 6609 TV ELLSFLPSDFF P GMLPVCPLIPG 1250 >900000 400 1220 250000 SSTTSTGP LGFFPDHQLDP 1667 12027 333 2941 250000 AFRANT GYKVLVLNPSV 16 72407 27 2116 145 1516 115 8789 LMAFTAAVTS 2511 >73952.34 321 20577 627 240 >40562.91 160 TFALWRVSAEE >5279.83 88348 342 569 72 927 1433 517 Y ALWRVSAEEY >6337.14 >76595.74 6543 6669 >35315.99 7954 4099 698 EEYVEIRQVGD >1957.71 74884 >5365.53 11627 26 11323 13890 11154 FH VGGVYLLPRRG 177 236639 22323 12756 2764 351 PRLGV VGGAYLLPRRG 131 308534 26164 125056 >12230.45 703 PRLGV VGGVALLPRRG 849 326288 48233 23669 >12230.45 61558 PRLGV VGGVYALPRRG 134 348950 25750 30504 >12230.45 749 PRLGV VGGVYLAPRRG 746 202660 33672 >116550.12 >12230.45 878 PRLGV VGGVYLLARRG 60 23276 485 4396 2199 595 PRLGV VGGVYLLPARG 12 68070 3644 3213 4579 49 PRLGV VGGVYLLRRAG 202 39751 12252 32330 6432 433 PRLGV GAPLGGAARAL 690 3145 10408 19762 >13044.97 10773 AHGV GAALGGAARAL 1081 26944 21362 60600 >13044.97 29786 AHGV GAPLAGAARAL 588 2983 39885 19692 >13044.97 8178 AHGV GAPLGAAARAL 226 17703 10255 52041 >13044.97 6490 AHGV GAPLGGLARAL 537 351525 13941 6564 >13044.97 66 AHGV GAPLGGALRAL 68 >486486.49 14977 977 1271 1418 AHGV GAPLGGAAAAL 147 82088 5472 1272 >3365.21 31907 AHGV GAPLGGAARLL 398 22959 14984 21017 >3365.21 57549 AHGV GAPLGGAARAA 797 377964 25279 >110132.16 >3365.21 31308 AHGV GAPLGGAARAL 541 23298 11270 16747 >3365.21 7419 AAGV FPDWQNYTPGP 13766 >223880.6 23394 >109170.31 >10101.01 59625 592 3013 GTRF RFPLTFGWCFK 5913 406579 316 21384 121 4100 748 1848 LVPV RQDILDLWVYH 2390 98327 1202 1624 1136 1628 5039 1665 TQGY RQEILDLWVYH 1050 10530 5928 1414 3362 3052 2730 3679 TQGF LSHFLKEKGGL 537 >340909.09 2442 86814 2114 13676 1561 23191 EGL LSFFLKEKGGL 172 >340909.09 1275 >109170.31 983 19957 1127 3501 DGL LEPWNHPGSQP >33557.05 >328467.15 >33333.33 >96525.1 >8232.24 >72254.34 69223 34468 KTACT QVCFITKGLGI 114 166744 1529 1391 295 91 41 296 SYGR QLCFLKKGLGI 185 158381 4436 1613 443 3634 40 200 SYGR PPEESFRFGEE >2500 >900000 267 500000 >12500 KTTPS CIVYRDGNPYA 8464 147 1084 3473 >17182.13 31865 VCDK HYCYSLYGTTL 546 1127 9713 76 9858 12359 EQQY CYSLYGTTLEQ 1086 1317 2836 71 >9964.13 25989 QYNK NTSLQDIEITC >12106.54 10930 6143 4584 >17182.13 30884 VYCK VFEFAFKDLFV 6716 1059 2156 120 11583 16797 VYRD EFAFKDLFVVY 8944 2220 11721 33 3688 1882 RDS DLFVVYRDSIP 1186 82 218 3591 5213 2374 HAAC FVVYRDSIPHA 587 200 10 87 704 5085 2122 ACHK NTGLYNLLIRC 127 13429 686 358 258 6743 4759 LRCQ IRCLRCQKPLN 7240 6334 8464 1229 16787 32024 PAEK PRKLHELSSAL 156 16146 5276 694 80 103 213 EIPY EIPYDELRLNC 3299 15532 11292 7321 >35612.54 >39432.18 VYCK TEVLDFAFTDL 2073 1542 185 1083 871 1432 349 TIVY VLDFAFTDLTI 354 30 313 6061 721 230 252 VYRD DFAFTDLTIVY 463 23 80 3373 40 725 1443 RDDT TIVYRDDTPHG 3798 22 1269 >9753.59 >35612.54 >39144.05 VCTK WYRYSVYGTTL 163 26561 249 3448 8.5 107 284 EKLT ETTIHNIELQC 3623 1996 3327 6561 >35612.54 >39432.18 VECK SEVYDFAFADL 31 2996 260 2180 101 1850 174 TVVY VYDFAFADLTV 173 119 5281 133 7012 155 VYRE DFAFADLTVVY 3293 141 4948 60 1728 322 REGN TVVYRBGNPFG 168 121 1833 >13089.91 10064 2407 ICKL GNPFGICKLCL 189 1227 2073 377 13916 45631 RFLS NYSVYGNTLEQ 14059 1933 91506 822 >14602.8 47481 TVKK KKPLNEILIRC 1363 315 1070 347 7972 13328 IICQ NEILIRCIICQ 7945 11739 23082 7704 16901 26483 RPLC IRCIICQRPLC 7549 5960 23092 2973 >14602.8 40269 PQEK CIVYRDCIAYA 11166 928 8560 3973 >14602.8 10186 ACHK NTELYNLLIRC 1108 1366 1293 873 >14602.8 12528 LRCQ IRCLRCQKPLN 7012 6668 9890 8982 >14602.8 >32271.94 PAEK REVYKFLFTDL 8.7 23 112 738 52 54 204 RIVY RTVYRDNNPYG 524 325 20 432 2307 8307 24147 VCIM NNPYGVCIMCL 1075 1378 2522 454 12020 30895 RFLS EERVKKPLSEI 1286 11896 9772 1470 9454 19968 TIRC IRCIICQTPLC 10847 12270 3812 1407 25186 28062 PEEK EIPLIDLRLSC 7610 1876 5012 336 10468 1961 VYCK SCVYCKKELTR 6466 2411 7510 465 8446 2010 AEVY VCLLFYSKVRK 960 276 286 987 73 258 1798 YRYY YYDYSVYGATL 1008 186 9855 230 744 1403 ESIT IRCYRCQSPLT 10947 13358 83166 10327 13356 >36023.05 PEEK VYDFVFADLRI 98 2.2 475 5856 717 5962 198 VYRD DFVFADLRJVY 6699 867 7197 133 9847 1962 RDGN RIVYRDGNPFA 116 144 19 209 1812 6638 4962 VCKV GNPFAVCKVCL 134 3805 322 522 56 1034 29300 RLLS KKCLNEILIRC 9357 424 1229 365 16288 3997 HCQ NEILIRCIICQ 10992 14069 9339 4621 18947 22062 RPLC RTAMFQDPQER 9372 154 28192 39014 7977 32947 >25346.4 PRKL LFVVYRDSIPH 131 62 3.0 24 690 1998 2855 AACH LTIVYRDDTPH >15384.62 187 23 203 >8593.4 >72254.34 >25346.4 GVCT LCIVYRDCIAY 996 1855 357 1293 628 40121 10660 AACH YKFLFTDLRIV 109 8.8 292 256 91 1516 1255 YRDN YNFACTELKLV 7522 346 1976 4246 3147 2867 2084 YRDD LKLVYRDDFPY 778 237 123 9269 830 28971 18677 AVCR YDFVFADLRIV 1160 13 1914 3264 829 21352 5419 YRNG LRIVYRDGNPF 142 181 16 25 557 8985 14207 AVCK HEYMLDLQPET 1377 222 3997 2291 >18559.76 21277 TDLY TLRLCVQSTHV 1517 11996 8650 169 3257 6368 DIRT IRTLEDLLMGT 16 5211 95 43 61 895 1718 LGIV LEDLLMGTLGI 104 1136 353 1116 261 1994 VCP DLLMGTLGIVC 966 1324 984 639 963 2614 PICS KATLQDIVLHL 1204 1987 811 1173 9094 17726 EPQN IDGVNHQHLPA 1060 34272 165545 >16971.86 >18559.76 >39914.85 RRAE LRAFQQLFLNT 1.5 648 7.4 13 8.3 75 174 LSFV FQQLFLNTLSF 118 1321 134 1585 222 134 2062 VCPW QDYVLDLQPEA 13441 253 45281 5585 >18559.76 >39914.85 TDLH DIRILQELLMG 88 3252 166 290 552 1591 282 SFGI IRILQELLMGS 67 31840 724 710 1208 1998 271 FGIV ELLMGSFGIVC 628 1078 8518 1853 4183 949 PNCS KEYVLDLYPEP 5949 131 89674 391 >72254.34 >49867.02 TDLY LRTIQQLLMGT 13 23182 108 208 179 513 181 VNIV IQQLLMGTVNI 71 93701 107 483 624 444 156 YCPT QLLMGTVNIVC 1192 2874 10062 4688 2947 2209 PTCA RETLQEIVLHL 1592 2941 6583 829 25856 19109 EPQN LRTLQQLFLST 8.3 801 18 18 9.0 60 166 LSFV LQQLFLSTLSF 121 2045 113 754 94 272 152 VCPW KDYILDLQPET 6409 1022 30309 2771 >72254.34 >49867.02 TDLH LRTLQQMLLGT 80 >3750000 437 644 79 6909 5077 LQVV LQQMLLGTLQV 168 1496 631 1068 929 1692 VCPG QMLLGTLQVVC 957 2773 425 3074 3722 2082 PGCA VPTLQDVVLEL 16056 214 4764 5409 >35360.68 >30612.24 TPQT LQDVVLELTPQ 1487 101 1094 417 5673 2180 TEID QDVVLELTPQT 1269 83 1537 53 2716 1684 EIDL CKFVVQLDIQS 1251 196 1642 374 4547 19282 TKED VVQLDIQSTKE 1060 11122 8625 46 3762 13906 DLRV DLRVVQQLLMG 8.4 25971 325 89 84 508 1845 ALTV LRVVQQLLMGA 5.7 21650 115 28 85 82 204 LTVT VQQLLMGALTV 10 34257 239 614 116 71 180 TCPL QQLLMGALTVT 75 1142 1286 201 743 1170 CPLC QLLMOALTVTC 54 >3750000 595 870 1019 389 303 PLCA RBYILDLHPEP 154 132 9957 354 7257 29316 TDLF TCCYTCGTTVR 1230 19884 719 2269 132 63 1374 LCIN VRTLQQLLMQT 36 32360 322 39 114 1820 496 CTIV LQQLLMGTCTI 197 1147 483 522 2098 1638 VCPS MLDLQPETTDL 10076 720 1913 12241 4249 >72254.34 >32230.34 YCYE VLDLYPEPTDL 11201 121 203 2193 212 >72254.34 >32230.34 YCYE LRBYILDLHPE 134 891 23 9235 968 21989 16462 PTDL HIEFTPTRTDT 50000 30000 667 10000 >12500 YACRV LWWVNNESLPV 315 SPRL YEEYVRFDSDV 50000 400 500000 250000 GE EEYVRFDSDVG 50000 216 500000 250000 E APPRLICDSRV 1374 6.3 9735 5794 7141 8937 11214 9348 LERY ICDSRVLERYL 2758 236 1984 10984 11016 57605 808 >78947.37 LEAK VLERYLLEAYE 933 59010 2598 12139 5019 13067 3150 6382 AENI EHCSLNENITV 9837 27481 2294 28297 1205 32375 6191 >78947.37 PDTK NENITVPDTKV >24154.59 4.8 >21390.37 7612 >18572.83 42846 1850 >78947.37 NFYA VPDTKVNFYAW 2764 259 1742 4131 1328 38622 422 >78947.37 KRME VNFYAWKRMEV 193 2871 10 291 15 40163 35 1238 GQQA WKRMEVGQQAV 62 514 24 2591 94 46062 139 14696 EVWQ VGQQAVEVWQG 161 >174081.24 10294 6283 923 4230 >40511.09 >78947.37 LALL VEVWQGLALLS 86 13293 1310 1357 79 6863 13411 8151 EAVL GLALLSEAVLR 83 816 11 21 1435 4606 2000 15148 GQAL SEAVLRGQALL 11 70855 2064 4207 17446 1087 >63636.36 >78947.37 VNSS RGQALLVNSSQ 1118 93874 1697 1168 3434 319 29454 8450 PWEP LVNSSQPWEPL 2178 26138 >21505.3 13031 19689 8344 16920 >78947.37 QLNV QPWEPLQLHVD 11567 4862 1296 6135 1111 24157 >63636.36 34819 KAVS LQLHVDKAVSG 192 22 9.7 44 13571 3213 801 >78947.37 LRSL DKAVSGLRSLT 13 4331 1014 25 247 615 16375 >78947.37 TLLR GLRSLTTLLRA 8.5 2345 24 9.2 30 509 14 1136 LGAQ TTLLRALGAQK 19 107164 339 199 103 4281 652 4607 EAIS ALGAQKEAISP 194 >204081.63 >21505.3 93062 13015 >71225.07 >60214.56 15337 PDAA KEAISPPDAAS 15531 48560 6590 4389 28755 6661 6391 5735 AAPL PPDAASAAPLR 309 14900 566 68 1555 24937 >63636.36 8674 TITA SAAPLRTITAD 1166 1262 1185 261 1456 3646 28110 2505 TFRK RTITADTFRKL 148 139 1042 928 1957 3448 792 4692 FRVY DTFRKLFRVYS 12 6946 70 104 93 10 39 307 NFLR LFRVYSNFLRG 43 6156 643 1816 1275 5.5 28 3508 KLKL SNFLRGKLKLY 143 9583 2883 2375 7182 3783 1433 8099 TGEA KLKLYTGEACR 122 18435 5964 3505 36294 8082 7683 2860 TGDR APPRLITDSRV 10144 15 6680 3168 7765 629 26382 8391 LERY ITDSRVLERYL 1571 6501 1303 1990 13339 7498 967 >78947.37 LEAK EHTSLNENITV 43921 33635 12379 2769 1245 37154 >16333.33 >78947.37 PDTK KLKLYTGEATR 178 118459 15 3230 1426 8234 2008 >78947.37 TGDR PQPFRPQQPYP Q PFRPQQPYPQ PQPFRPQQPYP PQPFRPQQP KQPFRPQQPYP Q PKPFRPQQPYP Q PQPFKPQQPYP Q PQPFRKQQPYP Q PQPFRPQKPYP Q PQPFRPQQPKP Q PQPFRPQQPYK Q PQPFRPQQPYP K QFLGQQQPFPP Q FLGQQQPFPPQ LGQQQPFPPQ QFLGQQQPFPP QFLGQQQPF IRNLALQTLPA MCNVY NLALQTLPAMC NVY LALQTLPAMCN VY IRNLALQTLPA M IRNLALQTLP EGDAFELTVSC 572 3578 QGGLPK ESTGMTPEKVP >50000 >47368.42 510 >71428.57 >31250 VSEVMGT FPTIPLSRLFD 8071 114611 228 22 7210 3175 4969 9876 NASL RLFDNASLRAH 89 97 77 2043 10328 1921 14985 23832 RLHQ LRAHRLHQLAF 162 15603 5076 2197 10139 123 5621 15115 DTYQ QLAFDTYQEFE >20491.8 7981 >10738.2 33446 5399 2580 >33333.33 >59523.81 EAYI QEFEEAYIPKE >20491.8 >171755.73 >21276.6 >88339.22 395 31344 >33333.33 >59523.81 QKYS IPKEQKYSFLQ 128 49978 217 3633 9.0 8305 13553 79800 NPQT SFLQNPQTSLC 595 8617 6376 16880 >25832.77 48620 >33333.33 93856 FSES TSLCFSESIPT 604 182762 48 229 852 1064 >33333.33 4395 PSNR REETQQKSNLE 8921 91054 9341 1324 1433 51179 22467 9680 LLR SNLELLRISLL 72 43487 621 189 379 642 >33333.33 3422 LIQS ISLLLIQSWLE 184 27922 885 177 0.86 83 >33333.33 6247 PVQF SWLEPVQFLRS 11 167103 1128 152 883 589 3416 3998 VFAN FLRSVFANSLV 4.3 15221 6.7 43 59 16 13436 15127 YGAS NSLVYGASDSN 7313 81158 190 1585 1055 201 >33333.33 3896 VYDL SDSNVYDLLKN 24369 54982 11032 >25680.53 95 182355 >33333.33 >59523.81 LEEG GIQTLMGRLED 98 >55900.62 11914 2458 3745 18952 >33333.33 37821 GSPR RLEDGSPRTGQ 15693 76675 7906 1729 22125 35120 >33333.33 >59523.81 IFKQ RTGQIFKQTYS 1555 20341 1680 1831 40 46 16432 8515 KFDT QTYSKFDTNSH 17352 >55900.62 97 11218 78 54569 7726 31341 NDDA TNSHNDDALLK 16457 26397 20308 >25680.53 16329 245523 >33333.33 >59523.81 NYGL ALIYNYGLLYC 137 9819 446 1286 551 11915 >33333.33 676 FRKD DMDKVETFLRI 1277 4813 867 1135 622 10484 1673 16127 VQCR FLRIVQCRSVE 106 33536 185 164 191 7199 7262 5311 GSCGF FPTIPLSRLFD 6923 46707 9458 175 923 5529 1051 14964 NAM RLFDNAMLRAH 2.3 27 6289 1520 4247 3297 212 >59523.81 RL QLAFDTYQEFE >17985.61 7851 28586 47399 4843 21064 >33333.33 >59523.81 QNPQ SFLQNPQTSLC 106 1829 671 1816 1230 7026 7069 3082 CFRK SNLELLRICLL 731 61913 1526 2303 1112 1222 19782 3970 LIQS ICLLLIQSWLE 8511 50874 11303 5708 71 643 >33333.33 >59523.81 PVQF NSLVYGASDSN 13068 >51428.57 240 3683 1229 297 >33333.33 >59523.81 IYDL SDSNIYDLLKD >17985.61 124500 17458 25922 137 >85034.01 >33333.33 50134 LEEG DKVETFLRIVQ 953 18325 1158 259 397 697 581 4080 CCGF SFLQNPQTSLT 1191 2395 7780 15527 9558 6197 >33333.33 17714 FSES TSLTFSESIPT 182 17425 18 98 686 682 17602 2461 PSNR ALLKNYGLLYT 19 5982 160 266 303 5923 3616 2628 FRKD LLYTFRKDMDK >17985.61 23871 10623 17771 1133 53362 10448 >59523.81 VETF DMDKVETFLRI 1111 11194 2030 133 454 436 183 51511 VQTR FLRIVQTRSVE 6.4 3944 11 16 99 9.8 445 778 GSTGF HLDMLRHLYQG 304 37552 9417 2741 3593 27027 5384 12508 CQVV RLRIVRGTQLF 4.8 11287 8389 2929 1024 12 6325 1834 EDNYAL GVGSPYVSRLL 19 167949 1570 49 4156 190 1317 2614 GICL TLERPKTLSPQ 10103 134367 >22471.91 103285 >28592.93 25988 >75384.62 >300000 KNGV KIFGSLAFLPE 597 74162 1195 1897 37 377 >75384.62 15796 SFDGDPA ELVSEFSRMAR 201 1026 120 4882 15120 21259 4082 91575 DPQ GEALSTLVLNR 719 11783 3045 305 14802 3191 192 20167 LKVG AYVLLSEKKIS 78 136 943 359 9471 3848 27 3338 SIQS VASLLTTAEVV 604 136308 7431 810 6517 369 >118357.49 1955 VTE KCEFQDAYVIL 14 5791 73 943 351 336 489 185 LSEKK ALSTLVLNRLK 49 153 517 31 2167 647 4.0 2166 VGLQ MSYNLLGFLQR 115 156715 366 1584 788 1060 3421 3646 SSNC LGFLQRSSNCQ 437 112406 120 401 827 767 218 3729 CQKL RSSNCQCQKLL 9665 >191897.65 1046 2987 12652 9689 4530 74405 WQLN QCQKLLWQLNG 181 133472 360 460 1004 3702 2519 4669 RLEY LWQLNGRLEYC 1108 2356 816 8882 1024 10586 >16333.33 5206 LKDR GRLEYCLKDRR 9854 853 918 4155 3238 12108 1318 25159 NFDI RNFDIPEEIKQ 6969 26262 18107 5375 >114457.83 47893 >144117.65 >77319.59 LQQF PEEIKQLQQFQ 1026 40154 1618 618 7875 49505 11908 >77319.59 KEDA QLQQFQKEDAA 85 17383 231 27473 1121 500 4862 55351 VTLY QKEDAAVTIYE 8376 >156521.74 9437 75877 785 45455 >144117.65 5989 MLQN AVTIYEMLQNI 17 23730 101 808 163 267 6873 4540 FAIF EMLQNIFAIFR 395 9544 685 689 456 3313 10429 9738 QDSS IFAIFRQDSSS 132 402 9.6 71 118 1186 4725 970 TGWN RQDSSSTGWNE >102040.82 38681 4637 184507 40847 36320 15135 9075 TIVE STGWNETIVEN 21407 >156521.74 1755 10422 7060 3960 >144117.65 >77319.59 LLAN ETIVENLLANV 659 40053 789 802 326 21681 >144117.65 8151 YHQR NLLANVYHQRN 152 40328 1039 1440 1492 8000 453 4160 HLKT VYHQRNHLKTV 617 3135 7757 76003 153 6180 2101 >77319.59 LEEK LEKEDFTRGKR 21965 50733 >20887.79 3968 5694 946 804 >77319.59 MSSL FTRGKRMSSLH 13 3302 1013 970 484 136 553 10925 LKRY RMSSLHLKRYY 275 2181 993 4793 34 283 277 14964 GRIL HLKRYYGRILH 26 3709 135 666 86 214 237 2896 YLKA YGRILHYLKAK 30 42429 2343 917 23 900 704 7577 EDSH HYLKAKEDSHC 1128 34758 2064 12153 3701 581 34851 >77319.59 AWTI KBDSHCAWTIV 4835 >46656.3 353 1090 74 30 40000 2937 RVEI CAWTIVRVEIL 66 3561 158 640 135 746 43672 757 RNFY VRVEILRYFYV 1.8 429 140 47 18 14 3585 485 INRL RNFYVINRLTG 1.7 2199 219 4618 182 527 167 7600 YLRN MSYNLLGFLQR 25 107838 1152 813 433 8867 900 8972 SSNT LGFLQRSSNTQ 142 26455 18 211 1068 420 939 1345 TQK RSSNTQTQKLL 10515 44338 2139 15497 12590 27678 1283 >77319.59 WQLN QTQKLLWQLNG 32 3555 55 35283 86 3099 2042 2083 RLEY LWQLNGRLEYT 698 511 757 16171 94 20198 43286 16619 LKDR GRLEYTLKDRR 7252 30 3228 97035 1379 4961 4917 >77319.59 NFDI HYLKAKEDSHT 232 70237 553 10677 15067 801 8526 10140 AWTI KEDSHTAWTIV 1909 44754 746 2178 302 35 >79032.26 6079 RVEI TAWTIVRVEIL 7.8 2997 44 84 115 29 57243 404 RYFY LGFLQRSSNCQ 192 4888 8.1 93 228 305 405 13167 SQKL RSSNCQSQKLL 2050 57946 595 16721 4010 8922 6943 4062 WQLN QSQKLLWQLNG 127 33374 84 741 55 1166 991 5920 RLEY GIVEQCCTSIC 11123 777105 10911 2995 17793 >79872.2 >10047.16 13855 SLYQ TSICSLYQLEN 11391 >154109.59 20462 3791 12457 >85616.44 >54444.44 >63025.21 YCN GILEQCCTSIC 11025 >187500 14862 5106 15983 54113 >54444.44 16714 SLYQ GIVEQTTTSIT 6354 107486 121 115 818 788 >54444.44 13304 SLYQ EQTTTSITSLY 18953 >143769.97 170 258 272 2230 >54444.44 17381 QLEN TSICSLYQLEN 1125 202253 8841 1986 1089 247525 >54444.44 >83333.33 YCG TSITSLYQLEN 1253 81293 1468 138 851 6055 26791 9947 YTN TSITSLYQLEN 1132 96727 1628 129 115 8371 14562 46268 YTG GIVEQCCCGSH 10043 >74750.83 19904 2892 6626 41276 >54444.44 >63025.21 LVEA SLYQLENYCCG 3568 54469 7313 1527 2356 12308 >54444.44 >83333.33 ERGF CCTSICSLYQL 11655 71239 8383 1604 629 35604 >54444.44 29845 ENY GSHLVEALYLV 194 >59681.7 2280 11512 2509 302 >54444.44 37166 CCN CCGSHLVEALY 880 >55693.07 10081 20487 5230 1822 >54444.44 >63025.21 LVCC FVNQHLCGSHL 583 >187500 19209 39746 >20663.4 679 >54444.44 >63025.21 VEAL QHLCGSHLVEA 170 48557 12954 4303 9825 86 >54444.44 7422 LYLV GSHLVEALYLV 525 >187500 8292 1603 4609 560 >54444.44 5386 CGER VEALYLVCGER 76 17558 209 124 1044 3869 24623 2233 GFFY YLVCGERGFFY 11063 37210 1439 22980 730 64644 >54444.44 1520 TPKT FVNQHLCGSDL 117 >74750.83 19154 36693 14913 38662 >54444.44 >63025.21 VEAL FYNQHLTGSHL 9.2 67240 858 14916 1065 15 >54444.44 41482 VEAL QHLTGSHLVEA 9.3 50338 >16096.5 3952 7423 38 >54444.44 42312 LYLV GSHLVEALYLV 645 >176470.59 15781 1693 14443 553 >54444.44 >63025.21 TGER VEALYLVCGER 88 9972 833 194 6108 6485 >54444.44 6311 GSFY VEALYLVCGER 14 11587 167 31 1027 5351 10565 3063 GFLY VEALYLVTGER 9.9 2011 60 23 2342 195 1224 683 GFFY YLVCGERGFLY 155 2033 >20460.3 >38550.5 >30134.81 12842 >54444.44 124 TPKT YLVCGERGFFY 17260 11790 >20460.3 >38550.5 >30134.81 92272 >54444.44 317 TDKT YLVCGERGFFY 3207 42139 >20460.3 >38550.5 >30134.81 969 >54444.44 1673 TDKT YLVTGERGFFY 779 517 >20460.3 >38550.5 30457 7737 29236 6295 TPKT YLVTGERGFFY 3259 7326 >20460.3 >38550.5 >30134.81 5328 >25789.47 2909 TDKT YLVTGERGFFY 1152 4801 >20460.3 >38550.5 >30134.81 78 4304 195313 TKYT VCGERGFFYTP 9622 1989 >20460.3 >38550.5 >15103.34 5494 419 14379 KTRR VTGERGFFYTP 18906 3018 7226 147000 13417 27824 9407 >300000 KTRR MWDLVLSIALS 205 1846 3032 23046 1727 VGCT DLVLSIALSVG 1197 13038 4029 >245000 2200 CTGA HPQWVLTAAHC 22 1103 875 563 1693 822 LKKN QWVLTAAHCLK 895 >40000 3402 98000 4813 KNSQ GQRVPVSHSFP 1563 >40000 629 >245000 102 HPLY RVPVSHSFPHP 67 >16000 101 100021 97 LYNM PHPLYNMSLLK 19079 819 20691 3315 1592 HQSL HPLYNMSLLKH 232 13007 499 1282 382 199 QSLR NMSLLKHQSLR 3131 >40000 20620 26496 96825 PDED SHDLMLLRLSE 56 2396 2244 106 1327 112 PAK HDLMLLRLSEP 16 1406 3063 109 544 43 AKIT PEEFLRPRSLQ 2001 >26666.6 5156 2207 5839 CVSL PRSLQCVSLHL 1111 16000 2217 6107 28307 LSND NGVLQGITSWG 1093 8433 2285 52234 50111 PEPC KPAVYTKVVHY 5000 1433 2401 53 3677 RICWI LHLLSNDMCAR 2104 938 4277 27685 50230 59904 AYSE VGNWQYFFPVI 37 4.1 100 FSKA ESEFQAALSRK 579 29617 VAKL IGHLYIFATCL >816.33 12199 GLSYDGL VGNWQYFFPVI 654 3846 FSK ASDSLQLVFGI ELMEVD PAYEKLSAEQS 479 >250000 PPPY RNGYRALMDKS 512 5779 LHVGTQCALTRR FFKNIVTFFKN 50000 >666.67 500000 >12500 IVT YKSAHKGFKGV 70 >900000 889 25000 108 DAQGTLSKI VDAQGTLSKAF 25 1383 1600 314 1171 KLGGRDSRS ACASQKRPSQR 50000 >900000 889 25000 2362 HGSKYLATAST ENPVVHFFKNI VTPR ENPVVAFFKNI VTPR ENPVVHAFKNI VTPR ENPVVHFFANI VTPR ENPVVHFFKNI VTPA NPVVHFFIQII VT HFFKNIVTPRT PPY NPVVHFFKNIV TPR LPVPGVLLKEF 57 15058 14 12 12 57 TVSGNILTI WITQCFLPVFL 679 25534 88 2804 216 74162 AQPPSGQRR DHRQLQLSISS 1356 42666 1322 210 725 736 CLQQLSLLM YLAMPFATPME 46 46591 266 814 405 526 AELARRSLA AAPLLLARAAS 6.8 35410 139 160 30 64 LSLG APLLLARAASL 8.4 56250 202 59 76 124 SLGF PLLLARAASLS 10 >81818.18 521 162 37 58 LGFL SLSLGFLFLLF 11417 4711 22727 >122500 24620 FWLD LLFFWLDRSVL 2.9 6.3 2.6 135 163 518 AKEL DRSVLAKELKF 705 569 2016 15815 4719 VTLV AKELKFVTLVF 787 30000 783 606 1953 2355 RHGD RSPIDTFPTDP >50000 13095 >62500 >245000 6124 IKES FGQLTQLGMEQ 2259 3210 >62500 109567 >187500 HYEL DRTLMSAMTNL 97 64286 13 383 2362 222 AALE MSAMTNLAALF 1757 700 36084 73870 >187500 PPEG MTNLAALFPPE 24 >40000 >125000 39231 22822 GVS PEGVSIWNPIL 111 1778 15030 28577 103096 LWQP GVSIWNPILLW 44 56250 10328 4992 11008 3985 QPIP WNPILLWQPIP 208 >81818.18 695 521 115494 607 VHTV NPILLWQPIPV 31 >81818.18 206 41 12999 575 HTVP PILLWQPIPVH 44 >81818.18 258 46 21244 168 TVPL ILLWQPIPVHT 45 >81818.18 170 19 13091 131 VPLS WQPIPVHTVPL 6386 >26666.67 159 >81666.67 17518 SEDQ LSGLHGQDLFG 148 >26666.67 >35714.29 >81666.67 >125000 IWSK YDPLYCESVHN 1597 16625 8889 838 30867 643 FTLP LPSWATBDTMT 20274 973 >35714.29 >81666.67 >125000 KLRE LRELSELSLLS 655 371 4010 9368 1614 LYGI LSELSLLSLYG 482 >81818.18 1549 20906 1186 1450 IHKQ LSLLSLYGIHK 656 >81818.18 4444 >35714.29 1637 4959 QKEK KSRLQGGVLVN 362 >26666.6 2838 >81666.67 5516 EILN GGVLVNEILNH 2165 700 359 29463 3239 54411 MK IFSYKKLIMYS 9.9 9728 510 1946 60 351 AHDT YKKLIMYSAHD 17 22678 207 292 309 107 TTVS LIMYSAHDTTV 4496 24 731 24812 813 SGLQ DTTVSGLQMAL 171 4424 14706 >245000 2876 DVYN ALDVYNGLLPP 18 485 >83333.33 588 86603 YASC LDVYNGLLPPY 15 348 >83333.33 404 31277 ASCH YNGLLPPYASC 42 6189 >83333.33 14027 8022 HLTE FAELVGPVIPQ 12 4690 24056 >245000 39472 DWST TVPLSEDQLLY 4012 332 10755 11313 42162 37369 LPFR LTELYFEKGEY 2249 592 8051 13062 18841 26949 FVEM GPVIPQDWSTE 52098 CMTT QAHSLERVCHC 50000 667 500000 >250000 LGKWLGHPDK WTTCQSIAFPS 17308 22 KTSASIGSL QKGRGYRGQHQ >47368.42 88 AHSLERVCH AATYNFAVLKL >52941.18 533 MGRGTKF VATGLCFFGVA >112500 351 LFCGCGHEA FLYGALLLAEG FYTTGAVRQ SAVPVYIYFNT WTTCQSIAF TLSVTWIGAAP 3.1 >81818.18 7273 16 840 5.4 LILS SVTWIGAAPLI 4.1 >81818.18 3152 83 139 30 LSPI VTWIGAAPLIL 8.1 >81818.18 8000 195 731 82 SRIV SQPWQVLVASR 66 >81818.18 7628 385 386 621 GRAV GRAVCGGVLVH 386 >26666.6 3582 >245000 8069 PQWV GVLVHPQWVLT 87 21320 67 153 1931 365 AAHC HPQWVLTAAHC 13 3632 1621 283 1305 107 IRNK QWVLTAAHCIR 50 19403 214 2598 967 NKSV AHCIRNKSVIL 578 29704 69 2573 104 715 LGRH SVILLGRHSLF 717 1400 12649 26088 500 5216 HPED VILLGRHSLFH 273 8744 8208 30625 737 18520 PEDT GQVFQVSHSFP 288 45000 8.2 27 548 33 HPLY VFQVSHSFPHP 16 >75000 25 51 8751 17 LYDM PHPLYDMSLLK 1315 20787 10699 29813 12836 NRFL SHDLMLLRLSE 532 6215 4051 58 3538 64 PAEL HDLMLLRLSEP 62 2867 6193 152 3914 22 AELT TDAVKVMDLPT >50000 >80000 >41666.67 20875 >107142.8 QEPA LHVISNDVCAQ 789 8318 790 17451 >122500 32671 VHPQ CAQVHPQKVTK 10206 2566 32275 8731 34893 FMLC GGPLVCNGVLQ 3353 68 >35714.29 9334 16308 GITS GPLVCNGVLQG 1724 30 4893 4187 32640 ITSW NGVLQGITSWG 945 24942 560 485 5874 819 SEPC RPSLYTKVVHY 6041 53785 339 652 39 5484 RKWI HSLFHPEDTOQ 65260 VFQV PRWLCAGALVL 46 >20000 766 26531 1439 AGGF LGFLFGWFIKS 10 >75000 1338 2261 1421 1701 SNEA LDELKAENIKK 1136 1370 4842 7470 1248 12778 FLYN IKKFLYNFTQI 449 8080 43 29 512 160 PHLA KFLYNFTQIPH 340 13805 217 30 415 54 LAGT WKEFGLDSVEL 1139 85 96 3511 19971 7052 AHYD LAHYDVLLSYP 79 37533 1117 3617 415 1009 NK GNEIFNTSLFE 20412 >20000 >35714.29 >163333.33 10415 PPPP GKVFRGNKVKN 612 1087 2350 4121 31277 AQLA GNKVKNAQLAG 677 13333 >83333.33 28904 7882 AKGV EYAYRRGIAEA 5.1 213 70 596 67 VGLP AEAVGLPSIPV 5.4 9923 2015 >490000 23102 HPIG AVGLPSTPVHP 3.6 4193 1080 4432 15377 IGYY IGYYDAQKLLE 1923 12649 >83333.33 8236 47246 KMGG TGNFSTQKVKM 11180 833 9407 10282 1450 HIHS TRIYNVIGTLR 14 33333 6.3 4806 70 2900 GAVE ERGVAYINADS 2440 6761 34021 >163333.33 25516 SIEG GVAYINADSSI 1054 146 6244 23360 3048 EGNY DSSIEGNYTLR 16667 3360 14458 >163333.33 >187500 VDCT NYTLRVDCTPL 6804 45 9.9 24597 6323 48412 MYSL CTPLMYSLVHN 93 19437 245 140 223 249 LTKE DFEVFFQRLGI 143 221 21926 122 2005 ASGR EVFFQRLGIAS 28 >75000 22 5311 6.3 2976 GRAR TNKFSGYPLYH 3402 5521 30853 614 741 SVYE YDPMFKYHLTV 9.0 >75000 19 158 172 179 AQVR DPMFKYHLTVA 5.7 >75000 9.1 168 43 258 QVRG MFKYHLTVAQV 16 29032 18 72 70 266 RGGM KYHLTVAQVRG 137 33658 806 228 1519 5860 GMVF VAQVRGGMVFE 228 662 4449 >98000 499 LANS RGGMVFELANS 10 37118 229 41 8682 33 IYLP GMVFELANSIV 15 4604 230 30 4995 81 LPFD VFELANSIVLP 19 667 999 39 36123 50 FDCR ADKIYSISMKH 22361 5310 4098 1136 3512 PQEM IYSISMKHPQE 8452 16000 11573 1357 12293 MKTY PQEMKTYSVSF 15143 3024 1192 >98000 1981 DSLF TYSYSFDSLFS 219 101 73 346 2256 526 AVKN VLRMMNDQLMF 118 183 29 17334 1700 10684 LERA LRMMNDQLMFL 2704 392 17507 2492 4601 ERAF RHVIYAPSSHN 2174 481 31250 11667 481 KYAG RQIYVAAFTVQ 3.7 28347 1.2 292 36 91 AAAE QIYVAAFTVQA 1.6 26609 1.6 324 102 65 AAET VAAFTVQAAAE 14 >75000 58 793 1420 127 TLSE YISIINEDGNE 498 397 624 23719 >122500 83056 IFNT ISIINEDGNEI 507 559 >12965.96 >23105.36 >122500 >52337.75 FNTS EDFFKLERDMK 2710 468 226 8550 1439 >52337.75 INCS FFKLERDMKIN 4419 121 483 >23105.36 8109 >52337.75 CSGK GVILYSDPADY 1566 17 7508 7848 106291 2473 FAPG GAAVVHEIVRS 12409 FGTL NSRLLQERGVA 614 318 5089 7997 3224 2616 YINA VAYINADSSIE 4716 531 411 9745 105832 5467 GNYT DQLMFLERAFI >19667.83 DPLG KSNFLNCYVSG 2500 >900000 296 3125 8333 FHPSD ACNPDAENWNS 500000 >25000 QFEILEDAA EYLILSARDVL 508 AVVS YKTIAYDEEAR 50000 143 4000 500000 250000 R GEALSTLVVNK 292 29687 1535 246 30057 2325 383 40840 IRGT PYILLVSSKVS 1.1 106 64 13 136 38 12 134 TVKD EAVLEDPYILL 34 479 233 172 681 933 1666 15032 VSSK IAGLFLTTEAV 6.8 27189 13 106 67 230 3893 409 VADK ALSTLVVNKIR 75 274 648 40 3626 396 20 18035 GTFK MKHILYISFYF 5893 189 3385 1250 15558 ILVN KSLLSTNLPYG 4226 690 50000 RTNL HFFLFLLYILF 337 260 42443 19641 LVKM LFLLYILFLVK 1160 283 4868 10869 MNAL ILFLVKMNALR 0.80 5.6 56 19 RLPV MNALRRLPVIC 2.1 13 488 265 SFLV SAFLESQSMNK 549 113 523 21493 IGDD LKELIKVGLPS 99 163 542 1493 FENL FENLVAENVKP 56 2372 120215 >25025.54 PKVD PATYGIIVPVL 1.03 15 139 181 TSLF YGIIVPVLTSL 6.0 2.0 60 793 FNKV LLKIWKNYMKI 121 132 395 132 MNHL MTLYQIQVMKR 1219 117 31053 166 NQKQ QKQVQMMIMTK 121 213 3618 182 FMGV MIMIKFMGVIY 2905 312 68040 66150 IMII GVIYIMIISKK 10 22 476 137 MMRK LYYLFNQHIKK 27 1324 10244 1771 ELYH HFNMLKNKMQS 12 18 3225 185 SFFM LDIYQKLYIKQ 2834 1492 >88339.22 1204 EEQK QKKYIYNLIMN 73 24 11942 13255 TQNK YEALIKLLPFS 55 1839 3578 180 KRIR ENEYATGAVRP 4438 281 4970 17329 FQAA NYELSKKAVIF 713 536 5498 141 TPIY QKILIKIPVTK 993 303 534 2240 NIIT KCLVISQVSNS 628 16 46383 17859 DSYK SKIMKLPKLPI 824 6485 83674 110 SNGK FIHFFTWGTMF 745 273 489 1699 VPKY LCNFKKNIIAL 9.7 312 423 21324 LIIP KKNIIALLIIP 13 203 495 157 PKIIA ALLIIPPKIHI 648 1738 8.4 11957 SIEL SMEYKKDFLIT 939 24 776 8897 ARKP KSKFNILSSPL 0.80 16 65 152 FNNF FKKLKNHVLFL 2.3 28 11 695 QMMN KNHVLFLQMMN 12 32 757 >120098.04 VNLQ VLFLQMMNVNL 6.3 30 8441 56770 QKQL NVNLQKQLLTN 96 2460 555 11245 HLIN QKQLLTNHLIN 675 228 4412 20984 TPK NHLINTPKIMP 1378 4798 625 1296 HHII YILLKKILSSR 220 183 8.3 18 FNQM FNQMIEVSSIF 483 2091 854 16504 ISFY KVSCKGSGYTF 5000 381 50000 2946 TAYQMH IAKVPPGPNIT 50000 >30000 >666.67 500000 >12500 AEYGDKWLD TAEYGDKWLDA 50000 >30000 >666.67 16667 3125 KSTWYGKPT AKSTWYGKPTG 50000 >30000 667 500000 >12500 AGPKDNGGA GAGPKDNGGAC 50000 >30000 >666.67 500000 >12500 GYKDVDKAP FNGMTGCGNTP 50000 51962 >666.67 500000 >12500 IFKDGRGCG PIFKDGRGCGS 50000 6784 >666.67 500000 >12500 CFEIKCTKP SCFEIKCTKPE 50000 >900000 >666.67 500000 12500 SCSGEAVTV AFGSMAKKGEE 50000 >30000 >666.67 50000 >12500 QNVRSAGEL TPDKLTGPFTV 50000 >900000 >666.67 500000 >12500 RYTTEGGTK VRYTTEGGTKS 50000 >30000 >666.67 500000 >12500 EVEDVIPEG TCVLGKLSQEL 26 29529 14848 7566 9001 18653 7656 17895 HKLQ KLSQELHKLQT 19 196889 19684 2076 12198 85464 28656 19129 YPRT LHKLQTYPRTN 2118 >205479.45 15182 9921 >7403.08 40226 1618 >29228.37 TGSG KLQTYPRTNTG >10060.36 >205479.45 >26490.07 114672 >9806.45 >99206.35 >51578.95 >29228.37 SGTP CCVLGKLSQEL 34 17387 19764 31253 5299 41656 5640 21704 HKLQ CSNLSTCVLQK 296 >205479.45 14339 28603 5340 31837 3516 7225 LSQE TSNLSTTVLGK 298 86798 8016 32358 9280 31275 2058 2469 LSQE TTVLGKLSQEL 133 92782 22449 36802 >9806.45 26113 16182 23824 HKLQ DIAAKYKELGY >900000 >470.59 ALVRQGLAKVA 1250 190 500000 PATLIKAIDGD 278 6429 296 3846 8333 TVKLMYKGQ TPETKHPKKGV >1000 >900000 >500 500000 12500 EKYGPEASA VEKYGPEASAF 50000 >900000 1333 500000 12500 TKKMVENAK FTKKMVENAKK >1000 11619 >500 500000 8333 IEVEFDKGQ YIYADGKMVNE 65 500 4167 1563 ALVRQGLAK HEQHLRKSEAQ 50000 90000 80000 16667 6250 AKKEKLNIW QAKKEKLNIWS 50000 >900000 364 3125 >250000 EDNADSGQ YFNNFTVSFWL 50000 615 25000 RVPK FSYFPSI 50000 889 16667 YSFFPSI 50000 889 500000 YSYFPSIR 50000 >900000 667 16667 7217 DPNANPNVDPN 738 >5494.51 >15625 AN PNVNANPNANP NANP(X4) QKWAAVVVPS 50000 1000 50000 TWQLNGEELIQ 50000 889 2273 DM ELVETRPAG PEFLEQRRAAV 5000 80000 500000 250000 DTYC STORKUSP33 617 2069 DYSYLQDSDPD >50000 189 >500000 >126666.67 >250000 >61250 >107142.86 SFQD DFSYLQDSDPD 264 >500000 >126666.67 >250000 >61250 >107142.86 SFQD QNILFSNAPLG 195 PQFP QNILLSNAPLV 538 PQFP DYSYLQDSDPD 316 >166666.67 SFQD KYVKQNTLKLA 9.9 6.2 25000 T P(X)KQNTLKL 1.7 AT BEDIEIIPIQE >9057.97 >18549.05 >7518.8 12203 849 >6742.18 128305 EBY QAISPRTLNS 1961 298315 6214 1314 3450 39701 14848 286179 PAIF YTDVFSLDPTF 217 TIETT YAGIRRDGLLL 9.6 RLVD LFFYRKSVWSK 19 30163 913 1383 84 84 65 LQSI RPIVNMDYVVG 29 22 3.1 21 812 346 748 ARTFRREKR RPGLLGASVLG 1789 35768 6522 4414 3183 506 >61250 LDDI LYFVKVDVTGA 16 9.6 2.8 13 14 5892 413 YDTI FAGIRRDGLLL 2381 3.6 7092 3820 >3365.21 41148 7650 RLVD AKTFLRTLVRG 104 54159 208 3326 105 25 9.2 VPEY YGAVVNLRKTV 13509 150175 4194 4531 >95000 8274 113 VNFP GTAFVQMPAHG 1.6 37275 8.1 34 18 90 99 LFPW WAGLLLDTRTL 2016 22 49 323 1238 186 >61250 EVQS RTSIRASLTFN 1430 256 770 177 5131 411 5475 RGFK RVIKNSIRLTL 3650 584 9249 5389 80682 2239 1175 2566 PVIKNSIKLRL 1549 198 34245 14612 277735 4091 541 2851 ATSTKKLHKEP 4.6 8018 113 1020 2083 ATLIKAIDG

TABLE 27 HLA-DR SUPERTYPE SEQ DRB1 DRBI DRBI DRB3 DRB4 DRB5 DRB5 Sequence ID NO. *1101 *1302 *1501 *0101 *0101 *0101 *0201 AC- >33333.33 >10000 200000 101 1250 NPTKHKWEAAHVAEQ LAA DDYVKQYTKQYTKQN >1111.11 >11111.11 35 TLKK AAAKAAAAAAYAA 200000 6250 2857 AC- AAAKAAAAAAYAA (20)AYA(20)A(20) 200000 2857 A(20)K(20)A(20) AC-AAAKATAAAAYAA AC-AAAKAAAAAAFAA AC- AAAKATAAAA(10)AA AC- AAAKATAAAA(23)AA AAKAAAAAAA(10)AA AAYAAAATAKAAA AALAAAAAAKAAA 2222 67 AAEAAAATAKAAA AAYJJAAAAKAAA AAYAAAAJJKAAA AFLRAAAAAAFAA AFLRQAAAAAFAAY AAFAAAKTAAAFA 4.6 20000 25 6.4 YAAFAAAKTAAAFA 2.6 33333 30 9.5 AALKATAAAAAAA YAR(15)ASQTTLKAK 3.9 3.6 T YARF(33)QTTLKAKT PKYFKQRILKFAT PKYFKQGFLKGAT PKYGKQIDLKGAT AAFFFFFGGGGGA AADFFFFFFFFDA AAKGIKIOFGIFA AAFIFIGGGKIKA AAKIFIGFFIDGA AAFIGFGKIKFIA AAKIGFGIKIGFA AAFKIGKFGIFFA AADDDDDDDDDDA (43)AAIGFFFFKKG IA (43)AAFFGIFKIGK FA (43)AADFGIFIDFI IA (43)AAIGGIFIFKK DA (43)AAFIGFGKIKF IA (43)AAKIGFGIKIG FA (43)AAFKIGKFGIFF AAAAKAAAAAAAAF AAAKAAAAAAAFA AAAKAAAAAAFAA AAAKAAAAFAAAA FAAAAAAAAAAAA AAAAAAAAAAAAN AAAAAAAAAAANA AAANAAAAAAAAA AAAAAAAAAAAAS AAAAASAAAAAAA ASAAAAAAAAAAA AFAAAKTAA YARFLALTTLRARA YAR(15A)SQTTLKAK 2.5 1.4 48 T YAR(15A)RQTTLKAA 1.2 0.94 62 A (15A)RQTTLKAAA 1.8 9.5 3095 (16A)RQTTLKAAA 77 4000 (46)AAKTAAAFA (39)AAAATKAAA (52)AAAATKAAAA (55)AAAATKAAAA A(14)AAAKTAAA 43 120 AA(14)A(35)ATKAA AA AA(14)AA(36)TKAA AA AFAAAKTAA(72) (49)AAAKT(64)AAA (49)AAAKTA(64)AA HQAISPRTLNGPGPGS 9875 638 5570 232 32930 PAIF YAAFAAAKTAAAFA >4347.83 TEGRCLHYTVDKSKPK >1250 4082 2857 AWYAWRNRCK >5000 >11111.11 44 IVSDGNGMNAWVAWR 6667 >6250 >2222.22 NRC PHHTALRQAILSWGEL 3116 5.3 48 261 MTLA WMYYHGQRHSDEHHH >10000 >7692.31 >5000 Y1VMSDWTGGA >6666.67 >33333.33 >10000 AHAAHAAHAAHAAHAA 200000 200000 MD1DPYKEFGATVELL 2415 SFLPSDFFP GMLPVCPLIPGSSTTS 2500 >25000 200000 TGP LGFFPDHQLDPAFRAN 6667 1449 6667 TGYKVLVLNPSV 26 21 126 995 >11441.65 LMAFTAAVTS >23337.22 >2464.79 1934 11687 >12586.53 TFALWRVSAEEY 342 >2569.75 >12709.5 >6608.93 25499 ALWRVSAEEY 243 >6398.54 >15268.46 >7930 >35587.19 EEYVEIRQVGDFH 4683 >1895.99 2060 2063 9754 VGGVYLLPRRGPRIGV 88 >15350.88 4.2 60753 19239 12 VGGAYLLPRRGPRLGV 507 24663 4.1 >66533.6 37640 50 VGGVALLPRRGPRLGV 154 >15350.88 8.5 >66533.6 25688 20459 VGGVYALPRRGPRLGV 12 >15350.88 451 >66533.6 26122 34 VGGVYLAPRRGPRLGV 35 >15350.88 55 >66533.6 >42059.46 76 VGGVYLLARRGPRLGV 6.5 10325 2.8 17030 4338 17 VGGVYLLPARGPRLGV 694 201 6.5 18073 18960 40 VGGVYLLRRAGPRLGV 67 >15350.88 6.2 91912 30707 7.9 GAPLGGAARALAHGV 24 8739 1615 >70972.32 3959 11983 GAALGGAARALAHGV 168 19335 4483 >70972.32 3509 25372 GAPLAGAARALAHGV 9.5 7215 2810 >70972.32 2963 7688 GAPLGAAARALAHGV 36 15091 3920 >70972.32 16533 4502 GAPLGGLARALAHGV 12 76 1805 123762 3950 4256 GAPLGGALRALAHGV 83 340 2068 >51098.62 4889 5396 GAPLGGAAAALAHGV 43842 23810 7682 >51098.62 31 12916 GAPLGGAARLLAHGV 80 29412 631 >51098.62 2549 26684 GAPLGGAARAAAHGV 3633 >23489.93 >8666.67 >51098.62 41441 42463 GAPLGGAARALAAGV 45 23179 5714 >51098.62 3865 8354 FPDWQNYTPGPGTRF >51282.05 >12027.49 35058 33923 >20533.88 RFPLTFGWCFKLVPV 62289 4797 514 964 >20533.88 RQDILDLWVYHTQGY >51282.05 6775 723 1326 16155 RQEILDLWVYHTQGF 11113 5384 985 1071 >20533.88 LSHFLKEKGGLEGLI 9460 >12027.49 >39737.99 18709 >20533.88 LSFFLKEKGGLDGLI 614 >12027.49 >39737.99 13214 15272 LEPWNHPGSQPKTACT >15325.67 >11041.01 2665 92 2939 QVCFITKGLGISYGR 31 92 3555 876 3950 QLCFLKKGLGISYGR 9.5 88 4212 282 1190 PPEESFRFGEEKTTPS >10000 >14285.71 >2857.14 CIVYRDGNPYAVCDK >14662.76 1646 650 >24786.32 >10666.67 HYCYSLYGTTLEQQY 12397 >13725.49 4849 1292 >10666.67 CYSLYGTTLEQQYNK >14662.76 >13725.49 5060 189 >10666.67 NTSLQDIEITCVYCK >14662.76 14857 678 11710 >10666.67 VFEFAFKDLFVVYRD 10923 7675 4871 18117 >10666.67 EFAFKDLFVVYRDSI 9496 9996 5355 9072 5998 DLFVVYRDSIPHAAC 1163 11172 2832 2676 10741 FVVYRDSIPHAACHK 1194 1851 349 18144 2343 NTGLYNLLIRCLRCQ 14 5692 67 222 598 IRCLRCQKPLNPAEK >14662.76 >13725.49 6928 611 >10666.67 PRKLHELSSALEIPY 5990 51 1116 1710 >10666.67 EIPYDELRLNCVYCK >18001.8 858 2084 9047 >62305.3 TEVLDFAFTDLTIVY >18001.8 >13059.7 561 110 >62305.3 VLDFAFTDLTIVYRD 7474 3102 645 11294 14839 DFAFTDLTIVYRDDT 14334 5008 3651 21621 675 TIVYRDDTPHGVCTK >18001.8 6280 5449 >21521.34 >62305.3 WYRYSVYGTTLEKLT 1670 805 421 1039 62 ETTIHNIELQCVECK >18001.8 6282 11191 112 >62305.3 SEVYDFAFADLTVVY >18001.8 >13059.7 955 1325 11802 VYDFAFADLTVVYRE >18001.8 >13059.7 9446 10720 27275 DFAFADLTVVYREGN >18001.8 9627 4915 17973 39785 TVVYREGNPFGICKL >18001.8 >13059.7 13850 16200 48840 GNPFGICKLCLRFLS 1084 9737 1139 196 6594 NYSVYGNTLEQTVKK >56657.22 8614 15587 >25108.23 14326 KKPLNEILIRCHCQ 1299 965 1870 140 26273 NEILIRCIICQRPLC 20827 7174 18927 883 >29761.9 IRCIICQRPLCPQEK 6757 7295 25349 510 15154 CIVYRDCIAYAACHK 35566 12898 3847 2578 1912 NTELYNLLIRCLRCQ 259 5674 2449 797 854 IRCLRCQKPLNPAEK 21581 >9641.87 27591 447 20171 REVYKFLFTDLRIVY 2263 80 258 203 155 RIVYRDNNPYGVCIM 3446 119 821 1403 20474 NNPYGVCIMCLRFLS 7786 4797 6662 207 7258 EERVKKPLSEITIRC 6877 8919 132 2990 7910 IRCIICQTPLCPEEK 5461 17444 9766 916 >51020.41 EIPLIDLRLSCVYCK 47355 6936 656 861 16853 SCVYCKKELTRAEVY 569 23385 4374 673 3197 VCLLFYSKVRKYRYY 326 309 61 2343 182 YYDYSVYGATLESIT 9122 8923 1106 32378>51020.41 IRCYRCQSPLTPEEK 6645 >14403.29 480 28659 >51020.41 VYDFVFADLRGVYRD 12168 79 855 4392 >51020.41 DFVFADLRIVYRDGN 6957 162 1253 6709 8433 RIVYRDGNPFAVCKV 174 122 81 1606 3148 GNPFAVCKVCLRLLS 296 7389 117 126 657 KKCLNEILIRCIICQ 7579 731 3176 257 >9925.56 NEILIRCIICQRPLC 16056 10184 8177 372 >22909.51 RTAMFQDPQERPRKL 1034 17086 73192 20481 7474 LFVVYRDSIPHAACH 1582 697 437 3580 7854 LT1VYRDDTPHGVCT 15880 1852 27048 16993 >15267.18 LCIVYRDCIAYAACH 9886 5662 2269 2881 9738 YKFLFTDLRIVYRDN 10122 77 2912 1342 800 YNFACTELKLVYRDD 11615 10167 3082 12866 1673 LKLVYRDDFPYAVCR 698 699 1877 3828 9156 YDFVFADLRIVYRDG 6540 8173 25727 10907 11161 LRIVYRDGNPFAVCK 109 123 169 1566 6820 HEYMLDLQPETTDLY >56179.78 12990 30895 2099 >22909.51 TLRLCVQSTHVDIRT 17613 932 3957 243 >22909.51 IRTLEDLLMGTLGIV 1156 789 2181 23 12385 LEDLLMGTLGIVCPI 8514 1693 229 1800 9475 DLLMGTLGIVCPICS >56179.78 1053 1427 4123 16198 KATLQDIVLHLEPQN 25948 603 6968 159 >9925.56 IDGVNHQHLPARRAE >56179.78 >11475.41 >36842.11 344 12573 LRAFQQLFLNTLSFV 106 1.01 20 2.2 253 FQQLFLNTLSFVCPW 10311 9.3 24792 309 17330 QDYVLDLQPEATDLH >11918.95 >11475.41 >62758.62 1851 >22909.51 DIRILQELLMGSFGI 18982 5796 1625 16 >55096.42 IRILQELLMGSFGIV 7978 1038 294 17 >55096.42 ELLMGSFGIVCPNCS >59171.6 933 1928 206 >55096.42 KEYVLDLYPEPTDLY >59171.6 >14767.93 3171 476 >55096.42 LRTIQQLLMGTVNIV 3641 6.4 265 15 32108 IQQLLMGTVNIVCPT 11062 9.0 2010 166 >55096.42 QLLMGTVNIVCPTCA >59171.6 118 >38396.62 11550 >55096.42 RETLQEIVLHLEPQN 7896 11360 16220 95 >55096.42 LRTLQQLFLSTLSFV 208 55 29 3.1 1994 LQQLFLSTLSFVCPW 11693 133 296 22 36943 KDYILDLQPETTDLH >17436.79 23654 >37448.56 490 >55096.42 LRTLQQMLLGTLQVV 907 616 1697 88 >46620.05 LQQMLLGTLQVVCPG >31645.57 395 1266 1014 29198 QMLLGTLQVVCPGCA >31645.57 874 4144 258 >31446.54 VPTLQDVVLELTPQT >31645.57 14985 12263 1000 >31446.54 LQDVVLELTPQTEID >31645.57 1145 >33090.9 1116 >31446.54 QDVVLELTPQTEIDL >31645.57 10274 >33090.9 1719 >31446.54 CKFVVQLDIQSTKED >31645.57 >11437.91 22851 301 >31446.54 VYQLDIQSTKEDLRV 7353 708 5044 226 8690 DLRVVQQLLMGALTV 667 57 132 9.5 10879 LRVVQQLLMGALTVT 314 8.9 56 7.7 8755 VQQLLMGALTVTCPL 11074 574 526 204 7151 QQLLMGALTVTCPLC 7657 1223 4461 1470 >31446.54 QLLMGALTVTCPLCA >31645.57 1817 3761 2224 >31446.54 REYILDLHPEPTDLF 4152 13183 >33090.9 316 >31446.54 TCCYTCGTTVRLCNG 8636 739 3820 891 16033 VRTLQQLLMGTCTIV 1409 37 1829 139 >15267.18 LQQLLMGTCTIVCPS 9447 753 2441 2667 >15267.18 MLDLQPEITDLYCYE >15209.13 >12027.49 >48404.26 20 >15267.18 VLDLYPEPTDLYCYE >15209.13 >12027.49 21591 18 >15267.18 LREYILDLHPEPTDL 9827 12365 10949 2040 >40404.04 HIEFTPTRTDTYACRV 200000 >7142.86 200000 LWWVNNESLPVSPRL YEEYVRFDSDVGE 200000 200000 EEYVRFDSDVGE 200000 200000 APPRLICDSRVLERY >1111111.11 149 1384 1617 2840 6087 ICDSRVLERYLLEAK 2945 20402 85 16159 8550 7295 VLERYLLEAKEAENI 17227 881 269 340 8920 6714 EHCSLNENITVPDTK >1111111.11 84 12013 8307 52943 6626 NENITVPDTKVNFYA 17921 9338 22568 >38167.94 >38461.54 12214 VPDTKVNFYAWKRME 8861 14795 333 >38167.94 23602 449 VNFYAWKRMEVGQQA 50 14798 1194 22507 1490 455 WKRMEVGQQAVEVWQ 512 159 1812 >42194.09 238 4300 VGQQAVEVWQGLALL >17241.38 1313 12 >38167.94 3901 >7785.13 VEVWQGLALLSEAVL 5157 4473 58 >38167.94 1334 13794 GLALLSEAVLRGQAL 2578 1216 1939 >38167.94 3.5 105 SEAVLRGQALLVNSS 3484 7.4 151 3997 23 1057 RGQALLVNSSQPWEP 7698 3.4 2876 6165 1554 558 LVNSSQPWEPLQLHV >8163.27 504 2359 18044 3412 10039 QPWEPLQLHVDKAVS 8897 695 12480 1924 103 2929 LQLHVDKAVSGLRSL 910 53 2707 1044 31 76 DKAVSGLRSLTTLLR 52 187 60 3150 2006 104 GLRSLTTLLRALGAQ 3.7 871 6.2 12947 283 2.7 TTLLRALGAQKEAIS 860 1512 89 33256 251 21 ALQAQKEAISPPDAA 4212 >12411.35 14216 >91743.12 27294 3963 KEAISPPDAASAAPL 601 9272 1201 27203 2988 310 PPDAASAAPLRTITA 2582 10205 1267 10584 182 1117 SAAPLRT1TADTFRK 3883 809 858 2111 17 45 RTITADTFRKLFRVY 166 95 35 672 1561 93 DTFRKLFRVYSNFLR 11 10 0.95 43687 1029 26 LFRVYSNFLRGKLKL 173 80 2.8 8981 2333 2.9 SNFLRGKLKLYTGEA 192 4730 30 4075 2442 5.7 KLKLYTGEACRTGDR >17241.38 880 130 17787 20089 636 APPRLITDSRVLERY 2750 92 238 710 2263 698 ITDSRVLERYLLEAK 5279 >14705.88 18 >42194.09 12401 621 EHTSLNENITVPDTK >408163.27 13 11082 >42194.09 >29029.03 5547 KLKLYTGEATRTGDR 4364 841 18 5298 14838 731 PQPFRPQQPYPQ 15 PFRPQQPYPQ 42 PQPFRPQQPYP 14 PQPFRPQQP 19 KQPFRPQQPYPQ 56 PKPFRPQQPYPQ 3.4 PQPFKPQQPYPQ 19 PQPFRKQQPYPQ 22 PQPFRPQKPYPQ 22 PQPFRPQQPKPQ 325 PQPFRPQQPYKQ 35 PQPFRPQQPYPK 22 QFLGQQQPFPPQ 2.8 FLGQQQPFPPQ 31 LGQQQPFPPQ 151 QFLGQQQPFPP 2.3 QFLGQQQPF 5.3 IRNLALQTLPAMCNVY 1.9 NLALQTLPAMCNVY 27 LALQTLPAMCNVY 153 IRNLALQTLPAM 2.0 IRNLALQTLP 3.0 EGDAFELTVSCQGGLP K ESTGMTPEKVPVSEVM >17500 >64444.44 FPTIPLSRLFDNASL 30675 7495 1390 2585 194 5799 RLFDNASLRAHRLHQ 12461 84 85 11411 3210 557 LRAHRLHQLAFDTYQ 3208 7590 90 19811 2.0 4471 QLAFDTYQEFEEAYI >15384.62 15167 23166 595 11495 >38610.04 QEFEEAYIPKEQKYS 12821 >15837.1 >15582.19 >54554.47 >41134.75 5418 IPKEQKYSFLQNPQT >15384.62 13695 16207 30572 55587 13118 SFLQNPQTSLCFSES >15384.62 190 6513 93809 21651 >9647.76 TSLCFSESIPTPSNR >15384.62 99 1944 3920 1883 >38610.04 RBETQQKSNLELLRI >15384.62 15709 9736 >270270.27 52 25133 SNLELLRISLLLIQS 23669 196 59 >91901.83 147 50110 ISLLLIQSWLEPVQF 2675 120 60 6765 2.5 >9960.16 SWLEPVQFLRSVFAN 2715 4322 136 >270270.27 291 4815 FLRSVFANSLVYGAS 973 5.6 13 157978 814 141 NSLVYGASDSNVYDL >15384.62 14038 3640 11769 1792 >13046.31 SDSNVYDLLKDLEEG >15384.62 >17857.14 >30536.91 219298 >137767.22 >13046.31 GIQTLMGRLEDGSPR 4474 10433 1348 186220 2110 18006 RLEDGSPRTGQIFKQ 7896 >17857.14 9106 18119 296 12580 RTGQIFKQTYSKFDT 6961 66 155 14736 201 64 QTYSKFDTNSHNDDA >15384.62 >17857.14 25883 38715 >137767.22 5787 TNSHNDDALLKNYGL >15384.62 5169 133 130378 >137767.22 >13046.31 ALLKNYGLLYCFRIW >15384.62 10 17 2309 1230 462 DMDKVETFLRIVQCR 885 1232 201 >27322.4 826 7447 FLRIVQCRSVEGSCGF 2708 1017 839 >27322.4 1078 7102 FPTIPLSRLFDNAML 46404 9313 2770 121212 216 11521 RLFDNAMLRAHRLHQ 267 738 18 >270270.27 1628 58 QLAFDTYQEFEQNPQ >15384.62 19718 >86666.67 738 >32842.58 >9510.22 SFLQNFQTSLCCFRK 3801 128 103 >270270.27 8500 3739 SNLELLRICLLLIQS >15384.62 773 90 17024 164 >11771.33 ICLLLIQSWLEPVQF >15384.62 954 1771 187970 49 >9510.22 NSLVYGASDSNIYDL >15384.62 10854 971 31616 3287 >9510.22 SDSNIYDLLKDLEEG >15384.62 >16203.7 >86666.67 >18726.59 24259 >9510.22 DKVETFLRIVQCCGF 1023 1034 383 6278 184 6350 SFLQNPQTSLTFSES >15384.62 121 1511 864 17824 12365 TSLTFSESIPTPSNR 22152 16 176 >95238.1 3476 >1335.38 ALLKNYGLLYTFRKD 1737 0.89 6.5 50 1335 29 LLYTFRKDMDKVETF 7905 >14522.82 886 941 12493 154 DMDKVETFLRIVQTR 206 3381 >86666.67 13712 190 1263 FLRIVQTRSVEGSTGF 143 1.5 9.8 27345 21 116 HLDMLRHLYQGCQVV 2076 2879 359 107066 163 7087 RLRIVRGTQLFEDNYA 2072 5.2 31 1198 120 46 L GVGSPYVSRLLGICL 696 955 46 148588 316 14197 TLERPKTLSPGKNGV >52631.58 835 23264 >263157.89 25739 11337 KIFGSLAFLPESFDGD >52631.58 1073 2264 43745 10020 8008 PA ELVSEFSRMARDPQ 4573 >71428.57 7891 15838 970 4055 GEALSTLVLNRLKVG 79 29 269 1023 46 AYVLLSEKKISSIQS 51 816 489 902 4517 VASLLTTAEVVVTEI >18674.14 >10294.12 >50837.99 >26435.73 >119047.62 KCEFQDAYVILLSEKK 1078 >10294.12 >47643.98 >19594.59 20 ALSTLVLNRLKVGLQ 9.1 4.6 191 17 3.9 MSYNLLGFLQRSSNC 3628 1190 89 >42194.09 6503 710 LGFLQRSSNCQCQKL 6025 112 1397 >42194.09 1167 649 RSSNCQCQKLLWQLN >408163.27 6153 802 3519 21 6981 QCQKLLWQLNGRLEY 1644 227 175 8709 209 924 LWQLNGRLEYCLKDR 4215 808 893 29028 15576 3241 GRLEYCLKDRRNFDI 1707 1240 940 5213 15870 64725 RNFD1PEEIKQLQQF 7326 >15418.5 2036 23832 311 6854 PEEIKQLQQFQKEDA 1953 13325 1873 >26315.79 215 675 QLQQFQKEDAAVTIY >408163.27 68 1724 348 1338 4270 QKEDAAVTIYEMLQN >408163.27 7315 1146 >42194.09 15173 >10482.18 AVTIYEMLQNIFAIF 29718 109 262 2828 1118 14047 EMLQNIFAIFRQDSS 36832 61 1718 726 164 3187 IFAIFRQDSSSTGWN 4558 775 204 2181 30 109290 RQDSSSTGWNETIVE >42553.19 848 >189583.33 9172 1497 8650 STGWNETIVENLLAN 20576 105 897 >26315.79 166 5822 ETIVENLLANVYHQR >42553.19 8.5 1603 >42194.09 2503 18559 NLLANVYHQRNHLKT 8258 61 20 >123456.79 3071 65 VYHQRNHLKTVLEEK 22002 1267 1662 >123456.79 9585 4.7 LEKEDFTRGKRMSSL 698 25362 14118 6267 16057 4903 FTRGKRMSSLHLKRY 81 10245 118 18836 2027 84 RMSSLHLKRYYGRIL 1035 2532 1.3 >26178.01 2255 491 HLKRYYGRILHYLKA 2721 868 0.69 6608 22 2.3 YORILHYLKAKBDSH 812 2783 16 454545 140 39 HYLKAKEDSHCAWTI >60606.06 11571 627 301205 7501 2632 KEDSHCAWTIVRVEI 9320 506 1397 >1754385.96 7.9 4056 CAWTIVRVEILRNFY 4167 147 196 10300 152 4143 VRVEILRNFYVINRL 504 5.8 1.04 80386 187 485 RNFYVINRLTGYLRN 55 9.4 18 689 1249 5.6 MSYNLLGFLQRSSNT 3069 1334 6.8 51787 4660 9.0 LGFLQRSSNTQTQKL 26247 21 2331 >1754385.96 1041 339 RSSNTQTQKLLWQLN >42553.19 169 2740 751 26 8545 QTQKLLWQLNGRLEY 20654 121 20 6582 88 417 LWQLNGRLEYTLKDR 6521 2447 853 4402 14310 6004 GRLEYTLKDRRNFDI 4998 1468 168 9901 21427 796 HYLKAKEDSHTAWTI >60606.06 2264 529 35829 11750 19617 KEDSHTAWTIVRVEI 7443 3046 1992 56205 18 575 TAWTIYRVEILRNFY 5052 72 242 14419 26 518 LGFLQRSSNCQSQKL 604 131 541 >1754385.96 124 508 RSSNCQSQKLLWQLN >60606.06 1960 2962 68823 27 4077 QSQKLLWQLNGRLEY >60606.06 155 108 5609 166 402 GIVEQCCTSICSLYQ 7940 239 1280 14353 4245 >37593.98 TSICSLYQLENYCN >10526.32 >15021.46 837 8048 13496 >40322.58 GILEQCCTSICSLYQ >10526.32 858 1097 >18726.59 5871 19231 G1VEQTTTSITSLYQ >10526.32 14 849 >95238.1 2303 >37593.98 EQTTTSITSLYQLEN >10526.32 16949 1078 >18726.59 29614 48505 TSICSLYQLENYCG >10526.32 10346 173 >95238.1 1645 >40322.58 TSITSLYQLENYTN 1095 >17073.17 99 >95238.1 3245 6048 TSITSLYQLENYTG 1014 >17073.17 182 92336 1658 16073 GIVEQCCCGSHLVEA >10526.32 15347 237 14184 11017 >43290.04 SLYQLENYCCGERGF >1111111.11 >15909.09 151 92336 30978 >43290.04 CCTSICSLYQLENYCC >1111111.11 7096 877 >18726.59 1582 >40650.41 GSHLVEALYLVCCN >1111111.11 3259 11191 >18726.59 14065 >46403.71 CCGSHLVEALYLVCC >10526.32 6027 12986 >18726.59 11357 >43290.04 FVNQHLCGSHLVEAL >1111111.11 10595 1195 >95238.1 3153 47170 QHLCGSHLVEALYLV >10526.32 7624 103 14819 1480 32049 GSHLVEALYLVCGER >10526.32 8030 1350 >18726.59 372 29283 VEALYLVCGERGFFY 3563 4403 181 4443 30 25543 YLVCGERGFFYTPKT >10526.32 9272 10655 92764 34450 95238 FVNQHLCGSDLVEAL >1111111.11 20248 9679 10031 24511 >43290.04 FVNQHLTGSHLVEAL >10526.32 12413 799 94518 4084 >43290.04 QHLTGSHLVEALYLV >10526.32 6862 184 4027 939 23716 GSHLVEALYLVTGER >10526.32 12185 1429 18215 225 11398 VEALYLVCGERGSFY >10526.32 4288 1240 >95238.1 129 804 VEALYLVCGERGFLY 55402 1871 149 843 19 5149 VEALYLVTGERGFFY 4860 1076 116 17156 13 78 YLVCGERGFLYTPKT >1111111.11 2120 >25633.8 >95238.1 33114 971 YLVCGERGFFYTDKT >60606.06 1014 >25633.8 616 48099 >28449.5 YLVCGERGFFYTKPT >60606.06 3467 >25633.8 12805 40379 >28449.5 YLVTGERGFFYTPKT 7625 2100 >25633.8 13737 20721 >28449.5 YLVTGERGFFYTDKT 16849 17353 >25633.8 359 30824 >28449.5 YLVTGERGFFYTKPT 9341 17869 >21016.17 9573 27915 11926 VCGERGFFYTPKTRR 3817 34669 >25633.8 17416 >30999.47 92 VTGERGFFYTPKTRR 10116 25362 2824 243902 >29820.05 540 MWDLVLSIALSVGCT 81096 108 11375 15205 158 70711 DLVLSIALSVGCTGA >200000 98 18200 >14918.69 459 >100000 HPQWVLTAAHCLKKN 981 483 1219 8114 1106 11 QWVLTAAHCLKKNSQ 14213 >35000 >45500 >14918.69 14395 382 GQRVPVSHSFPHPLY >200000 703 3960 >14918.69 9860 >200000 RVPVSHSFPHPLYNM >200000 377 5518 >14918.69 9213 11650 PHPLYNMSLLKHQSL 6455 3307 3873 >14918.69 49 1901 HPLYNMSLLKHQSLR 248 546 472 >14918.69 8.4 219 NMSLLKHQSLRPDED 25820 >35000 >30333.33 >14918.69 105 >100000 SHDLMLLRLSEPAKI 5267 1.8 365 5361 10 2031 HDLMLLRLSEPAKIT 1147 0.83 115 488 12 211 PEEFLRPRSLQCVSL 10675 11667 3193 >14413.38 117 57537 PRSLQCVSLHLLSND 11128 3731 1597 11650 544 46416 NGVLQGITSWGPEPC 32444 >17500 835 >14413.38 5761 >100000 KPAVYTKVVHYRKWI 327 1947 401 7186 4581 23 LHLLSNDMCARAYSE 26012 1876 >2367.33 1308 324 28817 VGNWQYFFPVIFSKA ESEFQAALSRKVAKL IGHLYIFATCLGLSYD GL VGNWQYFFPVIFSKAS DSLQLVFGIELMEVD PAYEKLSAEQSPPPY RNGYRALMDKSLHVG TQCALTRR FFKNIVTFFKNIVT YKSAHKGFKGVDAQG 2000 1333 2065 TLSKI VDAQGTLSKIFKLGGR 18 769 6667 1152 DSRS AC- 200000 200000 4561 ASQKRPSQRHGSKYLA TAST ENPVVHFFKNIVTPR 5.2 463 ENPVVAFFKNIVTPR 2.8 302 ENPVVHAFKNIVTPR 4.1 910 ENPVVHFFANIVTPR 2.9 6235 ENPVVHFFKIHVTPA 2.5 3333 NPVVHFFKNIVT 23 10000 HFFKNIVTPRTPPY 460 377 NPVVHFFKNIVTPR 3.7 1890 LPVPGVLLKEFTVSGN 216 52 84 349 1840 ILTI WITQCFLPVFLAQPPS 13208 23649 726 688 286 CIQRR DHRQLQLSISSCLQQL >98522.17 69 67 532 63772 SLLM YLAMPFATPMEAELAR 3754 2813 865 1965 641 RSLA AAPLLLARAASLSLG 100 3.2 35 10470 79 79 APLLLARAASLSLGF 322 12 91 13359 59 114 PLLLARAASLSLGFL 1255 12 118 >9742.79 52 151 SLSLGFLFLLFFWLD 100000 639 11375 3710 >10955.8 66667 LLFFWLDRSVLAKEL 154 24 34 86 7.5 134 DRSVLAKELKFVTLV 20966 4410 1359 >14413.38 53 2217 AKELKFVTLVFRHGD 12309 824 1529 8563 51 24 RSPIDTFPTDPIKES >200000 >35000 2373 >14413.38 469 28571 FGQLTQLGMEQHYEL 27217 >35000 >22750 >14413.38 543 100000 DRTLMSAMTNLAALF 2367 114 871 3927 57 26138 MSAMTALAALFPPEG >200000 249 12384 7158 1072 63246 MTNLAALFPPEGVSI 141421 1310 10370 >8829.24 4606 141421 PEGVSIWNPILLWQP 30861 444 7.2 4624 107 22222 GVSIWNPILLWQPIP 10287 207 5.0 4428 492 523 WNPILLWQPIPVHTV 19640 2259 14 >8829.24 81 100000 NPILLWQPIPVHTVP 599 250 4.6 >8829.24 67 25000 PILLWQPIPVHTVPL 4041 567 6.9 >8829.24 106 41491 ILLWQPIPVHTVPLS 2343 1111 65 >8829.24 712 28768 WQPIPVHTVPLSEDQ >66666.67 2692 >45500 >8829.24 1228 >100000 LSGLHGQDLFGIWSK 30151 >35000 32173 >8829.24 135 81650 YDPLYCESVHNFTLP 30151 >35000 2136 >8829.24 6901 28768 LPSWATEDTMTKIRE >66666.67 >35000 >45500 5973 >11134.57 343 LRELSELSLLSLYGI 6958 3218 235 >14956.63 544 5185 LSELSLLSLYGIHKQ 1657 1253 45 >13046.31 79 7.3 LSLLSLYGIHKQKEK 742 >35000 58 >14956.63 772 3.4 KSRLQGGVLVNEILN >66666.67 318 >30333.33 >14956.63 713 >100000 GGVLVNEILNHMKRA 255 49 576 8124 5.8 8.7 IPSYKKLIMYSAHDT 53 2122 17 9982 12 191 YKKLIMYSAHDTTVS 208 37 15 13224 5.8 5482 LIMYSAHDTTVSGLQ >66666.67 1752 184 6828 4381 >100000 DTTVSGLQMALDVYN >50000 3500 1042 10843 961 >200000 ALDVYNGLLPPYASC 182 >35000 1091 >14956.63 >10090.47 115470 LDVYNGLLPPYASCH 194 >35000 3035 >14956.63 >10918.67 25820 YNGLLPPYASCHLTE 5300 11667 252 >14956.63 >10918.67 100000 FAELVGPVIPQDWST >50000 >35000 >45500 >14956.63 983 >200000 TVPLSEDQLLYLPFR 26455 5300 >2367.33 4323 872 27221 LTELYFEKGEYFVEM >18903.59 3157 >2367.33 124 601 6655 GPVIPQDWSTECMTT 20295 961 QAHSLERVCHCLGKWL 2857 2500 GHPDK WTTCQSIAFPSKTSAS 40000 277 37450 505 400 IGSL QKGRGYRGQHQAHSLE 30151 >9100 >500000 17951 9759 RVCH AATYNFAVLKLMGRGT 17 239 70014 1218 18 KF VATGLCFFGVALFCGC 33333 117851 193333 GHEA FLYGALLLAEGFYTTG 45 256 AVRQ SAVPVYIYFNTWTTCQS 92 20000 IAF TLSVTWIGAAPLILS 6860 642 97 6031 3506 31 SVTWIGAAPLILSRI 2196 420 147 13676 42 104 VTWIGAAPLILSRIV 1779 2339 552 >10729.61 88 147 SQPWQVLVASRGRAV 135 32 11259 >12116.81 7562 84 GRAVCGGVLVHPQWV >50000 5456 12888 >12116.81 62 100000 GVLVHPQWVLTAAHC 263 2427 66 >10729.61 6.2 1062 HPQWVLTAAHCIRNK 785 1170 6500 1324 5518 40 QWVLTAAHCIRNKSV 2169 2062 13565 7342 3802 35 AHCIRNKSVILLGRH 93 75 88 4752 8.7 3630 SVILLGRHSLFHPED 96 96 106 13045 4411 16116 VILLGRHSLFHPEDT 344 543 426 >12116.81 10696 100000 GQVFQVSHSFPHPLY 103 146 2172 1071 416 128 VFQVSHSFPHPLYDM 881 83 2396 23433 >12491.92 897 PHPLYDMSLLKNRFL >50000 11667 712 >13533.63 7486 3104 SHDLMLLRISEPAEL 4471 5.8 1099 13577 12 100000 HDLMLLRLSEPAELT 2141 2.3 662 5305 45 10541 TDAVKVMDLPTQEPA >50000 >35000 >45500 >13533.63 747 >200000 LHVISNDVCAQVHPQ >50000 239 22750 1887 1087 >200000 CAQVHPQKVTKFMLC 18490 2192 809 >13533.63 604 1229 GGPLVCNGVLQGITS 1828 36 30333 >6567.28 815 13417 GPLVCNGVLQGITSW 915 49 6310 11615 646 6537 NGVLQGITSWGSEPC 9724 775 258 8038 4487 11619 RPSLYTKVVHYRKWI 350 4183 717 2982 4897 13 HSLFHPEDTGQVFQV 553 11503 PRWLCAGALVLAGGF >40000 20207 15167 13150 883 40825 LGFLFGWFIKSSNEA 7303 10104 355 681 9285 461 LDELKAENIKKFLYN 324 597 414 548 788 150 IKKFLYNFTQIPHLA 137 27 305 477 96 658 KFLYNFTQIPHLAGT 91 221 227 10212 256 1600 WKEFGLDSVELAHYD 4935 8413 22750 829 5925 89443 LAHYDVLLSYPNKTA 380 268 82 1406 589 172 GNEIFNTSLFEPPPP >40000 2804 >91000 >13164.82 835 >200000 GKVFRGNKVKNAQLA 894 46 3373 7591 7884 1385 GNKVKNAQLAGAKGV >66666.67 >35000 >45500 >12462.61 1065 1218 EYAYRRGIAEAVGLP 2590 5217 >45500 8773 6325 1204 AEAVGLPSIPVHPIG >66666.67 5456 56 >11848.34 12394 69336 AVGLPSIPVHPIGYY 33333 1191 518 >11848.34 5387 38517 IGYYDAQKLLEKMGG >28571.43 5729 1978 17305 13588 506 TGNFSTQKVKMHIHS 11856 6187 3745 >11848.34 508 1927 TRIYNVIGTLRGAVE 45 1460 1605 17550 447 32 ERGVAYINADSSIEG >50000 3689 30333 6846 87 200000 GVAYINADSSIEGNY >40000 497 7610 1420 477 66667 DSSLEGNYTLRVDCT >50000 7.6 1202 576 1262 16824 NYTLRVDCTPLMYSL 7116 9.0 5056 25 404 66667 CTPLMYSLVHNLTKE 590 260 426 18348 58 36 DFEVFFQRLGIASGR 128 10069 10249 30745 4.2 3559 EVFFQRLGIASGRAR 31 17500 4556 >15037.59 51 7.9 TNKFSGYPLYHSVYE 33333 >35000 489 >21853.15 12466 2942 YDPMFKYHLTVAQVR 252 1014 1348 8137 553 62 DPMFKYHLTVAQVRG 69 699 230 7297 467 11 MFKYHLTVAQVRGGM 147 1615 1198 3648 1062 5.8 KYHLTVAQVRGGMVF 859 193 1222 >21853.15 3446 86 VAQVRGGNIVFELANS >50000 2802 117 <21853.15 100 64366 RGGMVFELANSIVLP >50000 4.4 94 132 411 413 GMVFELANSIVLPFD >50000 12 83 234 4154 903 VFELANSIVLPFDCR 11765 24 477 128 1215 10815 ADKIYSISMKHPQEM 169 4957 8273 >21853.15 3550 26726 IYSISMKHPQEMKTY 213 >35000 5025 >21853.15 5356 2588 PQEMKTYSVSFDSLF >50000 24749 919 14564 579 100000 TYSVSFDSLFSAVKN 5981 5888 3223 8547 10461 61 VLRMMNDQLMFLERA 2353 130 127 98 88 85 LRMMNDQLMFLERAF 1833 1314 1411 1570 50 758 RHVIYAPSSHNKYAG 13363 8750 1291 >62814.07 5293 88 RQIYVAAFTVQAAAE 35 524 166 6808 47 143 QIYVAAFTVQAAAET 34 344 252 1324 50 216 VAAFTVQAAAETLSE 2126 446 18200 2116 464 378 YISIINEDGNEIFNT >18903.59 346 2713 30 3705 72993 ISIINEDONEIENTS >18903.59 343 3006 35 6394 >37807.18 EDFFKLERDMKINCS 10433 3188 >3490.6 4036 7886 3494 FFKLERDMKINCSGK 9687 382 >3490.6 4918 98 3796 GVILYSDPADYFAPG >18903.59 39 965 8.8 64 14168 GAAVVHEIVRSFGTL 788 89 NSRLLQERGVAYINA 12812 327 1229 3366 699 3473 VAYINADSSIEGNYT >18903.59 2147 >3490.6 471 841 >37807.18 DQLMFLERAFIDPLG 17115 6.6 KSNFLNCYVSGFHPSD 5000 2857 AC- >33333.33 >10000 >10000 1000 50000 NPDAENWNSQFEILED AA EYLILSARDVLAVVS 6860 2340 2527 4154 YKTIAYDEEARR 200000 >91000 >50000 200000 GEALSTLVVNKIRGT 977 55 2314 1514 108 PYILLVSSKVSTVKD 112 7.2 22 107 32 EAVLEDPYILLVSSK 4376 >10294.12 >50837.99 >26435.73 357 IAGLFLTTEAVVADK 867 >10294.12 >50837.99 >26435.79 606 ALSTLVVNK1RGTFK 32 7.6 160 214 38 MKHILYISFYFILVN 2082 >9523.81 KSLLSTALPYGRTNL HFFLFLLYILFLVKM 84 21473 1064 10083 LFLLYILFLVKMNAL 129 30829 1290 32446 ILFLVKMNALRRLPV 0.13 1.4 7.6 14 MNALRRLPVICSFLV 15 36 5.7 2557 SAFLESQSMNKIGDD 52 18689 302 243 LKELIKVGLPSFENL 147 361 110 41322 FENLVAENVKPPKVD 3029 >50837.99 9297 62661 PATYGIIVPVLTSLF 0.83 2557 118 52 VGIRTPVLTSLFNKV 0.30 223 97 80 LLKIWKNYMKIMNHL 3.7 6.8 12 35 MTLYQIQVMKRNQKQ 323 2429 82 22 QKQVQMMIMIKFMGV 17 363 5.3 915 MJMIKFMGVIYIMII 102 23611 145 12310 GVIYIMIISKKMMRK 38 173 157 46 LYYLFNQHIKKELYH 327 2861 1089 606 HFNMLKNKMQSSFFM 54 616 934 60 LDIYQKLYIKQEEQK 4346 47 70 6958 QKKYIYNLIMNTQNK 53 844 87 245 YEALIKLLPFSKRIR 230 36 15 11 ENEYATGAVRPFQAA 9302 3007 10026 >10303.97 NYELSKXAVIFTPIY 410 537 136 10581 QKILIKIPVTKNIIT 332 3614 953 297 KCLVISQVSNSDSYK 236 403 81 >42553.19 SK1MKLPKLPISNGK 6460 3570 6739 >10303.97 FIHFFTWGTMFVPKY 328 2375 387 9608 LCNFKKNIIALLHP 16 29302 99 >42553.19 KKNIIALLIIPPKIH 15 32 8.2 143 ALLIIPPKIHISIEL 162 1823 10 7135 SMEYKKDFLITARKY 3818 4610 10448 442 KSKFNILSSPLFNNF 25 5.9 135 32 FKKLKNHVLFLQMMN 20 29 14 59 KNHVLFLQMMNVNLQ 36 224 22 >7212.41 VLFLQMMNVNLQKQL 8.6 8200 12 >7212.41 NVNLQKQLLTNHLIN 28 4448 354 >7212.41 QKQLLTNHLINTPKI 1.6 514 904 6595 NHLINTPKIMPHHII 32 560 1632 8882 YILLKKILSSRFNQM 1.01 26 340 83 FNQMIFVSSIFISSFY 33 3903 1291 >12484.39 KVSCKGSGYTFTAYQM >200000 H IAKVPPGPNITAEYGD 200000 >20000 200000 KWLD TAEYGDKWLDAKSTW 200000 >20000 10000 YGKPT AKSTWYGKPTGAGPKD 200000 >20000 10000 NGGA GAGPKDNGGACGYKD 200000 >20000 200000 VDKAP FNGMTGCGNTPIFKDG 200000 >20000 200000 RGCG PIFKDGRGCGSCFEIK 200000 >20000 200000 CTKP SCFEIKCTKPESCSGE 200000 >20000 200000 AVTV AFGSMAKKGEEQNVRS 1818 >33333.33 200000 AGEL TPDKLTGPFTVRYTTE 200000 >25000 200000 GGTK VRYTTEGGTKSEVEDV 200000 >25000 200000 IPEG TCVLGKLSQELHKLQ 1398 >12589.93 2009 >263157.89 163 3986 KLSQELHKLQTYPRT 2375 >12589.93 287 >263157.89 870 37 LHKLQTYPRTNTGSG 6091 >12589.93 157 >263157.89 22948 40 KLQTYPRTNTGSGTP 8210 987 520 >263157.89 >104693.14 >14044.94 CCVLGKLSQELHKLQ 5243 >12589.93 570 >263157.89 346 5158 CSNLSTCVLGKLSQE 5263 7907 4538 >263157.89 11756 5709 TSNLSTTVLGKLSQE 534 9333 7697 >263157.89 13210 2529 TTVLGKLSQELHKLQ 3524 12715 525 >263157.89 241 10618 DIAAKYKELGY >10000 >25000 200000 ALVRQGLAKVA 200000 >10000 PATLIKAIDGDTVKLM >6666.67 2381 3333 YKGQ TPETKHPKKGVEKYGP >6666.67 >25000 >4000 EASA VEKYGPEASAFTKKMV 20000 16667 34 ENAK FTKKMVENAKKIEVEF 6667 >25000 1000 DKGQ YIYADGKMVNEALVRQ >6666.67 >5555.56 >4000 GLAK HEQHLRKSEAQAKKEK 200000 >5555.56 11 LNIW QAKKEKLNIWSEDNAD 200000 >5555.56 200000 SGQ YFNNFTVSFWLRVPK FSYFPSI YSFFPSI YSYFPSIR 20000 >200000 DPNANPNVDPNANPNV >12500 >7583.33 >72500 >2898.55 NANPNANPNANP(X4) QKWAAVVVPS TWQLNGEELIQDMELV ETRPAG PEFLEQRRAAVDTYC 488 200000 STORKUSP33 DYSYLQDSDPDSFQD >66666.67 >35000 >45500 >40000 DFSYLQDSDPDSFQD >35000 >91000 >40000 QNILFSNAPLGPQFP QNILLSNAPLVPQFP DYSYLQDSDPDSFQD KYVKQNTLKLAT P(X)KQNTLKLAT EEDIEIIFIQEEEY >20576.13 46083 HQAISPRTLNSPAIF 33686 1036 8106 >83333.33 130 >200000 YTDVFSLDPTFTIETT YAGIRRDGLLLRLVD LFFYRKSVWSKLQSI 12 121 20 5915 1933 18 RPIVNMDYVVGARTFR 222 73 43 3324 160 6.6 REKR RPGLLGASVLGLDDI >93896.71 2056 6000 30212 22038 >88888.89 LYFVKVDVTGAYDTI 221 79 9753 16 22 4962 FAGIRRDGLLLRIVD 804 1294 28 553 1670 1355 AKTFLRTLVRGVPEY 6.3 94 829 546 472 3484 YGAVVNLRKTVVNFP 89 11236 470 51496 302 36 GTAFVQMPAHGLFPW 17 2819 1.2 769 2361 43 WAGLLLDTRTLEVQS 20960 92 3468 862 >102040.82 RTSIRASLTFNRGFK 4807 49 497 79 52 RVIKNSIRLTL 1740 32 4317 143 8834 PVIKNSIKLRL 2772 77 2579 198 1039 ATSTKKLHKEPATLIK >6666.67 462 267 AIDG

TABLE 28 MURINE CLASS I SUPERTYPE SEQ ID Sequence NO. AA Organism Protein Position Analog SGPSNTPPEI 10 Adenovirus E1A RNPRFYNL 8 Artificial Consensus sequence QPQRGYENF 9 Artificial Consensus A sequence SEAAYAKKI 9 Artificial pool A sequence consensus AYAPAKAAI 9 Artificial Poly sequence AYAEAKAAI 9 Artificial Poly sequence AYANAKAAI 9 Artificial Poly sequence AYAGAKAAI 9 Artificial Poly sequence AYAVAKAAI 9 Artificial Poly sequence AAAAYAAM 8 Artificial sequence AAAAYAAAAM 10 Artificial sequence AAAANAAAM 9 Artificial sequence AAAAAANAAAM 11 Artificial sequence NAIVFKGL 8 Chicken Ova 176 SIINFEKL 8 Chicken Ova 257 IFYCPIAI 8 Chicken Ova 27 KVVRFDKL 8 Chicken Ova 55 VYSFSLASRL 10 Chicken Ova 96 SIINFEKL 8 Chicken Ova 257 KVVRFDKL 8 Chicken Ova 55 SENDRYRLL 9 EBV BZLF1 209 A SFYRNLLWL 9 Flu HA 142 YEANGNLI 8 Flu HA 259 A MGLIYNRM 8 Flu M1 128 MGYIYNRM 8 Flu M1 128 MGIIYNRM 8 Flu M1 128 MGLIFNRM 8 Flu M1 128 MGLIYNRM 8 Flu M1 128 RMIQNSLTI 9 Flu NP 55 RLIQNFLTI 9 FLu NP 55 GMRQNATEI 9 Flu NP 17 YMRVNGKWM 9 Flu NP 97 FYIQMATEL 9 Flu NP 39 FYIQMCTFL 9 Flu NP 39 AYERMANIL 9 Flu NP 218 AYQRMCNIL 9 Flu NP 218 AYERMCTIL 9 Flu NP 218 ASNENMETM 9 Flu NP 366 TYQRTRALM 9 Flu NP 147 A TYQKTRALV 9 Flu NP 147 A TYQPTRALV 9 Flu NP 147 A TYQFTRALV 9 Flu NP 147 A TYQLTRALV 9 Flu NP 147 A SDYEGRLI 8 Flu NP 50 MITQFESL 8 Flu NS 31 RTFSFQLI 8 Flu NS 114 FSVIFDRL 8 Flu NS 134 RTFSFQLI 8 Flu NS1 114 MITQFESL 8 Flu NS1 31 FSVIFDRL 8 Flu NS2 134 KSSFYRNL 8 FluA HA 158 SSLPFQNI 8 FluA HA 305 MNIQFTAV 8 FluA HA 403 MNYYWTLL 8 FluA HA 244 SFYRNLLWL 9 FluA HA 160 SSLPFQNI 8 FluA HA 305 MNIQFTAV 8 FluA HA 403 MNYYWTLL 8 FluA HA 244 KSSFYRNL 8 FluA HA 158 SIIPSGPL 8 FluA M1 13 LSYSAGAL 8 FluA M1 117 LSYSAGAL 8 FluA M1 117 SSISFCGV 8 FluA NM 426 TGICNQNII 9 FluA NM 46 ITYKNSTWV 9 FluA NM 54 FCGVNSDTV 9 FluA NM 430 TGICNQNII 9 FluA NM 46 FCGVNSDTV 9 FluA NM 430 ITYKNSTWV 9 FluA NM 54 SSISFGGV 8 FluA NM 426 IGRFYIQM 8 FluA NP 36 MMIWHSNL 8 FluA NP 136 ASNENMETM 9 FluA NP 366 IGRFYIQM 8 FluA NP 36 MMIWHSNL 8 FluA NP 136 FFYRYGFV 8 FluA POL1 495 KMITQRTI 8 FluA POL1 198 RSYLIRAL 8 FluA POL1 215 RFYRTCKL 8 FluA POL1 465 TALANTIEV 9 FluA POL1 141 TALANTIEV 9 FluA POL1 141 RSYLIRAL 8 FluA POL1 215 RFYRTGKL 8 FluA POL1 465 VYINTALL 8 FluA POL2 463 VYINTALL 8 FluA POL2 463 VYIEVLHL 8 FluA POL3 227 VYIEVLHL 8 FluA POL3 227 WYIPPSLRTL 10 GAD MURTAZAKDPEPTIDES 0 GAD65 107 IYSTVASSL 9 HA 553 LYEKVKSQL 9 HA 462 LYQKVKSQL 9 HA 462 LYEKMKSQL 9 HA 462 LYEKVFSQL 9 HA 462 LYQNVGTYV 9 HA 204 MGLKFRQL 8 HBV core 122 VSYVNTNM 8 HBV core 115 SYVNTNMGL 9 HBV core 116 MGLKFRQL 8 HBV core 122 VSYVNTNM 8 HBV core 115 SYVNTNMGL 9 HBV core 116 WGPSLYSI 8 HBV env 364 ASARFSWL 8 HBV env 329 WGPSLYSIL 9 HBV env 364 TGPCRTCMT 9 HBV env 281 WYWGPSLYSI 10 HBV env 362 IPQSLDSWWTSL 12 HBV env 28 IPQSLDSYWTSL 12 HBV env 28 A ASARFSWL 8 HBV env 329 WYWGPSLYSI 10 HBV env 362 APQSLDSWWTSL 12 HBV env 28 IPQALDSWWTSL 12 HBV env 28 A IPQSLASWWTSL 12 HBV env 28 A IPQSLDAWWTSL 12 HBV env 28 A IPQSLDSAWTSL 12 HBV env 28 A IPQSLDSWWASL 12 HBV env 28 A IPQSLDSWWTAL 12 HBV env 28 A EPQSLDSWWTSL 12 HBV env 28 A IPESLDSWWTSL 12 HBV env 28 A IPQSLDEWWTSL 12 HBV env 28 A IPQSLDSWWTEL 12 HBV env 28 A RPQSLDSWWTSL 12 HBV env 28 A IPRSLDSWWTSL 12 HBV env 28 A IPQRLDSWWTSL 12 HBV env 28 A IPQSRDSWWTSL 12 HBV env 28 A IPQSLRSWWTSL 12 HBV env 28 A IPQSLDRWWTSL 12 HBV env 28 A IPQSLDSRWTSL 12 HBV env 28 A IPQSLDSWWRSL 12 HBV env 28 A IPQSLDSWWTRL 12 HBV env 28 A YPQSLDSWWTSL 12 HBV env 28 A IPYSLDSWWTSL 12 HBV env 28 A IPQYLDSWWTSL 12 HBV env 28 A IPQSLYSWWTSL 12 HBV env 28 A IPQSLDYWWTSL 12 HBV env 28 A IPQSLDSWYTSL 12 HBV env 28 A IPQSLDSWWTYL 12 HBV env 28 A IPGSLDSWWTSL 12 HBV env 28 A IPQSLDSGWTSL 12 HBV env 28 A IPQSLDSPWTSL 12 HBV env 28 A IPQSLDSWGTSL 12 HBV env 28 A IPQSLDSWPTSL 12 HBV env 28 A IPQSLDSWWTGL 12 HBV env 28 A IPQSLDSWWTPL 12 HBV env 28 A IPQVLDSWWTSL 12 HBV env 28 A IPQFLDSWWTSL 12 HBV env 28 A IPQPLDSWWTSL 12 HBV env 28 A IPQMLDSWWTSL 12 HBV env 28 A IPQILDSWWTSL 12 HBV env 28 A IPQLLDSWWTSL 12 HBV env 28 A IPQGLDSWWTSL 12 HBV env 28 A IPQTLDSWWTSL 12 HBV env 28 A IPQHLDSWWTSL 12 HBV env 28 A IPQCLDSWWTSL 12 HBV env 28 A IPQNLDSWWTSL 12 HBV env 28 A IPQQLDSWWTSL 12 HBV env 28 A IPQWLDSWWTSL 12 HBV env 28 A IPQDLDSWWTSL 12 HBV env 28 A IPQKLDSWWTSL 12 HBV env 28 A IPQSLVSWWTSL 12 HBV env 28 A IPQSLFSWWTSL 12 HBV env 28 A IPQSLPSWWTSL 12 HBV env 28 A IPQSLMSWWTSL 12 HBV env 28 A IPQSLISWWTSL 12 HBV env 28 A IPQSLLSWWTSL 12 HBV env 28 A IPQSLGSWWTSL 12 HBV env 28 A IPQSLSSWWTSL 12 HBV env 28 A IPQSLTSWWTSL 12 HBV env 28 A IPQSLHSWWTSL 12 HBV env 28 A IPQSLCSWWTSL 12 HBV env 28 A IPQSLNSWWTSL 12 HBV env 28 A IPQSLQSWWTSL 12 HBV env 28 A IPQSLWSWWTSL 12 HBV env 28 A IPQSLKSWWTSL 12 HBV env 28 A IPSLDSWWTSL 11 HBV env 28 A IPQSLDSWTSL 11 HBV env 28 A IPQSLDSWWTL 11 HBV env 28 A IPQALASWWTSL 12 HBV env 28 A IPQSLDSWWTSM 12 HBV env 28 A IPQSLDSWWTSF 12 HBV env 28 A KTPSFPNI 8 HBV pol 75 HAVEFHNL 8 HBV pol 289 VSAAFYHL 8 HBV pol 419 VIGCYGSL 8 HBV pol 588 KQYLNLYPV 9 HBV pol 668 CYGSLPQEHI 10 HBV pol 591 VSAAFYHL 8 HBV pol 419 HAVEFHNL 8 HBV pol 289 VIGCYGSL 8 HBV pol 588 KTPSFPNI 8 HBV pol 75 RPQSLDSWWTSL 12 HBVs env 28 A IPQRLDSWWTSL 12 HBVs env 28 A IPQSLRSWWTSL 12 HBVs env 28 A IPQSLDRWWTSL 12 HBVs env 28 A IPQSLDSRWTSL 12 HBVs env 28 A IPQSLDSWWRSL 12 HBVs env 28 A IPQSLDSWWTRL 12 HBVs env 28 A IPQELDSWWTSL 12 HBVs env 28 A IPQSLYSWWTSL 12 HBVs env 28 A IPQSLDSWETSL 12 HBVs env 28 A IPQSLDSWWESL 12 HBVs env 28 A VESENKVV 8 HCV Entire 2253 AGPYRAFVTI 10 HIV env 18 A RAPYRAFVTI 10 HIV env 18 A RGPYRAFVTA 10 HIV env 18 A KGPYRAFVTI 10 HIV env 18 A RGPYRAFVTK 10 HIV env 18 A RGPGRAFVTI 10 HIV env 18 RGPGRYFVTI 10 HIV env 18 A RGPGRAYVTI 10 HIV env 18 A RGPGRAFYTI 10 HIV env 18 A VESMNKEL 8 HIV POL 903 TDSQYALGI 9 HIV POL 689 RGAYRAFVTI 10 HIV 18 A RGPARAFVTI 10 HIV 18 A RGPYRAAVTI 10 HIV 18 A RGPYRAFATI 10 HIV 18 A RGPYRAFVAI 10 HIV 18 A RGKYRAFVTI 10 HIV 18 A RGPFRAFVTI 10 HIV 18 A RGPYKAFVTI 10 HIV 18 A RGPYRKFVTI 10 HIV 18 A RGPYRAYVTI 10 HIV 18 A RGPYRAFKTI 10 HIV 18 A RGPYRAFVKI 10 HIV 18 A NEILIRCII 9 HPV E6 97 QEKKRHVDL 9 HPV E6 113 LFVVYRDSI 9 HPV E6 52 FYSRIRELRF 10 HPV E6 71 A SSIEFARL 8 HSV 498 KVPRNQDWL 9 Human gp100 VYDFYVWM 8 Human TRP2 A KNKFFSYL 8 Human Tyrosinase 131 LAVLYCLL 8 Human Tyrosinase 3 YMVPFIPL 8 Human Tyrosinase 425 GQMNNGSTPM 10 Human Tyrosinase 157 IVTMFEAL 8 LCMV GP 4 ISHNFCNL 8 LCMV GP 118 GVYQFKSV 8 LCMV GP 70 HYISMGTSGL 10 LCMV GP 99 SGVENPGGYCL 11 LCMV GP 276 KAVYNFATM 9 LCMV GP 33 CMANNSHHYI 10 LCMV GP 92 A CSANNSHHYM 10 LCMV GP 92 A SMVENPGGYCL 11 LCMV GP 276 A SGVENPGGYCM 11 LCMV GP 276 A KAVYNFATM 9 LCMV GP 33 KAVYNAATM 9 LCMV GP 33 A KAVANFATM 9 LCMV GP 33 A KAVYNYATM 9 LCMV GP 33 A KAVYNFAAM 9 LCMV GP 33 A YTVKYPNL 8 LCMV NP 205 FQPQNGQFI 9 LCMV NP 396 VGLSYSQTM 9 LCMV NP 356 FQPQNGQFI 9 LCMV NP 396 FQPQNGQFIHFY 12 LCMV NP 396 RPQASGVYM 9 LCMV NP 118 RPQASQVYM 9 LCMV NP 118 A YTYKYPNL 8 LCMV NP 205 A RPQASGVYM 9 LCMV NP 118 A RPQASGVAM 9 LCMV NP 118 A RPQGSGVYM 9 LCMV NP 118 A RPNASGVYM 9 LCMV NP 118 A KAVYNFATCGI 11 LCMV KAVYNFATB 9 LCMV VYAKECTGL 9 Lysteria listeriolysin 479 YPHFMPTNL 9 MCMV 168 YPHYMPTNL 9 MCMV 168 A HETTYNSI 8 Mouse beta actin 275 A YEDTGKTI 8 Mouse p40 phox 245 RNA LGYDYSYL 8 Mouse Tyrosinase 445 SSMHNALHI 9 Mouse Tyrosinase 360 ANFSFRNTL 9 Mouse Tyrosinase 336 SYLTLAKHT 9 Mouse Tyrosinase 136 HYYVSRDTL 9 Mouse Tyrosinase 180 YYVSRDTLL 9 Mouse Tyrosinase 181 SFFSSWQII 9 Mouse Tyrosinase 267 SYMVPFIPL 9 Mouse Tyrosinase 424 PYLEQASRI 9 Mouse Tyrosinase 466 SYLTLAKHTI 10 Mouse Tyrosinase 136 HYYVSRDTLL 10 Mouse Tyrosinase 180 SQVMNLHNL 9 Mouse TYRP2 363 YENDIEKKI 9 P. falciparum CSP 375 NEEPSDKHI 9 P. falciparum CSPZ 347 EEKHEKKHV 9 P. falciparum LSA1 52 SYVPSAEQIL 10 P. yoelii CSP 280 RYLENGKETL 10 Unknown HLA-A24 170 RYLKNGKETL 10 Unknown HLA-Cw3 170 IYTQNRRAL 9 Unknown P815 12 VYDFFVWM 8 Unknown TRP2 181 A SVYDFFVWL 9 Unknown TRP2 180 SVYDFYVWM 9 Unknown TRP2 180 A ASNENMDAM 9 unknown FAPGYNPAL 9 unknown SIQFFGERAL 10 unknown SIQFFGEL 8 unknown RGYVYQGL 8 VSV NP 52 RGPRLNTL 8 HMWNFIGV 8 GGAYRLIVF 9 KYLVTRHADV 19 FSPRRNGYL 9 SHYAFSPM 8 FQPQNGQFI 9

TABLE 29 MURINE CLASS I SUPERTYPE SEQ ID Sequence NO. Dd Kb Kd Db Ld Kk SGPSNTPPEI 18500 >31000 >10000 8.1 RNPRFYNL 7.9 >44000 QPQRGYENF 319 SEAAYAKKI 3.9 AYAPAKAAI 3.5 AYABAKAAI 50 AYANAKAAI 60 AYAGAKAAI 48 AYAVAKAAI 42 AAAAYAAM 375 >44000 AAAAYAAAAM 228 >44000 AAAANAAAM 10960 23 AAAAAANAAAM 31000 257 NAIVFKGL 484 SIINFEKL 3.7 IFYCPIAI 195 KVVRFDKL 92 VYSFSLASRL 303 SIINFEKL >37000 1.5 >10000 30508 KVVRFDKL 37 SENDRYRLL 13 SFYRNLLWL >10000 304 YEANGNLI 0.65 MGLIYNRM 16 MGYIYNRM 2.3 MGIIYNRM 14 MGLIFNRM 21 MGLIYNRM 9.9 RMIQNSLTI 4.6 RLIQNFLTI 40 GMRQNATEI 81 YMRVNGKWM 50 FYIQMATEL 0.31 FYIQMCTFL 1.1 AYERMANIL 233 AYQRMCNIL 2.7 AYERMCTTL 4.1 ASNENMETM >37000 >31000 >10000 33 TYQRTRALM 69 TYQKTRALV 44 TYQPTRALV 17 TYQFTRALV 371 TYQLTRALV 110 SDYEGRLI 0.60 MITQFESL 64 RTFSFQLI 26 FSVIFDRL 201 RTFSFQLI 27 MITQFESL 42 FSVIFDRL 115 KSSFYRNL 209 SSLPFQNI 53 MNIQFTAV 131 MNYYWTLL 169 SFYRNLLWL 46 SSLPFQNI 9.5 MNIQFTAV 26 MNYYWTLL 56 KSSFYRNL 117 SIIPSGPL 393 LSYSAGAL 60 LSYSAGAL 31 SSISFCGV 29 TGIGNQNII 13 ITYKNSTWV 409 FCGVNSDTV 206 TGICNQNII 21 FCGVNSDTV 166 ITYKNSTWV 276 SSISFCGV 2.3 IGRFYIQM 42 MMIWHSNL 238 ASNENMETM 41 IGRFYIQM 24 MMIWHSNL 287 FFYRYGFV 350 KMITQRTI 300 RSYLIRAL 103 RFYRTCKL 117 TALANTIEV 16 TALANTIEY 3.7 RSYLIRAL 78 RFYRTCKL 47 VYINTALL 65 VYINTALL 14 VYIEVLHL 75 VYIEVLHL 21 WYIPPSLRTL 96 MURTAZAKDPE 0.96 PTIDES IYSTVASSL 4.1 LYEKVKSQL 2.2 LYQKVKSQL 2.8 LYBKMKSQL 1.6 LYEKVFSQL 7.4 LYQNVGTYV 6.9 MGLKFRQL 7.4 VSYVNTNM 60 SYVNTNMGL 19 MGLKFRQL 6.3 VSYVNTNM 33 SYVNTNMGL 12 WGPSLYSI 17 ASARFSWL 323 WGPSLYSIL 6.6 TGPCRTCMT 108 WYWGPSLYSI 8.3 IPQSLDSWWTS 2.2 L IPQSLDSYWTS 2.7 L ASARIFSWL 49 WYWGPSLYSI 16 APQSLDSWWTS 15 L IPQALDSWWTS 6.1 L IPQSLASWWTS 4.2 L IPQSLDAWWTS 4.0 L IPQSLDSAWTS 13 L IPQSLDSWWAS 0.34 L IPQSLDSWWTA 134 L EPQSLDSWWTS 86 L IPESLDSWWTS 13 L IPQSLDEWWTS 1.9 L IPQSLDSWWTE 3.0 L RPQSLDSWWTS 60 L IPRSLDSWWTS 160 L IPQRLDSWWTS 23 L TPQSRDSWWTS 21 L IPQSLRSWWTS 12 L IPQSLDRWWTS 5.0 L IPQSLDSRWTS 47 L IPQSLDSWWRS 485 L IPQSLDSWWTR 196 L YPQSLDSWWTS 91 L IPYSLDSWWTS 0.78 L IPQYLDSWWTS 92 L IPQSLYSWWTS 4.7 L TPQSLDYWWTS 1.6 L IPQSLDSWYTS 17 L IPQSLDSWWTY 0.89 L IPGSLDSWWTS 24 L IPQSLDSGWTS 70 L IPQSLDSPWTS 19 L IPQSLDSWGTS 138 L IPQSLDSWPTS 60 L IPQSLDSWWTG 2.5 L IPQSLDSWWTP 1.2 L IPQVLDSWWTS 5.1 L IPQFLDSWWTS 4.3 L IPQPLDSWWTS 6.3 L IPQMLDSWWTS 4.1 L IPQILDSWWTS 12 L IPQLLDSWWTS 0.25 L IPQGLDSWWTS 2.7 L IPQTLDSWWTS 7.7 L IPQHLDSWWTS 39. L IPQCLDSWWTS 25 L IPQNLDSWWTS 12 L IPQQLDSWWTS 1.7 L IPQWLDSWWTS 3.7 L IPQDLDSWWTS 22 L IPQKLDSWWTS 9.3 L IPQSLVSWWTS 11 L IPQSLFSWWTS 11 L IPQSLPSWWTS 16 L IPQSLMSWWTS 0.95 L IPQSLISWWTS 17 L IPQSLLSWWTS 0.84 L IPQSLGSWWTS 2.7 L IPQSLSSWWTS 0.49 L IPQSLTSWWTS 1.7 L IPQSLHSWWTS 1.5 L IPQSLCSWWTS 1.1 L IPQSLNSWWTS 1.5 L IPQSLQSWWTS 0.81 L IPQSLWSWWTS 2.4 L IPQSLKSWWTS 1.1 L IPSLDSWWTSL 119 IPQSLDSWTSL 0.22 IPQSLDSWWTL 1.3 IPQALASWWTS 26 L IPQSLDSWWTS 0.80 M IPQSLDSWWTS 1.9 F KTPSFPNI 270 HAVEFHNL 49 VSAAFYHL 7.0 VIGCYGSL 157 KQYLNLYPV 3.4 CYGSLPQEHI 303 VSAAFYHL 5.2 HAVEFHNL 158 VIGCYGSL 63 KTPSFPNI 155 RPQSLDSWWTS 144 L IPQRLDSWWTS 34 L IPQSLRSWWTS 11 L IPQSLDRWWTS 2.0 L IPQSLDSRWTS 2.6 L IPQSLDSWWRS 335 L IPQSLDSWWTR 27 L IPQELDSWWTS 18 L IPQSLYSWWTS 8.3 L IPQSLDSWETS 5.3 L IPQSLDSWWES 394 L VESENKVV 349 AGPYRAFVTI 5.0 RAPYRAFVTI 176 RGPYRAFVTA 126 KGPYRAFVTI 5.8 RGPYRAFVTK 91 RGPGRAFVTI 9.7 31000 >10000 22000 RGPGRYFVTI 2.7 RGPGRAYVTI 14 RGPGRAFYTI 7.2 VESMNKEL 114 TDSQYALGI 179 RGAYRAFVTI 3.4 RGPARAFVTI 1.04 RGPYRAAVTI 2.0 RGPYRAFATI 2.1 RGPYRAFVAI 1.3 RGKYRAFVTI 67 RGPFRAFVTI 0.78 RGPYKAFVTI 13 RGPYRKFVTI 3.6 RGPYRAYVTI 2.1 RGPYRAFKTI 2.3 RGPYRAFVKI 3.9 NEILIRCII 12 QEKKRHVDL 256 LFVVYRDSI 453 FYSRIRELRF 447 SSIEFARL 1.8 >10000 KVPRNQDWL 38 VYDFYVWM 145 KNKFFSYL 57 LAVLYCLL 72 YMVPFIPL 70 GQMNNGSTPM 242 IVTMFEAL 82 ISHNFCNL 411 GVYQFKSV 11 HYISMGTSGL 83 SGVENPGGYC >31000 60 L KAVYNFATM 3.3 CMANNSHHYI 220 CSANNSHHYM 42 SMVENPGGYC 154 L SGVENPGGYC 128 M KAVYNFATM 1.5 >27000 KAVYNAATM 2.0 >27000 KAVANFATM 1.2 27000 KAVYNYATM 2.1 >27000 KAVYNFAAM 4.4 27000 YTVKYPNL 204 FQPQNGQFI 6.9 VGLSYSQTM 71 FQPQNGQFI >31000 4.9 FQPQNGQFIHF 15500 280 Y RPQASGVYM >31000 >44000 0.99 RPQASQVYM 3.8 YTYKYPNL 1.8 RPQASGVYM 3.0 RPQASGVAM 12 RPQGSGVYM 39 RIPNASGVYM 19 KAVYNFATCGI 29 KAVYNFATB 7.9 VYAKECTGL 129 YPHFMLPTNL 7.5 YPHYMPTNL 9.5 HETTYNSI 1.8 YEDTGKTI 0.86 LGYDYSYL 3.4 SSMHNALHI 7.6 ANFSFRNTL 6.0 SYLTLAKHT 188 HYYVSRDTL 43 YYVSRDTLL 99 SFFSSWQII 16 SYMVPFIPL 144 PYLEQASRI 173 SYLTLAKHTI 4.4 HYYVSRDTLL 167 SQVMNLHNL 2.3 YENDIEKKI 3.8 NEEPSDKHI 40 EEKHEKKHV 284 SYVPSAEQIL 280 RYLENGKETL 80 RYLKNGKETL 217 IYTQNRRAL 144 VYDFFVWM 464 SVYDFFVWL 1.0 SVYDFYVWM 1.2 3365 ASNENMDAM 28 FAPGYNPAL 2.0 SIQFFGERAL 21 >44000 SIQFFGEL 16 >44000 RGYVYQGL >37000 2.1 >10000 >44000 RGPRLNTL 186 HMWNFIGV 202 GGAYRLIVF 3.5 KYLVTRHADV 33 FSPRRNGYL 2.7 SHYAFSPM 250 >88000 FQPQNGQFI 9513 17 

1. A composition comprising one or more peptides from any of Tables 11-29.
 2. A composition comprising nucleic acids encoding one or more peptides from any of Tables 11-29.
 3. The composition of claim 1, wherein at least one of the one or more peptides is an HTL epitope.
 4. The composition of claim 1, wherein at least one of the one or more peptides is a CTL epitope.
 5. The composition of claim 4, further comprising an HTL epitope.
 6. The composition of claim 1, further comprising a spacer molecule.
 7. The composition of claim 1, further comprising a carrier.
 8. The composition of claim 1, further comprising an MHC targeting sequence.
 9. The composition of claim 1, further comprising a lipid.
 10. The composition of claim 1, wherein the one or more peptides are incorporated as part of a liposome.
 11. The composition of claim 1, wherein at least one of the one or more peptides is a heteropolymer.
 12. The composition of claim 1, wherein at least one of the one or more peptides is a homopolymer.
 13. The composition of claim 1, wherein at least one of the one or more peptides is a peptide from an antigen selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSM), hepatitis B virus (HBV) antigen, hepatitis C virus (HCV) antigen, malignant melanoma antigen (MAGE), Epstein Barr virus, human immunodeficiency type-1 (HIV-1), human immunodeficiency type-2 (HIV-2), papilloma virus, Lassa virus, mycobacterium tuberculosis (MT), p53, murine p53 (mp53), CEA, HER2/neu, and tyrosine kinase related protein (TKP).
 14. A pharmaceutical composition comprising an active ingredient, wherein the active ingredient comprises the composition of claim
 1. 15. A vaccine composition comprising an active ingredient, wherein the active ingredient comprises the composition of claim
 1. 16. The use of the composition of claim 1, wherein the composition is a prophylactic composition for the prevention of viral infection or cancer.
 17. The use of the composition of claim 1, wherein the composition is a therapeutic composition for the treatment of viral infection or cancer.
 18. A diagnostic reagent comprising the composition of claim
 1. 19. The use according to claim 17, for the treatment of prostate cancer, hepatitis B, hepatitis C, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV or chondyloma acuminatum. 